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Non-small cell lung cancer represents 85% of all lung cancers with an average 5 year life 
expectancy of 15-20%.  A wealth of data suggests that altered glycosylation contributes to the 
progression of these tumors and efforts to improve the specificity of biomarkers have logically 
shifted towards glycoproteomic investigations.  For this purpose, recent innovations in 
experimental strategies and analytical techniques could be combined to provide a more detailed 
characterization of glycans than previously achievable. These new methods have not yet been 
assessed for feasibility in experimental procedures useful for discovery phase efforts. Therefore, 
we aimed to investigate the utility of novel glycoproteomic and glycomic approaches for 
defining alterations in glycosylation which may accompany disease progression. To this end, we 
implemented an azido-sugar metabolic labeling, alkyne-agarose bead enrichment, and liquid 
chromatography-tandem mass spectrometry for profiling glycoproteins in a cell model of lung 
cancer induced to express transforming growth factor beta ligand-1. This approach identified 
putative changes in the sialylation of glycoproteins related to metabolic, cell adhesion, glycan 
biosynthesis, and extracellular matrix-related proteins. The application of a secondary digest to 
glycopeptide-bound beads, using peptide-N-glycosidase-F, was useful for verifying N-glycan 
sites as well as exposing previously undetected glycoproteins. A stable isotope labeling of amino 
acids in cell culture approach was used to gauge if altered protein expression was contributing to 
differential capture, however this method provided limited information due to a low overlap of 
proteins identified from enriched vs. unenriched fractions. In another set of experiments, we 
applied a novel derivatization strategy combined with high resolution/high mass accuracy mass 
spectrometry for discerning glycan structures in human lung cancer proximal fluids. This 




and identified preliminary trends in the expression of oligomannose and complex glycans in 
clinically-relevant materials.  Finally, matrix-assisted laser desorption ionization imaging mass 
spectrometry was used to spatially resolve the distribution of N-glycans in lung tissues matched 
to the proximal fluids.  Histological assessment of these tissues facilitated cross-reference of 
acquired glycan species to regions of interest and provided a direct means for assessing how 
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Lung cancer accounted for the most cancer-related deaths in 2014, with 85% of 
these being classified as NSCLC. The late detection and heterogeneous progression of 
this disease plays a significant role in the mortality rate, therefore efforts to intervene are 
focused on the identification of biomarkers for early diagnosis and prognostic 
stratification. Here we present a review of the etiology, characteristics, and detection of 
NSCLC as a basic primer of disease pathology and why there is a need for additional 
metrics to predict outcomes. Next, TGFβ1 signaling is outlined to highlight a pathway 
hypothesized to promote the acquisition of invasive tumor phenotypes. This information 
establishes the relevance of our experimental model of NSCLC, H358 cells induced to 
express TGFβ1, as a system for screening for changes in the glycosylation of cell 
adhesion, extracellular matrix, and cytoskeletal proteins. We next provide an overview of 
glycoprotein biosynthesis, functional roles, and observed changes in glycans which often 
accompany transformation and metastasis. In addition, some of the mechanisms by which 
neoplastic cells produce specific glycan structures and the clinical utility for their 
identification are exemplified. These sections provide a base set of knowledge for 
understanding why cancer-associated glycosylation changes may occur and which 
structures are often modified. Furthermore, this information demonstrates the value of 
glycoproteomic endeavors by providing examples of how previous research has 
translated to clinical use. Finally, we present the methods utilized for mass spectrometry-
based glycoproteomic investigations. Strategies and experimental approaches for the 




reviewed. Recent innovations in glycoproteomic mass spectrometry and data analysis, 
and the benefits they provide relative to previous methods, are featured.   
 
1.1 Non-Small Cell Lung Cancer 
1.1.1 Introduction 
 
 Lung cancer, including both non-small cell and small cell carcinoma, is 
responsible for the most cancer-related deaths in the United States.  For 2014, the 
American Cancer Society estimates approximately 224,000 new cases of lung cancer and 
a mortality rate of about 159,000 for both sexes(1,2). Efforts introduced to reduce the risk 
for lung cancer development, such as smoking cessation therapy and early screening, 
have resulted in a decreasing mortality rate over the last 30 years for males and the last 
10 years for females. While these trends are encouraging, the need for further 
intervention is evidenced by the outstanding difference in mortality between lung cancer 
and other prominent neoplasms like breast, prostate, and colon. In addition, the 5-year 
survival rate of lung cancer is among the lowest (17% for all stages) and the probability 
of identifying a tumor while it is still localized is dismal (15%)(2,3).   
1.1.2 Etiology and Detection 
Cigarette smoking is by far the leading cause of lung cancer. Numerous 
epidemiological studies implicate cigarette smoking in the development of lung disease 
and current estimates suggest it is responsible for about 80% of respiratory 
malignancies(1,2,4). Smokers are estimated to have a 20x increased probability of 
acquiring lung cancer of in their lifetime relative to never-smokers. Former smokers 




tumor continues to decrease over time, albeit never returning to non-smoker levels. 
Further evidence of a causal link between smoking and lung cancer development is 
provided by the changes in the prevalence of histological subtypes over time 
accompanying public attitudes toward smoking; that is, as more people have quit 
smoking, there has been a shift in the occurrence of specific subtypes of lung cancer most 
associated with smoking(4). While smoking is clearly the most relevant environmental 
exposure in the etiology of lung cancer, it alone does not account for all cases. Other 
carcinogenic agents include asbestos, radiation, arsenic, chromium, uranium, nickel, 
polycyclic aromatic hydrocarbons, diesel exhaust, and radon ("extrinsic components")(4). 
From a pathological perspective, extrinsic factors insight an initial injury within the lung. 
As a normal biological response, inflammatory cells are recruited to these sites where 
they produce cytokines/chemokines, growth factors, and pro-angiogenic molecules to 
protect and induce healing of the affected tissue. Typically these responses are self-
limiting and wane following repair of the underlying insult. However in the context of 
repeated injury, such as in a smoker, inflammatory and wound-healing programs persist, 
inducing increased cell proliferation(5–7). This increased cellular replication, in 
combination with exposure to carcinogenic agents, reactive oxygen species from immune 
infiltrate, and an altered microenvironment signaling milieu, promotes the accumulation 
of genetic mutations and may induce the initial transformation. Intrinsic components, 
such as inherent genetic variation and epigenetic modifications, may also play a role in 
the transition to cancer. For example, alterations in genes that control the metabolic 
conversion of pro-carcinogens to carcinogens, chromosomal instability, and promoter 




The late detection of lung cancer plays a significant role in the high mortality rate. 
Signs and symptoms, including cough, hoarseness, bloody sputum, and weight loss, are 
often absent until the tumor has grown beyond a curable time-point. This is partially due 
to the formidable volume of the respiratory tract, allowing tumors to grow for some time 
before affecting other physiological processes. In addition, smokers may overlook 
signs/symptoms; attributing them as a consequence of the cigarettes themselves and not 
the underlying pathology. Efforts to reduce the mortality rate have therefore been focused 
on identifying tumors at earlier stages, when surgical intervention/chemotherapy may be 
curable(3,4,9). Imaging-based methods remain the gold-standard for the discovery of 
lung tumors, with low-dose spiral computed tomography (LDCT) being of particular 
utility(4). LDCT allows physicians to survey respiratory tissues for suspicious lesions in 
a manner more sensitive, faster, and with reasonable increases in radiation exposure 
relative to standard chest x-ray(9,10).  Studies evaluating the use of LDCT as an early 
screening method, such as the National Lung Screening Trial (NLST), demonstrated its 
ability to detect cancer sooner than other methods and thereby decrease the mortality rate 
in a specific patient population(11). These results were promising enough to prompt the 
American Cancer Society to publish screening guidelines based on its use; however the 
study also unveiled a high rate of false-positive diagnoses associated with LDCT 
assessment alone. Subsequent research approaches aimed at increasing the specificity of 
screening are now focused on identifying molecular/proteomic biomarkers of early 
tumors in serum, proximal fluids and tissue, which could be used in combination with 




The histological and molecular attributes of lung cancer play an important role in 
prognostic and therapeutic considerations. Classifying lung cancer generally begins by 
grouping tumors into either non-small lung cancer (NSCLC) or small cell lung cancer 
(SCLC) subsets based on cytological characteristics of the primary tumor(s). NSCLC 
represents about 85% of all lung tumors, SCLC around 10%, and other rare forms 
(carcinoid) less than 5%(1). Within NSCLC, histologic sub-classifications of 
adenocarcinoma (ADC), squamous cell carcinoma (SCC), and large cell carcinoma 
(LCC) are made based on examinations of biopsies or cytological specimens; with 
immunohistochemistry being the most reliable means to differentiate sub-
types(3,4,12,16). These sub-classifications were originally used to stratify patients into 
prognostic and therapeutic groups; however advances in molecular biology now permit 
for the identification of specific genetic mutations driving individual tumors. 
Consequently, therapeutic strategies have evolved for personalized medicine based on 
this information and a restructuring of the lung cancer classification system has been 
implemented to incorporate radiological, histological, and molecular typing(4,16,17).  
 1.1.3 Sub-types and Features 
Adenocarcinomas represent the most prevalent subtype of NSCLC, accounting for 
about 50% of all new diagnoses. This classification encompasses cancers arising in 
secretory epithelial cells associated with glandular structures; which tend to form 
peripherally and grow slowly(4). ADCs develop in smokers more commonly than non-
smokers; however, within the non-smoking population ADC is the predominant form. 
Within this classification (but not limited to), point mutations/overexpression in the 




serve as predictive biomarkers for therapeutic efficacy of specific tyrosine kinase 
inhibitors (TKI)(4,8,18). In addition, acquired mutation in EGFR following TKI therapy 
indicates resistance to these drugs. Alterations in the K-Ras gene occur at a high 
frequency in lung adenocarcinomas and result in the constitutive activation of signaling 
pathways for proliferation and survival programs. Targeting this mechanism is an area of 
intensive research for clinical management purposes; unfortunately with minimal gains as 
of yet(8). Several other genetic aberrations have been documented, mediating effects in 
epigenetics, transcription, proteolysis, tumor suppressor and cell cycle control 
proteins(19). An important observation regarding these genetic anomalies is that they 
tend to occur in a mutually exclusive manner and often drive ADC development in non- 
or light smokers (4,8,18). Continued research efforts to uncover the molecular pathology 
of ADC will likely provide novel therapeutic targets as well as diagnostic/prognostic 
biomarkers for stratification of patients presenting with this subtype.  
 Squamous cell carcinomas frequently originate in the central portions of the 
respiratory tract; particularly in epithelial cells lining the bronchi. SCC tumorigenesis is 
highly associated with smoking and its incidence (40% of all NSCLC) has declined 
following public disclosure of the dangers of cigarettes(1).  The pathology of SCC has 
been well-defined and follows a predictable progression in tissue dysplasia and genetic 
modification. Molecular changes accompanying this subtype include loss of 
heterozygosity in CDKNA, TP53, and RB1, as well as overexpression of genes SOX2 
and TP63(19,20).  Documentation of SCC driver mutations lags behind ADC, 
particularly because of sub-type prominence issues and tissue availability. More recently, 




identified in FGFR1, PI3KCA, and DDR2 genes. Conflicting information exists 
regarding the status of mutations associated with adenocarcinoma occurring in SCC; 
specifically EGFR, EML4-ALK, and K-Ras mutations. Some reports suggest that these 
particular events may be associated with SCC initiation /progression, while other research 
asserts that these findings were the result of mixed histologies in study specimens (i.e. 
adenosquamous carcinoma)(19,20). In fact, further definition of the molecular diversity 
in SCCs is currently an area of great interest. Importantly, this work will likely contribute 
to targeted therapies and prognostic indicators similar to the significance of findings in 
ADCs.   
Large cell carcinoma is the least prevalent sub-type, representing about 10% of 
NSCLC cases. LCC usually begins in the periphery of the lung, grows rapidly and may 
secrete hormones (1,4). LCC is difficult to diagnose using traditional methodologies (i.e. 
immunohistochemistry) because of the inability to distinguish it from non-differentiated 
forms of ADC and SCC; therefore the LCC diagnosis commonly used when there is no 
clear ADC or SCC differentiation(17).  
 
1.2 Inflammation and TGFβ1 in NSCLC 
1.2.1 Inflammation and the Pathogenesis of NSCLC 
Persistent inflammation and chronic tissue remodeling, from environmental 
factors such as smoking, as well as contributions from intrinsic components, characterize 
the initiation of tumorigenesis in NSCLC. Inflammatory pathways are activated in 
response to the initial insult, leading to recruitment of immune cells and restructuring of 




nature, chronic activation of these pathways not only propagates tumor formation, it is 
also hypothesized to advance existing cancer cells towards the acquisition of invasive 
phenotypes. Numerous cytokines, growth factors, and inflammatory mediators regulate 
these processes under tight temporal and spatial control. However, the dysregulated 
growth and signaling networks of tumor cells, in the presence of the inflammatory tumor 
microenvironment, may take advantage of these signals to propagate survival and 
metastasis.  Amongst the altered signaling milieu present in inflammatory 
microenvironment, the pleiotropic cytokine transforming growth factor beta ligand 1 
(TGFβ1) is of particular interest for the promotion of invasive phenotypes.  
1.2.2 Introduction to TGFβ1 
TGFβ1 is a multi-functional cytokine contributing to physiological processes 
including tissue development, regulation of immunological responses, epithelial/stromal 
cell proliferation and differentiation, induction and down-regulation of inflammation, and 
the initiation and resolution of wound-healing(21,22). Three family members of TGFβ 
ligands exist (i.e. TGFβ1, TGFβ2, TGFβ3). TGFβ1 is the major form produced relevant 
to immune functions/wound-healing regulation, however all 3 ligands have potential to 
mediate similar signal transduction pathways because they may share common 
downstream 2nd messengers (21,23). The initial synthesis of TGFβ1, in stromal or 
immune cell populations, results in the production of a pre-pro-protein form of the 
molecule, which requires proteolytic cleavage for activation. The latent precursor 
molecule is often secreted into the extracellular matrix, where it remains dormant until 
acted upon by molecules such as integrin αvβ6,  matrix metalloproteases (MMPs), 




dictates(21,24). Liberation of active TGFβ1 from its regulatory molecules, latent TGF 
binding protein (LTBP) and latency associated peptide (LAP), results in binding of 
dimeric-ligand complexes to type II TGFβ receptor (TGFβRII).  This binding induces 
conformational changes on the homodimeric TGFβRII, moving it into proximity to TGFβ 
receptor type I (TGFβRI or ALK5) homodimers. Ligand-bound TGFβRII  forms a 
heterotetrameric unit with TGFβRI, allowing cross phosphorylation of its (TFGβRI) 
cytoplasmic tail via TGFβRII’s Ser/Thr kinase domain(25). At this point, the activated 
ligand/receptor complex is primed for the activation of downstream effectors capable of 
inducing canonical and non-canonical effects of TGFβ1. An important consideration to 
note is that different TGFβRI isoform subtypes (ALK1-7) may be preferential activated 
depending on cell lineage, resulting in activation of diverging downstream signaling 
effectors(22,23,25). Although the predominant TGFβRI isoform activated in immune, 
epithelial, and fibroblast populations by TGFβ1 is ALK5, recent research suggests some 
outcomes may also be mediated through ALK1 in endothelial and epithelial 
cells(23,25,26).   
1.2.3 Canonical TGFβ1 Signaling 
The canonical pathway initiated by ligand-bound TGFβRII-ALK5 complexes 
begins with the phosphorylation of receptor-Smad proteins (R-Smads: Smad-2 and -3) by 
type I TGFβRI, a Ser/Thr kinase. R-Smads are brought into proximity to activated 
receptor complexes by Smad-anchor for receptor activation (SARA), allowing each to be 
phosphorylated. Following this activation, Smad-2 and Smad-3 individually form 
heterodimers with the common Smad (Smad-4) and translocate to the nucleus where they 




genes are targeted for modulation by a combination of R-Smad/Smad-4 and various co-
activators or co-repressor molecules. Importantly, these co-regulatory molecules, such as 
AP-1, Ets, basic helix loop helix, Forkhead and Homeobox-containing transcription 
factor families, confer tight binding and specificity to genes regulated by TGFβ1(22,28). 
R-Smads also recruit histone acetyltransferases (CBP/p300) and de-acetylases (Sno/Ski) 
in their complex orchestration of transcription control.  Depending on the biological 
context/cell type, different co-regulatory molecules may preferentially interact with the 
R-Smads to influence gene expression. Some of transcription targets of TGFβ1 relevant 
to inflammation/wound-healing include genes affecting morphology (α-actinin, 
tropomyosin), extracellular matrix-modifying enzymes (collagens, MMPs, plasminogen 
activator inhibitor), and cell adhesion properties (cadherins, integrins, 
fibronectin)(29,30).  In addition, canonical TGFb1 signaling results in the transcription of 
Smad-7 (inhibitory-Smad). Through this mechanism TGFβ1 is able to regulate its own 
signaling via negative feedback; by direct competition of Smad-7 with Smad-2/3 for 
binding at TGFβRI as well as the recruitment of an ubiquitin ligase for degradation of 
ALK5.   
1.2.4 Non-Canonical TGFβ1 Signaling 
Several studies have also uncovered the ability of TGFβ1-bound 
TGFβRII/TGFβRI to affect cell-signaling pathways that are Smad-independent or that 
interact with Smads outside of the mechanism described above ("non-
canonical")(22,27,31). Models of TGFβ1 signaling using mutated TGFβR1 or Smad-4 
deficiency demonstrate activation of pathways such as p38 MAPK, JNK, and Erk MAPK 




stimulated by kinase cascades following TGFβ1 ligand-binding; however the distinct 
means by which this is achieved has yet to be elucidated. One hypothesis is that TGFβ-
induced kinase (TAK1) and Ras propagate transduction through these pathways via direct 
TGFβ1 activation(27). An important outcome of non-canonical activation of these 
pathways is convergence with Smad-dependent signaling. TGFβ1 activation of MAPK 
signaling has been shown to regulate Smad-dependent transcription targets through 
effects on co-regulatory transcription factors(22). The potential results mediated by the 
interaction of these pathways are diverse and confer a further level of regulation for 
generating context-dependent outcomes in TGFβ1 signaling. Other effectors in non-
canonical TGFβ1 signaling include the Rho-like GTPases (RhoA, Rac, Cdc42) and 
PP2A(27,31). These molecules impart effects ranging from the modification of 
cytoskeletal organization, to serving as intermediates for the regulation of other non-
canonical pathway molecules, as well as affecting cell cycle progression. Detailed 
characterization of Smad-independent signaling, and its significance to physiological 
responses of TGFβ1 is still underway.  
1.2.5 Paradoxical Effects of TGFβ1 in Cancer 
TGFβ1 is well-known to promote growth-inhibition on non-transformed epithelial 
cells via canonical signaling; through modification of specific transcriptional targets 
controlling cell cycle and apoptosis(28). In the context of carcinogenesis, these actions 
suggest that the molecule promotes the suppression of tumor growth. In support of this 
role, retrospective analyses have identified mutated forms of TGFβ1 receptors/effectors 
present in tumors of various origins; inferring that altered signaling may contribute to 




following the observation that many advanced tumors over-express the ligand, and, that 
loss of growth-inhibitory response increased metastases and resulted in poor 
prognoses(25,33–36). Subsequent investigations, aimed at clarifying these apparently 
paradoxical roles for TGFβ as a tumor suppressor and promoter, were carried out using 
transgenic murine models of cancer with various modified components of the TGFβ1 
pathway. The studies confirmed the dual functionality of the cytokine and provided 
insight into some of the mechanisms established tumors use to overcome growth-
inhibitory effects of TGFβ1 and utilize them for the propagation of survival/invasion. 
1.2.6 TGFβ1 and Invasive Tumor Phenotypes 
TGFβ1 is initially secreted into inflammatory tumor microenvironments by 
immune infiltrate and stromal cells recruited to protect/repair underlying tissue damage. 
However, over time, transformed epithelial cells acquire the ability to produce and 
secrete the cytokine (37). In addition, latent TGFβ1 present in the extracellular matrix 
may be activated by the enzymes/proteases secreted by these cells during the process of 
tissue restructuring. The effects of active TGFβ1 within this physiological context 
influence the genetic programs of tumor and stromal cells, as well as regulating host-
tumor immune interactions and promoting angiogenesis. One such effect, hypothesized to 
play a central role in the acquisition of invasive phenotypes, involves modification of a 
set of genes controlling epithelial cell differentiation, morphology, and function. The 
phenotypic changes incurred as a result of targeting these genes are collectively referred 
to as the epithelial to mesenchymal transition (EMT). EMT is a normal biological 
occurrence during embryogenesis, tissue development, and wound-healing. It provides a 




into de-differentiated, migratory states (mesenchymal) for the colonization of tissues in 
processes like organ development or wound repair(38). This program is typically under 
tight regulatory control; requiring specific extracellular cues and the cooperation of 
several molecular effectors for coordination. However, in a state of altered signaling, 
such as chronic inflammation and/or carcinogenesis, the inappropriate activation of EMT 
may occur and propagate pathological progression(28). An example of this is evidenced 
in states of organ fibrosis. In such cases, habitual EMT, stemming from un-resolved 
inflammation, TGFβ1 production, and other molecular contributors, results in increased 
epithelial cell de-differentiation to fibroblast precursors(39). These fibroblast-like cells 
produce collagen in an attempt restructure the supporting tissue. Without resolution of the 
EMT-promoting events, hardening and dysfunction of the affected organ may result(40).   
More recently, EMT has been hypothesized to be a mechanism for initiating 
metastasis in epithelial based tumors. Murine models and In vitro experiments 
demonstrate the ability of tumorigenic epithelial cells to respond to EMT-inducing 
molecules and acquire phenotypic changes consistent with mesenchymal cells. These 
phenotypic changes include loss of epithelial cell markers E-cadherin, Zona Occludens-1, 
and MUC1. In addition, these cells gain markers such as α-smooth muscle actin, 
fibroblast-specific protein, N-cadherin, and vimentin; all highly suggestive of a 
mesenchymal-like state(28,38). TGFβ1, along with other growth factors from within the 
tumor microenvironment, has been shown to induce the genetic changes consistent with 
acquisition of these phenotypic alterations; for example, through the modification of 
genes such as Snail, Slug, Zeb-1/2, Goosecoid, and Twist. TGFβ1 imparts its pro-EMT 




of certain pathway effectors resulting in a synergistic effect. Canonical signaling 
influences the expression of target genes mentioned above, through direct 
activation/repression of transcription factors or epigenetic modifications. Smad-
independent signaling, such as through Ras activation, promotes EMT by modifying 
adherens junctions as well as working together with canonical signals for the induction of 
genes like Snail. In addition, non-canonical signaling contributes the cytoskeletal 
organization changes and the dissolution of tight junctions, through interactions with 
molecules like Erk, JNK/p38, Rho-like GTPases, and CDC42.  Each pathway is also 
hypothesized to contribute to the autocrine production of TGFβ1 by transformed cells, 
feeding back to strengthen these signaling outcomes(28,38,41). Furthermore, oncogenic 
changes within the cells may assist in TGFβ1-induced EMT. For example, loss of the p53 
tumor suppressor, in combination with TGFβ1 signaling, promotes the de-regulation of 
key mediators of cell cycle progression(42). Outside of the direct tumor cell effects of 
TGFβ1, the cytokine also primes the tumor microenvironment for invasion. Immune 
cells, such as neutrophils and monocytes, are recruited to the tumor by TGFβ1 and other 
inflammatory mediators. Upon arrival, these cells secrete matrix-modifying enzymes, 
growth factors and cytokines as a normal physiological response(21,43). The dissolution 
of the extracellular matrix by matrix-metalloproteases, collagenases, and other proteases 
by these cells may help facilitate intravasation of tumor cells as an initial step in 
metastasis.  Finally, TGFβ1 skews the phenotype of immune cells away from anti-tumor 






1.2.7 TGFβ1 and Glycosylation 
Several of the proteins targeted for modification by TGFβ1 in the acquisition of 
invasive tumor phenotypes share functional characteristics: being related to cell adhesion, 
cytoskeletal organization, and extracellular matrix (ECM) remodeling. The change in 
differentiation state of tumor cells stimulated with TGFβ1 requires a comprehensive re-
organization of these types of molecules and their biological properties. Beyond effects 
on protein expression levels, other characteristics likely regulated by TGFβ1 influence 
protein-protein interaction, localization and stability. Based on this rationale, 
investigations are now exploring additional mechanisms by which TGFβ1 influences 
tumor cell phenotypes.  For example, several studies are investigating alterations in 
protein glycosylation as a potential means to propagate TGFβ1-induced invasive 
characteristics(44–47).  The principle behind this is seeded in the abundance of relevant 
biological functions that glycans carry out and the high frequency with which these 
PTM's are attached to proteins modified during invasion. Glycans influence cell-cell and 
cell matrix-adhesion, protein-trafficking, ligand-receptor interaction, and immune 
recognition(48). Furthermore, a wealth of literature demonstrates alterations in 
glycosylation profiles accompanying embryonic tissue development and cell 
differentiation, neoplastic transformation, and metastatic dissemination(48–53). 
 Examinations of microarray data from cell models of cancer stimulated with 
TGFβ1 have uncovered significant differences in the mRNA levels of potentially relevant 
enzymes responsible for glycan synthesis, extension, and degradation. For example, 
Maupin et al. detected alterations in the levels sialyl-transferases and polypeptide N-




group further demonstrated that various pancreatic cancer cell lines, designated as either 
epithelial or mesenchymal, present with vast differences in expression profiles of genes 
vital to branching/lengthening of existing glycans and O-type glycosylation. Another 
complementary analysis revealed contrasts in glycan-related gene expression between 
actively migrating and stationary cancer cells. Conclusions drawn from their efforts 
indicate that glycosylation-related genes, as a group, are significantly enriched for 
modification following TGFβ1 stimulation. However, clear relationships regarding how 
TGFβ1 influences these genes have yet to be elucidated.  Zhang et al. provide evidence of 
a pSmad-2 dependent effect for the induction of the glycosyl transferase GCNT2 and 
demonstrate the requirement of its enzymatic activity in the induction of certain 
migratory characteristics(46). Other suspected pathways may be influenced by TGFβ1's 
ability to affect epigenetic modifications. The MGAT3 gene codes for the glycosyl 
transferase GnT-III, which catalyzes the addition of bisecting N-acetylglucosamine 
(GlcNAc) to core N-glycan structures. The presence of these bisecting structures 
precludes further branching of glycan chains catalyzed by the glycosyl transferase (GnT-
V). An important observation has been that increased levels of GnT-V, and decreased 
levels of GnT-III, are associated with increased metastases in some cancer models(54–
56). Pinho et al. used this information to research mechanisms by which aggressive 
cancers may modify the expression of these enzymes(47). Their work established that 
promoter hypermethylation of MGAT3 occurs following TGFβ1 exposure and they 
conclude that the subsequent loss of bisecting GlcNAc on E-cadherin may allow for an 
increased turnover rate of the cell adhesion molecule. Beyond cell-specific effects, other 




status of vital ECM components in contributing to invasion. Freire-de-Lima et al. 
revealed increased enzymatic activity of specific N-acetylgalactosaminyl transferases 
(GalNAc-T) following TGFβ1 stimulation of prostate cancer cell lines(57). These 
GalNAc-Ts were shown to be responsible for the addition of a specific O-linked glycan 
on fibronectin, which defines a variant form of the protein associated with metastatic 
cancer (oncofetal fibronectin). The authors conclude their study by demonstrating that 
blocking oncofetal fibronectin expression, through upstream inhibition of the GalNAc-
Ts, attenuates TGFβ1-mediated acquisition of invasive phenotypes in these cells.  
 
1.3 Glycosylation and Biomarker Discovery 
1.3.1 Introduction to Glycoproteins 
 Glycosylation is the most common post translational modification, estimated to 
occur on around 50% of all mammalian proteins. These sugar molecules ("glycans") 
carry out various biological functions, which can be broadly defined into 
structural/modulatory roles and the regulation of cell-cell and cell-environment 
recognition events. Glycosylation may occur on proteins, lipids, DNA, and other organic 
molecules; with the collective group of substrates being referred to as glycoconjugates. 
For proteins in particular, the attachment of carbohydrate molecules influences 
conformation, localization, retention, and protein-protein interaction. At the cellular level, 
this translates into effects on processes such as cell-cell and cell-matrix adhesion, 
receptor-ligand binding, ECM structure and integrity, and cytoskeletal dynamics (58,59). 
Consequently, glycans are often found attached to secreted or cell-membrane associated 




standpoint, glycosylation is thought to increase the diversity of functions that a limited set 
of molecules (proteins, lipids) may carry out for normal biological function and in 
responding to environmental stimuli. Supporting this idea is the array of mono- and 
polysaccharide molecules used to synthesize these structures. Carbohydrates may be 
attached in alternative orders, differing anomeric configurations, and in branched or 
linear configurations for a given glycosite on a single protein under different 
physiological conditions (48).  In addition, glycans may be further modified by sulfation, 
methylation, or acetylation following attachment. The relevance of glycosylation in 
influencing biological processes is evident in the multitude of disorders identified from 
its dysregulation. For example, glycans play a role in pathogenic, congenital, and 
acquired disease states.  The congenital disorders of glycosylation (CGD) are a collection 
of inherited maladies caused by ineffective glycan anabolism commonly presenting at 
early stages of life. In addition, several of the lysosomal storage syndromes, including 
Tay-Sachs disease, are related to the inability to properly degrade glycans(48,60,61). A 
common theme in these glycosylation disorders is that pathology is often evident at early 
stages of life, reflecting the nature of these molecules to carry out functions in 
developmental/differentiation cell programs(62). In line with this were observations that 
cancer cells present with an altered repertoire of glycans relative to non-transformed cells 
of the same origin. Studies using lectins (molecules which recognize glycan epitopes), 
glycan-specific antibodies, and protein separation techniques initially uncovered the 
changing "glycome" tumors often exhibit(63). Subsequent efforts confirmed that the 




hypotheses began being formed regarding how tumor cells may utilize these changes to 
propagate the neoplastic phenotype.  
1.3.2 Biosynthesis and Roles of Glycoproteins  
The potential for great diversity in glycan structures attached to proteins in 
mammalian cells exist. At present, 10 different precursor sugar molecules are known, 
which are derived from metabolic and/or glycan salvage pathways(64). These 
monosaccharide molecules are "activated" in the cytoplasm by attachment to high-energy 
nucleotide-phosphates and then transported to the endoplasmic reticulum and Golgi 
apparatus. Within these compartments, the molecules now serve as donor-substrates for 
the enzymes that initiate and elongate these structures. The glycosyltransferases (GTs), 
which catalyze the formation of substrate-glycan bonds, typically act in a manner 
consistent with one enzyme being responsible for the attachment of one donor sugar to an 
acceptor substrate in a specified linkage conformation(65).  However, within this large 
group of highly conserved enzymes (over 96 GT families exist), exceptions to the "one 
enzyme-one linkage" observation exist. For example, cases where more than one GT 
catalyzes the addition of the same donor-substrate and linkage conformation have been 
demonstrated (i.e. shared specificity). Other exceptions include single GTs being capable 
of adding a donor substrate in different linkages or being promiscuous in acceptor 
specificity(65). GTs may also compete amongst themselves for donor glycan substrates, 
and as well, cell/tissue specific expression of different GT families has been observed(64) 
. In addition, the enzymes which hydrolyze glycan-substrate linkages, the glycosidases, 
function along the anabolic pathway creating intermediate glycan structures. These 




glycan structures based on the presence/absence of specific GTs in different cell types. 
However, other useful information regarding these enzymes has been deduced with 
potential applications for uncovering specific glycan roles(66). For instance, the 
initiating-GTs tend to have higher levels of specificity for acceptor substrates 
(polypeptides, lipids, nucleic acids) relative to later-acting GTs which extend 
oligosaccharides (where acceptor substrates are previously attached glycans). Consensus 
sequence/motifs have been identified for some of the initiating enzymes, aiding in the 
calculation of where these structures may be attached. Furthermore, this information was 
useful for elucidating the molecular mechanisms by which carbohydrates are bound to 
other molecules. As an example, protein N-linked glycosylation only occurs in the amino 
acid consensus sequence Asn-X-Ser/Thr, where X is any amino acid other than Proline. 
The biological rationale for this consensus sequence is evidenced by amide bond 
formation between the initial GlcNAc molecule of the glycan and the nitrogen on the side 
chain of Asn. It should be noted for this particular example, however, that just because a 
consensus sequence is present does not necessarily mean glycosylation will be initiated; 
the same being true for glycan acceptor substrates of the extending GTs. Further 
complexity in carbohydrate structures are mediated through monosaccharide substrate 
availability, the potential for multiple anomeric configurations, and chemical 
modification of glycans(64,67). These examples provide only a partial insight into some 
of the mechanisms responsible for the exuberant amount of oligosaccharide diversity in 
mammalian cells. Importantly, cells utilize these assortments of glycan 
structures/attachments to influence the functionality of glycoconjugates and may alter the 




  Three major types of mammalian glycoproteins exist: N-linked, O-linked, and 
proteoglycans. As mentioned above, N-linked glycosylation is defined by bond formation 
between Asn residues in the consensus sequence Asn-X-Ser/Thr and a GlcNAc substrate. 
O-linked glycans are attached ambiguously at Ser/Thr, through a reaction with the side 
chain hydroxyl group of these amino acids. The third class of glycoproteins, 
proteoglcyans, is composed of a protein backbone with one or more glycosaminoglycan 
(GAG) branches occurring along the length of the core. These linear, highly-sulfated 
molecules are abundant in the ECM where they influence biological processes through 
charge state effects from the GAG molecules they carry(68). N- and O- glycans share 
some characteristics in their biosynthesis and function. Each of these molecules exerts 
distinct influences on the underlying protein to which they are attached based on the 
unique repertoire of sugars they carry.  
 The synthesis of N-linked glycans begins in the ER and is completed in the Golgi, 
where structural complexity may be added by concerted efforts of glycosyltransferases 
and glycosidases. The glycoprotein products are typically destined for secretion or 
insertion into the cell membrane; a fate that is inherently tied to the localization of 
enzymes required for their production (66). The N-linked glycan pathway is unique in 
that these molecules are first constructed by the transfer of a "core" set of glycans from a 
dolichol-phosphate donor. This highly conserved, constitutive pathway is orchestrated 
co-translationally, as a growing polypeptide chain enters the ER. First, a 14-sugar core 
(Glc3Man9GlcNAc2) is covalently linked to the substrate by the oligosaccharide complex 
(OST), yielding an immature N-glycan. Glycosidases present in the ER and Golgi cleave 




Man5GlcNAc2(69). These "fully trimmed" glycans may now be elongated with various 
monosaccharides through the action of medial and trans- Golgi-based GTs. However, not 
all N-linked glycans undergo full trimming, and as well, not all trimmed N-glycans will 
be elongated. The carbohydrate moieties present on N-linked glycoproteins which retain 
>5 core mannose sugars cannot be further processed by Golgi GTs. This type of N-glycan 
is referred to as "oligomannose" and variations in their presentation on final protein 
products range from fully trimmed (Man5GlcNAc2) to untrimmed (Man9GlcNAc2) and 
anywhere in-between(69). Another important biological consequence of the trimming 
reactions is the facilitation of protein quality control, through interactions with ER-based 
chaperones. Unfolded or mis-folded proteins may not be appropriately processed by the 
glycosidases responsible for removing core glucose molecules, resulting in retention and 
possible proteosomal degradation of the polypeptide(70).  Those glycans which 
successfully undergo complete trimming have the additional potential to become either 
"complex" or "hybrid" type N-glycans(69). Complex N-glycans are generated from the 
Man5GlcNAc2 core structures through reactions mediated by GlcNAc-transferase I & II 
as well as the glycosidase α-mannosidase II. The action of these enzymes further reduces 
the mannose content ( to Man3GlcNAc2) and adds GlcNAc residues to both of the core 
"branches", providing an acceptor substrate for further GT action. In addition each branch 
may form a bond with up to two GlcNAc linkages, resulting in bi-, tri-, and tetra-
antennary and bisecting complex glycans. Hybrid N-glycans, as the name implies, are a 
combination of oligomannose and complex structures. This type of N-glycan is produced 
when α-mannosidase II cleaves only 1 mannose from the fully trimmed core, resulting in 




may be extended with other sugars (like complex) while the other branch is terminated 
with core-derived mannose (like oligomannose). As complex and hybrid N-glycans 
progress through the Golgi, various modifications may occur to the core and GlcNAc 
branches. For example, the addition of a fucose molecule to the GlcNAc bound to Asn 
("core fucosylation") or glycosidic linkages between GlcNAc antennae and galactose 
("LacNAc"). Capping sugars, or the terminal carbohydrates added to elongated branches 
of complex/hybrid glycans, include GalNAc, sialic acid, fucose, and galactose. These 
monosaccharides may protrude from the secondary structure of repeated sugar units 
(poly-LacNAc) commonly present in complex/hybrid antennae. In this manner of 
presentation, these carbohydrates play a central role in determining the interaction of N-
linked proteins with their environment(69).  
  O-linked glycosylation on protein substrates is a broad term for the attachment of 
various carbohydrate molecules to the hydroxyl group of Ser/Thr residues(50,71). For 
this type of glycosylation, several subdivisions can be made by categorizing the initiating 
sugar attached to the polypeptide. For example, the O-GalNAc type O-glycosylation, 
which are commonly synthesized on cell-membrane and secreted proteins, mediate 
effects similar to N-glycans in cell-cell and cell-ECM interaction. Another type, O-
GlcNAc, may be synthesized on cytosolic and nuclear proteins and are hypothesized to 
regulate signaling cascades(64). Other forms of O-glycosylation include linkages 
beginning with as xylose, mannose and fucose. For simplicity, relevance, and  functional 
similarities to N-glycans, all further information presented here will based on O-GalNAc 




 The synthesis of O-GalNAc glycans on proteins (also termed "mucins") begins 
with transfer of the sugar molecule to Ser/Thr residues on proteins transiting through the 
Golgi. The reaction is carried out by the polypeptide-GalNAc-transferase family of 
enzymes (ppGalNAcT), who require the GalNAc molecule to be attached to the high-
energy donor UDP. There is no consensus sequence required for the initiation of the 
reaction; however steric effects from proximal amino acids may influence the access of 
ppGalNAcTs to specific residues(71). Once the first GalNAc is attached to the 
polypeptide, additional linkages may be made using GlcNAc or galactose. This results in 
the production of various O-GalNAc core structures, to which other sugars may be 
further added ("extended core").  8 distinct core structures exist, some of which present 
with differential tissue distributions. The most common arrangements, cores 1-4, are 
defined by secondary monosaccharide linkages to the initial GalNAc molecule. 
Glycoproteins carrying these types of sugars tend to be widely distributed in glandular 
tissues(50). Other configurations are seemingly more limited in their expression and may 
be associated with pathological states. For example, the minimum requirement for an O-
GalNAc glycans is simply the linkage of the first GalNAc to Ser/Thr (termed "Tn 
Antigen"). The Tn Antigen, and its sialic-acid linked form ("Sialyl-Tn Antigen"), are 
rarely expressed as final glycan architectures in normal tissues, yet they have been 
identified in several tumor types(63,72). In a manner similar to N-glycans, the O-GalNAc 
glycans may be extended (core structures 1-4 and 6 only) with repeating units of GlcNAc 
and galactose, producing poly-LacNAc. This again allows terminal sugars such as fucose, 
sialic acid, galatcose, and GlcNAc to protrude for roles in cell-environment interaction. 




the expression/activity, distribution/order, and acceptor specificities of GTs and substrate 
availability(71). Importantly, these factors may be modified in different biological 
contexts, such as pathological conditions, and in response to external stimuli such as 
growth factors/cytokines.  
 The biological roles for the O-GalNAc glycosylation often overlap with those of 
N-glycans. For example, these molecules may impact cell-cell and cell-matrix interaction 
through protein conformation effects or by acting as ligands themselves. The importance 
of O-glycosylation in cell adhesion is exemplified by the Lewis blood group 
determinants(73). These molecules are fucosylated extended core O-glycans presented on 
cell membrane-based proteins which may undergo further modification by the addition of 
sialic acid. A vital role for the sialylated epitopes has been demonstrated in selectin-
mediated adhesion, where they serve as ligands for leukocyte homing and extravasation 
during inflammation/tissue injury(51). Since the elucidation of this function, subsequent 
roles for the altered expression of sialylated Lewis antigens have been identified in 
invasive forms of cancer. In addition to adhesion effects, these carbohydrate moieties 
may protect protein substrates from protease digestion, mask antigens, and affect cell 
receptor turnover rates. Outside of the cell, secreted O-glycoproteins induce the 
formation of a protective barrier from pathogenic organisms for epithelial cell 
populations. This layer of mucinous glycans is composed of negatively charged sugars 
(sialic acid) which induce the formation of a hydration layer along luminal surfaces(74). 
A critical role for O-glycosylation in differentiation and development has also been 
observed through studies using Drosophila melanogaster. These investigations exposed 




junction formation during organogenesis(50).  As well, this work showed that efficient O-
glycosylation is required for the secretion of vital ECM and basement membrane 
components during development. Furthermore, transgenic murine models deficient in 
specific core-extending GTs present with embryonic-lethal phenotypes due to ineffective 
cell adhesion in vasculature development(50).  
1.3.3 Sialic Acid  
N-acetylneuraminic acid (Neu5Ac or sialic acid) is a monosaccharide frequently 
found at the non-reducing terminus of N-glycans and may occur as an intermediate or 
terminal sugar in O-glycans. The molecule is a nine carbon, acidic α-keto sugar which is 
produced by metabolic conversion of N-acetylmannosamine (ManNAc) or from glycan 
salvage pathways(75).  Neu5Ac is activated as a substrate for glycan linkage by reaction 
with the nucleotide donor CMP in the nucleus. The high energy donor molecule is 
transported to the cytoplasm and eventually to the Golgi, where its addition to acceptor 
glycan substrates are carried out by members of the sialyltransferase family(76). This 
group of enzymes exhibits remarkable specificity in linkage conformation and acceptor 
substrates; they may as well be sensitive to chemical modifications occurring on the 
donor sugar. Neu5Ac may be linked to other sugars (or itself) through three different 
anomeric configurations, with each linkage the result of specific sialyltransferases(76,77). 
The α2-3 and α2-6 linkages are found in both N- and O-glycans, where sialic acid is 
added on terminal galactose or GalNAc residues. Glycans bearing α2-3 linked sialic acid 
may act as substrates for the addition of other sugars on interior residues or inhibit further 
chain elongation(73). α2-6 configurations have additionally been identified in linkages to 




monosaccharides(73,78). This type of bond generally hinders supplementary sugar 
extensions, with a notable exception being the addition of α2-8 linked sialic acid. The 
final connection, α2-8, is initiated on α2-3 or α2-6 linked sialic acid for the production of 
polymeric chains of the sugar composed of up to 200 residues. The product of this 
linkage, polysialic acid (PSA), is rarely found outside of the biological process of 
embryogenesis or in neuronal development; however, one α2-8 sialyltransferase, ST8Sia-
IV, is expressed in various tissues through adulthood(73,79). Sialic acid residues can be 
found in any tissue where O- and N-glycans are produced, however tissue-specific 
expression of certain sialyltransferases may limit the types of attachments present at a 
given site. The general biological properties influenced through sialic acid attachments 
are related to the electronegative charge of this sugar at physiological pH(76). At the 
cellular level, the charge state of Neu5Ac impacts protein conformation, which in turn 
regulates protein-protein interaction, receptor-ligand affinity and protein turnover.  Sialic 
acid may also facilitate binding of glycan epitopes to lectins or even mask antigenic 
sequences from recognition. In a broad sense, the chemical attributes of this sugar affect 
cell-environment interactions through its distribution on both cell-membrane and ECM 
glycoprotein populations. Altered states of sialic acid biosynthesis and degradation are as 
well implicated in pathological conditions. The inborn errors of metabolism, as well as 
neurological disorders such as Parkinson's disease, Schizophrenia, and Alzheimer's 
disease, are all hypothesized to be impacted by sialylation(75,76). Furthermore, a general 
increase cell-surface sialylation and a shift toward production of α2-6 linkages are 
frequently observed on transformed cells and several lines of evidence suggest a role for 




1.3.4 Glycosylation Alterations in Cancer  
 Aberrant glycosylation on cell-membrane and secreted glycoproteins is 
inherently tied to the progression of carcinoma. Alterations in the abundance, structure, 
and sites of glycosylation contribute to the acquisition of invasive phenotypes through 
effects on cell-cell adhesion, cytoskeletal dynamics, and extracellular matrix 
properties(53,63,78,84,85). Cancer cells acquire the ability to produce a selected subset 
of glycans configurations, including incomplete/truncated structures, changes in N-glycan 
branching patterns, and the altered presentation/secretion of mucins. In addition, 
increased sialylation, fucosylation, and the reappearance of embryonic-associated glycan 
structures (oncofetal antigens) are correlated with poor prognoses in several different 
cancers(63,86–89). 
  β1-6 branching on the core structure of N-glycans, catalyzed by the enzyme GnT-
V, produces a scaffold upon which other sugars may be added for the production 
complex tetra-antennary oligosaccharides. While this process is a normal part of the N-
glycan biosynthetic pathway, transformed cells often exploit this mechanism to over-
produce these "bulky" molecules on cell surface-associated proteins. Hypotheses on how 
neoplastic cells carry out this function include direct transcriptional regulation of the gene 
MGAT5 during carcinogenesis. This gene, which codes for the GnT-V 
glycosyltransferase, contains 5' promoter region sequences which may be functionally 
regulated by downstream effectors of common cancer-cell signaling pathways including 
V-Src, Her-2, and H-Ras(63,85). In addition, TGFβ1 has been shown to increase the 
stability of MGAT5 transcripts in melanoma cells, although the mechanism for this effect 




oligosaccharide groups may be attached on proteins including integrins, cadherins, 
cytokine/growth factor receptors, and other classes of membrane-bound 
glycoproteins(52).  The biological consequence for the over-production of these 
structures varies with the function of the underlying protein. For example, increased β1-6 
branching on E-cadherin in a mouse mammary tumor model resulted in decreased 
homotypic interaction of the cell-cell adhesion proteins(91). The molecular rationale for 
these observations is most likely increased turnover of E-cadherin from the cell 
membrane and/or decreased protein-protein interaction conferred from the steric effects 
on the underlying protein. Alternatively, increased branching of N-glycans attached on 
cytokine receptors, like EGFR and TGFβR, has been shown to reduce endocytosis of 
these molecules from the cell membrane(92,93). This outcome is hypothesized to be 
carried out by the stabilization of these receptors at the cell surface through lattice 
formation via increased interaction of these molecules with galectin-3; allowing 
continued signaling through these pathways. Interestingly, this specific example 
highlights a potential positive feedback mechanism to amplify cell programs for invasive 
phenotypes, granted the stabilizing effect of TGFβ1 on MGAT5 transcripts discussed 
previously. The α5β1 integrin, a receptor for fibronectin, is a heavily N-glycosylated 
membrane-bound protein integral to cell-cell and cell-ECM interactions. Guo et al. 
elegantly demonstrated that the over-expression of GnT-V in fibrosarcoma cells resulted 
in increased β1-6 branching of the β1 subunit of this cell adhesion protein(85). The 
authors established that through this mechanism cells were able to decrease attachment to 
fibronectin and increase migration/invasion. Furthermore, this group showed that 




these phenotypes and restored attachment to fibronectin. The glycosyltransferase GnT-III 
is responsible for adding a β1-4 linked GlcNAc moiety to the central mannose residue of 
core GlcNAc N-glycan structures. The addition of this "bisecting GlcNAc" prevents 
complex glycan formation by blocking the action of downstream core trimming enzymes. 
Studies using various models of cancer have identified paradoxical roles for the GnT-III 
catalyzed product associated with metastatic phenotypes. For example, GnT-III 
expression and the presence of increased bisecting GlcNAc in ovarian cancer and 
hepatocellular carcinoma were able to differentiate tumor from adjacent normal tissue 
and were associated with higher rates of metastasis in these models, respectively(94,95). 
However in mouse models of melanoma, the overexpression of GnT-III resulted in a 
decrease of β1-6 branching and correlated with less-aggressive tumor phenotypes(96,97).  
 The production of truncated or incomplete O-glycan structures are another feature 
associated with cancer-induced glycosylation changes. The normal biosynthesis of O-
glycans begins with the attachment of GalNAc to Ser/Thr residues on polypeptides as 
they progress through the secretory pathway. Further sugar extensions are typically added 
to produce core and extended core O-glycans structures; which may be further modified 
by capping sugars such as sialic acid and/or fucose. Shorter, intermediate O-glycan 
architectures, such as the T and Tn antigens and their sialyated forms (sT and sTn), are 
almost exclusively expressed in association with pathologies such as cancer(63,84).  
These types of structures are often ubiquitously attached on various membrane-associated 
protein populations and therefore described as a generalized phenomenon rather than an 
effect on specific proteins. The Tn antigen (GalNAc-Ser/Thr) is considered a pan-




This particular glycan epitope may be found on both membrane-associated and 
extracellular (luminal) proteins during carcinogenesis and is correlated to poor outcomes 
in multiple cancer types. Several mechanistic theories have been formed to explain the 
production of this biosynthetic intermediate. Following the addition of GalNAc to 
Ser/Thr by ppGalNAcT, the resulting Tn antigen may be extended by either T-synthase 
or C3GnT for the production of core-1 or core-3 structures, respectively. T-synthase is a 
widely expressed enzyme that requires the chaperone protein COSMC for appropriate 
Golgi localization and full catalytic activity(71,99). Reports using various models of 
cancer show that the loss of T-synthase or C3GnT activity, as well as COSMC mutation 
and epigenetic silencing, provide a means for accomplishing the overproduction of Tn 
antigen during tumor progression(100,101)). Unlike the Tn antigen, the sialylated form of 
this epitope (sTn) does not serve as a precursor in the construction of other O-glycan 
configurations(71). sTn is produced by the action of ST6GalNAc-1 within the Golgi, 
where this enzyme catalyzes the α2-6 linkage of Neu5Ac to the initiating GalNAc 
carbohydrate. sTn expression is thought to occur as a byproduct of increased Tn 
production through the same mechanisms described above, because both epitopes are 
often identified in parallel. Investigations into alternative pathways for its accumulation, 
such as the over-expression or increased activity of ST6GalNAc-1, demonstrate mixed 
results as a means to accomplish this outcome(102–104). The T antigen ("core-1") is 
composed of a galactose molecule attached to the GalNAc residue of the Tn antigen 
(Galβ1-3GalNAc-Ser/Thr). Fates of the T antigen in normal O-glycan processing include 
GlcNAc addition for core-2 production and/or the attachment of Neu5Ac for mono-/di- 




various epithelial-based tumors, usually in association Tn and sTn epitopes. However, 
difficulty in differentiating T antigens from similar glycan attachments on lipid substrates 
has hindered efforts to define the prognostic significance of these molecules in cancer 
progression(72). The functional relevance for the production of these incomplete O-
glycan structures in cancer is evidenced by their roles in immune detection and cell 
adhesion. Ogata et al. established that tumor cells are able to evade natural killer cell 
induced lysis through the production of sTn antigens(105). In addition, others have 
shown that these glycan structures may inhibit interaction with cytotoxic T-lymphocytes 
and prevent the accumulation of antigen-presenting cells in the tumor 
microenvironment(106,107). A potential role for these molecules affecting cell adhesion 
properties has been demonstrated using prostate and breast cancer cell lines. Glinsky et 
al. showed a critical requirement for T antigen-mediated binding to galectin-3 on 
endothelial cells as a potential means of promoting metastasis(108).  Another study 
showed that pancreatic cancer cells genetically modified to over-produce Tn antigens 
manifest with enhanced growth, migration, and invasive capabilities relative to controls. 
In this particular study, a knockout model of the COSMC chaperone incited these 
phenotypes which were reversed upon its re-expression(100). Studies targeting the 
expression of sTn have identified it on adhesion-related proteins such as CD44, integrin 
β1, Muc1, and osteopontin; where its presence is correlated with increased metastatic 
potential(78). However, a few conflicting reports exist regarding these substrates and this 
trend between different models of cancer(109,110). Clarification of the functional 
mechanisms and substrate specificity for sTn attachment is therefore of great interest 




 The increased production of the sialyl LewisX antigen (SLex) by tumor cells also 
contributes to attainment of invasive characteristics. The SLex motif, a tetrasaccharide 
structure defined by α1-3 fucose linked to GlcNAc and α2-3Neu5Ac to galactose, 
functions as a ligand for selectin-mediated cell adhesion during inflammatory 
responses(111). The epitope is expressed at low-levels on N- and O-linked glycans for 
non-transformed epithelial cells. However a generalized increase in the abundance of 
these structures, typically on O-GalNAc glycans, has been noted for several carcinomas 
with aggressive phenotypes. Hypotheses on how cancer cells gain a selective advantage 
for metastasis through this alteration are based on its function as a ligand for P-, L-, and 
E-selectin(63,73,78,84). Specifically, SLex/selectin interaction is thought to promote 
aggregate formation of tumor cells with leukocytes and platelets in the blood stream, 
facilitating interactions with activated endothelium and decreasing the likelihood of 
immune detection(63,112). The mechanistic-underpinnings of SLex over-expression may 
be rooted in dysregulated signaling from the inflammatory tumor microenvironment or 
the incomplete synthesis of more complex structures. From a molecular perspective, 
alterations in sialyltransferase/fucosyltransferase expression, epigenetic modification of 
genes required for further processing of these structures, and possible contributions from 
hypoxia-regulated pathways are all implicated in cancer-associated SLex 
production(6,111,113).   
Finally, transformed cells may alter the topology of mucins and display a 
generalized increase in cell-surface sialylation during cancer progression. Mucin 
1(MUC1) is an integral membrane glycoprotein bearing both O- and N-linked glycans, 




which greatly outnumber N-linked, are typically configured as core-2 structures that are 
extended and capped with fucose and sialic acid. These extended configurations mediate 
an essential function of MUC1 on non-transformed epithelial cells: they provide high-
levels of negative charges which allow for the formation of a gel-like, protective barrier 
on the luminal surface of secretory tissue(69,74). Transformed cells may exploit O-
glycosylation biosynthetic machinery for the preferential production of incomplete or 
over-sialylated structures on MUC1. For example, breast cancer cell-derived MUC1 has 
been identified carrying T-antigen or sialylated Lewis structures rather than extended 
core-2 O-glycans(114). As a result of altered glycosylation, MUC1 may be 
inappropriately internalized and redistributed on basal cell surfaces where its charge state 
may influence cell adhesion(74,115,116). Additionally, hypo-glycosylated forms of 
MUC1 are suspected to allow increased access of extracellular proteases to the 
underlying peptide structure, resulting in liberation of the N-terminus to systemic 
circulation. This observation, which is also noted in states of inflammation, led to the 
development of a breast and pancreatic biomarker utilized in monitoring cancer treatment 
regimens (CA15-3)(117,118). Interestingly,  the shedding of N-terminal MUC1 is 
thought to leave a remnant C-terminal peptide protruding from the cell membrane, which 
some studies suggest may propagate a signaling mechanism promoting stemness(119).   
1.3.5 Sialic Acid in Cancer 
 Including, but not limited to, the expression of specific O-glycan sialylated 
structures (sT, sTn, SLe), is the observation that aggressive tumors often present with 
global increases in cell-surface sialylation. Early studies targeting the properties of 




binding to transformed models. Subsequent investigations aimed at clarifying a role for 
up-regulated Neu5Ac demonstrated that induced deficiency in its expression at the cell-
surface decreased invasive characteristics and returned cells to normal growth 
dynamics(63,76,78). Further probing into this phenomenon identified alterations in 
sialyltransferases and sialidases which utilize N- and O-linked glycans, as well as lipids, 
as substrates(81). Furthermore, an apparent tendency for tumor cell glycoconjugates to 
carry sialic acid in a α2-6 linkage-dependent manner was observed(78). Hypotheses 
formed to explain the rationale for increased sialylation highlight the potential 
implications of this molecule on several biological processes, including: cell adhesion, 
receptor-ligand interactions, masking of glycan epitopes, and retention time of molecules 
at the cell surface(76,78,81). Specifically, these biological roles for sialic acid are thought 
to be conferred from the chemical nature of the molecule; at physiological pH, Neu5Ac 
carries a negative charge and may therefore mediate charge repulsion and/or influence 
protein conformation. Mechanistic research has provided insights into cancer-pathway 
regulation of sialic-acid modifying enzymes which may be partially responsible for its 
increased abundance. For example, the RAS oncogene has been shown to induce the 
expression of the sialyltransferase ST6Gal-I in a cell model of colon cancer(78,120). 
Other efforts demonstrate the feasibility for sialidase down-regulation in the propagation 
of invasive phenotypes. Uemura et al. used a transgenic model of colon cancer, capable 
of either NEU1 over-expression or knock-down, to show that there was an inverse 
relationship between sialidase levels and invasive properties(121). The identification of 
differentially regulated enzymes may also explain the inclination of tumor cells to 




attachment is evident as a means for decreased binding of extracellular glycan-binding 
proteins, such as galectins, to cell-surface glycoproteins bearing sialic acid in this 
configuration. Integrin β1, for example, is a specific target for the α2-6 sialic acid linkage 
in cancer progression(120,122). Importantly, this cell adhesion receptor connects binding 
to the ECM with cytoskeletal elements through various heterodimeric interactions with 
other integrin subunits. In addition, the integrin molecules mediate vital intercellular 
signaling pathways that help cells respond dynamically to alterations in binding states. 
Multiple studies have highlighted differential glycosylation of the integrins occurring in 
parallel with altered biological scenarios, including pathological states(123,124). 
However, only recently have these changes been tied to specific outcomes, such as the 
modified binding affinity for extracellular substrates by integrin heterodimers containing 
Neu5Ac α2-6 linked to β1 subunits(120,125–128). Other observed changes in sialic acid 
dynamics, associated with aggressive phenotypes, include the appearance of N-
glycolyneuraminic acid (Neu5Gc) and polysialic acid chains. Neu5Gc is a variant form of 
sialic acid in which the acetyl group on C5 of Neu5Ac is hydroxylated. This sub-type of 
sialic acid is not synthesized by humans due to homozygous loss of the gene responsible 
for the conversion of Neu5Ac to Neu5Gc; however it is produced by other mammalian 
species(76). Early observations indicating the presence of this structure in humans during 
embryogenesis and carcinogenesis led to hypotheses regarding a specific role for this 
molecule as an oncofetal antigen. However, further investigation indicated the presence 
of low-levels of anti-Neu5Gc antibodies in adults without any pathology(129). 
Subsequent studies showed that humans are capable of incorporating Neu5Gc into 




theories suggest that Neu5Gc is detected at higher levels during malignancy due to 
dietary intake of animal products in conjunction with the altered sialylation profiles these 
cells commonly exhibit. As a consequence, reactivity of endogenous antibodies to 
increased Neu5Gc epitopes could promote chronic inflammation and thereby serve to 
propagate tumor progression(82). Polysialic acid is a negatively charged linear chain of 
α2-8 linked sialic acid residues normally restricted to expression on select proteins in 
neural and immune cell populations. The structure may be linked to N- or O- glycans and 
is thought to influence biological functions through charge repulsion due to its poly-
anionic nature. For example, during brain development the addition of these large 
polymers on NCAM and SynCAM1 mediate neurite outgrowth and synapse formation 
through inhibition of homophilic interactions between adjacent cells(79). PSA synthesis 
is a highly regulated process, with temporal and cell-specific expression mediated 
through the dynamic regulation of the polysialyltransferases ST8Sia-II and ST8Sia-
IV(130). Under normal circumstances, brain PSA levels are down-regulated following 
specific developmental cues, leaving the PTM only in areas critical to neural plasticity. 
Outside of the brain, an additional role for PSA in dendritic cell chemotaxis has recently 
been resolved(131). The presence of PSA on tumor cell NCAM of has been detected in 
several forms of aggressive disease, including small and non-small cell carcinomas, 
pituitary tumors, neuroblastoma, and Wilms tumor(130,132–135). Hypotheses formed to 
explain why tumor cells might express PSA are primarily based on the monosaccharides 
ability to interrupt cell adhesive processes. Subsequent examinations into the relationship 
between PSA and cancer progression have revealed correlations between 




tumors of neuroendocrine origin(132,134). Furthermore, inhibition of 
polysialyltransferase activity was demonstrated as a feasible approach to decrease 
migratory capabilities in some tumor models(136).  
1.3.6 Introduction to Glycoprotein Cancer Biomarkers 
The mechanisms by which tumor cells manipulate glycosylation pathways for the 
production of specific structures are an area of intense research. Recent studies have tied 
transcriptional regulation and epigenetic modification of fundamental glycogenes to 
commonly dysregulated cancer-signaling networks; yet, much remains to be elucidated in 
this realm(45,120). In the past, the functional redundancy of the glycosyltransferases was 
a key roadblock to dissecting how specific genetic programs could be modified for 
altered glycosylation. However, progress is being made through the production of highly 
specific transgenic cancer cell models, capable of over-expression or knockdown of 
specific glycan-related enzymes in combination with various oncogenic drivers. 
Additional efforts are focused on defining the biological consequences of altered 
glycosylation on specific protein targets. Importantly, it should be considered that some 
cancer-specific glycan structures are likely a "side-effect" of carcinogenesis and may not 
have functional relevance. Regardless, elucidation of the mechanisms and outcomes of 
dysregulated glycosylation will likely have implications for the identification of 
potentially targetable pathways for therapeutic intervention. Integral to these functional 
investigations are continued efforts to catalog cancer-specific protein glycoforms. This 
research is significant for diagnostic/prognostic stratification and will likely feedback to 
provide insights into mechanistic/functional research. Several cancer biomarkers in use 




CA-125(137). As well, therapeutic strategies based on the antigenic-properties of cancer-
specific glycan epitopes have resulted in the production of anti-cancer vaccines(51). In 
light of newer research methods and technologies, capable of detailed characterization of 
complex oligosaccharides and their carriers, a resurgence of interest in identifying 
cancer-associated glycoforms as putative biomarkers has emerged.  
1.3.7 Current Glycoprotein Cancer Biomarkers 
 MUC1, as discussed  in section 1.3.4, is a transmembrane glycoprotein highly 
decorated with core-2 O-glycans capped with sialic-acid or fucose. In non-pathological 
states, MUC1 carries out an essential function in glandular tissues by facilitating the 
production of a mucinous layer for protection and lubrication of underlying epithelial 
cells. Observations that MUC1 was alternatively glycosylated and could be detected in 
circulation during inflammation/cancer initiated investigations into its clinical utility as a 
biomarker. As a result, assays were developed for the quantification of the shed portion 
of extracellular MUC1, which was termed Carbohydrate Antigen 15-3 (CA15-3)(118). 
The relevance of CA15-3 as a prognostic indicator is exemplified by the increased 
circulating levels of the molecule typically associated with the progression of various 
adenocarcinomas(138–141). For example, following surgical or chemotherapeutic 
intervention of breast cancer, rising levels of CA15-3 may indicate the presence of 
otherwise undetected micro-metastases(118,142). Unfortunately in this particular case, 
earlier detection of disease recurrence does not translate into delayed time to progression 
or improvements in quality of life for these patients. Therefore the recommendations for 
use of CA15-3 in breast cancer prognosis is limited to monitoring therapy in advanced 




 The identification of specific glycan epitopes have also been utilized in 
development of biomarker assays. For example, the detection of glycolipids or 
glycoproteins carrying sialylated-Lewisa structures (SLea) may be of prognostic value in 
advanced gastric, colorectal, and pancreatic adenocarcinomas(143–145). SLea is a 
structural isomer of the SLex pentasaccharide whose production may be favored during 
carcinogenesis due to inefficient production of extended core O-glycans(111). The SLea 
epitope, also termed CA19-9, was first evaluated for use as a biomarker in colon cancer 
following the production of cancer-specific monoclonal antibodies in the 1970’s(146). 
Since that time, clinical utility for CA19-9 has perhaps been most well defined for 
pancreatic cancer; where it may be used in diagnostic and/or prognostic criteria, 
evaluation of therapy response, or in predicting recurrence. In reference to the diagnosis 
of pancreatic cancer, a comprehensive review by Ballehaninna and Chamberlain indicates 
values for the sensitivity and specificity of CA19-9 as 79-81% and 82-90% (respectively) 
in symptomatic patients(144). Low positive-predictive values generated in these studies 
were alleviated by incorporating imaging studies for targeted evaluation of patients 
presenting with pancreatic masses(147). In addition, pre-operative CA19-9 levels have 
been shown to correlate with pathological grade which may be useful for predicting 
resectable disease(148,149). Furthermore, several studies have evaluated CA19-9 use in 
pre- and post-operative prognostic stratification. Although multiple experimental designs 
were employed and variations in CA19-9 values became evident, these studies 
overwhelmingly support the use of this biomarker as an independent predictive value for 
survival(150–152). Despite the applicability of this biomarker in several clinical contexts, 




the potential for false positives preclude the use of CA19-9 as a stand-alone parameter for 
the diagnosis of pancreatic cancer in non-symptomatic patients. Several non-cancerous 
conditions, including chronic pancreatitis, gall bladder-related disease, and diverticulitis, 
may result in elevated levels of CA19-9(147,153). In addition, approximately 5-10% of 
the population are incapable of producing SLea epitopes due to genetic variation affecting 
the production of an enzyme critical for its synthesis(73,144). Therefore, there is a wide 
range of applications for CA19-9 testing in pancreatic cancer, however the potential for 
false positives/negatives limit the information it provides and require guarded use in a 
clinical setting.  
 CA125, or Mucin16, is the most thoroughly explored biomarker for ovarian 
cancer. The molecule was first identified in the 1980's from a highly aggressive model of 
ovarian cancer using a monoclonal antibody(154). Subsequent investigations into the 
binding specificity of the Ab revealed targeting against the tandem repeat core of Muc16; 
in an area of heavy O-glycosylation similar to MUC1. Further development of antibodies 
to this peptide region resulted in the production of commercial assays for the 
quantification of CA125, which in turn facilitated research into its utility as a serum 
biomarker. Since that time, CA125 has been extensively studied in the contexts of serous-
tissue based cancers, including lung and gastrointestinal; however current applications 
are most well defined for ovarian cancer. For this disease, examinations of CA125 levels 
in screening/early diagnosis indicate a positive correlation between biomarker levels and 
advanced disease state(155). However, as with CA19-9, clinicians are cautioned against 
using CA125 as a single entity for diagnosis in non-symptomatic patients due to low 




combinatorial approaches which integrate other biomarkers and imaging approaches, as 
well as longitudinal surveillance of CA125 levels(142,155,156). Another utilization of 
CA125 is in the stratification of post-menopausal women presenting with pelvic masses.  
For this patient population, increasing levels of the biomarker, in conjunction with other 
clinical criteria, may indicate the presence of malignant disease(142). However, the 
potential for false positives due to benign fluctuations of CA125 during 
ovulation/menstruation prevents its application to the pre-menopausal 
population(157,158). In addition, non-cancerous pathological conditions such as liver 
disease, inflammatory conditions, or even recent surgery may affect CA125 abundance in 
circulation. Relevance to monitoring therapeutic response and detection of recurrent 
disease have also been investigated and are currently accepted in clinical 
practice(142,157). Serial measurements of CA125 before, during, and after chemotherapy 
may be used in treatment decisions as a factor indicating the efficacy of response. For 
example, a decrease in 50% or more of pre-treatment levels for 28 days or greater is 
considered a positive indicator for therapeutic efficacy(159,160). Additionally, elevated 
levels of CA125 following treatment may predict relapse and help guide appropriate 
intervention. Finally, prognostic significance of CA125 in ovarian cancer, as an 
independent indicator, has demonstrated utility in predicting outcomes following 
surgical/therapeutic intervention. In this context, both the rate of change of CA125 levels 
and the amount of time the changes are observed for appear to correlate with trends in 
overall survival(142,157).  
 Alpha-Fetoprotein (AFP), a 70kDa N-linked glycoprotein, has been extensively 




contexts AFP is synthesized by the fetal liver and is detectable in maternal circulation 
during pregnancy. Following birth, AFP levels drop dramatically in both the infant and 
the mother and remain within a precise range in the absence of pathological 
circumstances. The biological functions of the molecule, while still under investigation, 
are hypothesized to be similar to that of albumin for fetal circulation(161). Observations 
that increased AFP levels are associated with hepatic pathologies in adults were first 
noted more than 50 years ago, prompting investigations into the clinical utility for 
monitoring. Initial examinations demonstrated promising results as elevated AFP levels 
tend to correlate well with larger liver tumors (>2cm). However upon continued 
evaluation, it was  revealed that fluctuations in serum AFP were also occurring due to 
benign liver disorders(hepatitis, cirrhosis) and a low sensitivity for early-stage tumors 
(<2cm) also became evident. Therefore the quantification of AFP in serum for HCC 
surveillance was hindered by the potential for false positives due to chronic liver disease 
and false negatives due to inconsistent AFP elevation with small tumors(161,162). In the 
1990's, glycoproteomic evaluations of AFP's single N-linked glycan, using lectin affinity 
methods, discerned differential binding of the molecule between alternative disease 
states(163). This data supported the hypothesis that differential glycan structures were 
preferentially attached to AFP in various pathological contexts. Ensuing investigations 
focused on quantification of a “cancer-specific” AFP glycoform (AFP-L3), in 
combination with total AFP and other biomarkers, resulting in modest increases in 
sensitivity for detecting early HCC(161). Current diagnostic applications of AFP utilize 
the biomarker as an adjunct to imaging-based methods for surveillance of patient 




monitoring in post-surgical/therapeutic contexts as well as an indicator for recurrence of 
undetected disease(161,164). 
The advantage of monitoring glycoproteins as disease biomarkers is rooted in the 
nature of these molecules to dynamically respond to changes in physiological states. In 
addition, their inherent biosynthesis along the secretory pathway provides a convenient 
route for collection (e.g. serum/secreted fluids). Current biomarker assays primarily focus 
on assessing quantitative changes in the underlying substrate rather than directly 
accounting for alterations in the glycans they carry. While this approach has 
demonstrated value, it often fails to achieve levels of sensitivity and specificity required 
for confident clinical use(89,137). To overcome these limitations, efforts have been set 
forth to re-focus biomarker discovery research towards the elucidation of site-specific 
and structural glycan changes that accompany pathogenesis. A recent increase in 
analytical technologies available for glycoproteomic analyses, now capable of detailed 
characterization of the underlying peptide, glycosylation sites, and glycan compositions, 
has facilitated a renewed vigor in this type of approach. For example, newer mass 
spectrometry (MS) platforms and data-acquisition strategies provide a highly-sensitive 
method for global and protein-specific characterization of disease associated 
glycosylation changes. These innovative MS-based analyses provide a means for high-
throughput, confident identification of peptides, glycans, and/or glycopeptides from 
samples stemming from minute amounts of complex starting materials. Together with 
advances in separation chemistry, enrichment/affinity/labeling techniques, and the 
development of bioinformatic glycan databases, detailed characterization of 




1.4 Mass Spectrometry Methods for Glycoproteomics 
1.4.1 Introduction to MS-based Glycoproteomics 
Mass spectrometry based proteomic and glycoproteomic evaluations are integral to 
discovery phase biomarker research for several reasons. First, this approach allows for 
the characterization of either intact proteins or peptides, enriched or in complex mixtures, 
from a host of starting materials. A variety of MS instruments are available, each suited 
to specific applications, which may be combined with up-front techniques for 
optimization of experimental parameters. Modern platforms are capable of providing 
comprehensive qualitative and quantitative data as well as information on post-
translational modifications and protein-protein interactions(165). In addition, decreased 
turn-around-time and moderate up-front sample preparation make this methodology well-
suited for discovery-phase efforts. Previous approaches to glycoproteomics, such as 2D 
gels or lectin microarrays, failed to achieve the depth of coverage or sensitivity inherent 
to current MS systems(165). Furthermore, older MS technologies lacked the ionization 
efficiency and mass accuracy required to make high confidence identifications of glycan 
species. Newer, hybrid-type mass spectrometers, like the OrbiTrap, are capable of 
providing detailed glycan structural (anomeric linkages, branching patterns) and site 
specific information, as well as evaluating the underlying peptide backbone(166–168). In 
addition, modern ionization and fragmentation strategies out-perform previous methods 
in producing glycan fragment ions amenable to high-resolution characterization. Further 
supporting the use of MS for glycoproteomic applications are an abundance of options 
for enrichment, chemical derivatization, and chromatographic separations prior to 




likelihood for successful analysis by reducing sample complexity and/or modifying 
glycan structures so that they can be more efficiently analyzed. Several variations in MS 
workflows have been described, often involving different combinations of sample 
preparation, MS acquisition (ionization techniques, fragmentation strategies, various 
mass analyzers), and data processing(166,169–175)). Each unique configuration has 
distinct advantages and disadvantages for glycoproteomic analysis and therefore should 
be carefully considered during experimental design.  
1.4.2 Enrichment Strategies for Glycoproteomics  
One of the greatest challenges in MS-based glycoproteomics is derived from the 
fact that proteins are not equally distributed in biological fluids. This observation, known 
as the “dynamic range problem”, describes how a limited number of proteins dominate 
the proteome of secreted matrices such as serum. This may result in the inability to 
effectively characterize low-abundance proteins, such as those carrying PTMs, unless 
pre-fractionation of the starting material is carried out(176,177). Several strategies exist 
for the enrichment of glycoconjugates prior to MS analysis, typically targeting the 
chemical properties of the carbohydrate moieties as a means to selective isolate these 
molecules. These methods have been optimized for both bottom up (glycopeptides) or 
top-down (glycoproteins) approaches, allowing increased flexibility in experimental 
design. For example, lectin affinity, hydrazide chemistry, titanium dioxide (TiO2) and 
hydrophilic interaction liquid chromatography (HILIC) are all feasible means to 
accomplish this end.  
Lectin affinity enrichment is based on the innate ability of these plant and animal-




To date, over 150 lectins have been characterized with results demonstrating both broad 
and narrow-spectrum specificity for different glycoforms(178). For example, 
concanavalin A (con A) targets oligomannose structures, inferring a broad specificity of 
this lectin for N-glycans. Others, like Sambucus nigra (SNA) and L-phytohemagglutinin 
(L-PHA) are extremely specific in their preference for epitopes like sialic acid α2-6 
linked to terminal galactose and β1,6 branched N-glycans, respectively(176). Lectins may 
also be combined for use in one preparation to increase the robustness of initial screening 
efforts. Alternatively, sequential lectin affinity enrichments may be of value if a 
particular glycan species is of interest. Important considerations for this strategy include 
the experimental conditions (pH, metal co-factors) and appropriate elution strategies 
(competing sugars, ↓pH, glycosidases) for optimal results.  
Hydrazide chemistry is another means to accomplish selective isolation of 
glycosylated substrates from complex starting materials. This procedure, often carried out 
in a solid-phase extraction format (SPE), relies on the chemical conversion of 
monosaccharide cis-diol functionalities to aldehydes, which then react with hydrazide 
groups on an immobilized support(14).  Following the covalent linkage glycans to the 
hydrazide resin, glycosidase digestion is used to release glycan-carrier substrates for MS 
analysis. Although hydrazide approaches provide higher selectivity for isolating total 
glycan fractions relative to lectin affinity, there are a few inherent drawbacks to this 
method. Perhaps most obvious is the lack of information that downstream analysis can 
provide on glycan structure. Typical protocols use enzymatic digestion with Peptide-N-
glycosidase-F (PNGase-F) to liberate the proteins/peptides, leaving the glycans bound to 




at the initial GlcNAc linkage to asparagine (except where α1,3 fucose is linked), results 
in a detectable deamidation reaction at former sites of N-linked glycosylation (179). 
Therefore this approach has utility for identifying underlying carrier peptides and N-
linked glycosites. However, the lack of an equivalent glycosidase for releasing O-linked 
glycans and the irreversible chemical modification of oligosaccharide structure during the 
reaction limit the resourcefulness of this approach. Several reports have described the use 
of hydrazide chemistry in combination with other strategies, such as depletion of high 
abundance proteins, multiple protease digestions, and isotopic labeling methods, to 
successfully increase the range of information derived from single experiments(180–
183).  
Hydrophilic interaction chromatography (HILIC) exploits the polar nature of 
monosaccharide moieties for isolation of glycopeptides. This technique utilizes 
zwitterionic-based stationary phases which facilitate hydrogen bonding and electrostatic 
interactions with glycan moieties in the presence of organic solvents(184). Importantly, 
HILIC is amenable to downstream glycan structural analysis because no chemical 
alterations to the sugar structures are necessary for binding/elution(185). Subsequently 
this method may be used for glycomic, intact glycopeptide, and formerly-glycosylated 
peptide evaluations. As a drawback, a bias towards N-linked glycans may occur because 
of the nature of the molecules to be longer and more complex than O-glycans. 
Additionally, non-specific binding of peptides carrying hydrophilic amino acids, other 
polar biological molecules, or the presence of salt in sample preparations may reduce the 




The use porous graphitized carbon (PGC) for selective enrichment of glycosylated 
species also has demonstrated relevance for MS applications. This method is based on the 
interaction of hydrophilic glycopeptides with a crystalline carbon structure through 
adsorption and may be used for glycomic or intact glycopeptide analyses(186). Benefits 
of this technique include the ability to separate isomeric glycan structures, durability, and 
tolerance to mobile phase pH range fluctuations(168,186). Another enrichment approach 
targets the chemical nature of sialic acid-containing glycans for binding and isolation of 
carrier substrates. Titanium dioxide (TiO2) is an affinity strategy originally described for 
phosphoproteomic applications because of its ability to bind molecules with the 
characteristics of a Lewis base(187). The overall negative charge carried by sialic acid-
containing glycopeptides facilitates multi-point interaction with TiO2. Therefore the use 
of low pH mobile phases and pre-treatment of samples with broad-specificity 
phosphatases are important experimental considerations. Bound substrates are eluted with 
increasing concentrations alkaline solutions and may be directly interfaced for MS-
analysis. TiO2 chromatography is tolerant to the presence of salt and detergents in sample 
preparations and has been successfully combined with other enrichment methods for 
increased coverage of sialic-acid containing glycopeptides(188,189).  
1.4.3 Glycan Metabolic Labeling  
Glycan metabolic labeling strategies represent an alternative means to interrogate 
the glycoproteome for in vitro studies(190). These methods are typically based on the 
stable conjugation that occurs between azide and alkyne functional groups in the presence 
of copper(I) (“Click Chemistry”). For this type of experiment, cells are incubated with 




groups are small and biologically-inert, the modified sugars are incorporated onto nascent 
glycoproteins by normal biosynthetic pathways (Figure 1). Following labeling, selective 
enrichment/detection of modified glycoconjugates proceeds through reaction with 
exogenous substrates fixed with the reciprocal chemical group in the presence of copper. 
For example, azido-sugars may be reacted with alkynes bound to agarose beads, biotin-
conjugated materials, or various fluorophores. Accordingly, this technique has 
applications in MS-analysis, imaging, and flow cytometry(190). Several glycan precursor 
analogs, including GlcNAc, GalNAc, sialic acid, and fucose, are commercially available 
and an increasing number of studies have taken advantage of this technology to detect 
alterations in both N- and O- glycosylation(191–193).. This method is of particular utility 
in studies of secreted glycoproteins, making it highly suitable for efforts in biomarker 
discovery. For example, our group used the sialic acid analog (ManNAcAz) to 
successfully capture and quantify low-abundance glycoproteins in prostate cancer stromal 
cell secretomes. Remarkably, our approach maintained efficacy in MS analysis without 
the complete removal of serum protein supplements from the culture media(194).  
Similarly, Slade et al. profiled secreted glycoproteins using an azido-GalNAc analog for 
the detection of mucin type O-glycans stemming from CHO cell cultures(192). For MS-
based applications, metabolic labeling and affinity enrichment precludes detailed glycan 
structural elucidation because of the irreversible nature of the Click reaction. Therefore a 
typical proteomic workflow relies on proteolytic release (trypsin) of non-glycosylated 





















Further utility of this strategy by might be attained through the application a secondary 
digest, such as with PNGase-F, to release the bound glycopeptides for determination of 
potential N-linked glycosites(191). Newer developments in glycan metabolic labeling 
design include introduction of copper-free ligation techniques, which negates cytotoxicity 
and therefore may allow use of this method for in vivo studies(195).   
1.4.4 Strategies for MS-based Glycoproteomics   
The abundance of options to selectively isolate/separate glycosylated 
proteins/peptides has greatly facilitated progress in MS-based biomarker endeavors. 
These up-front preparations may be used as stand-alone entities or in combination, offline 
or directly-interfaced to MS instrumentation, and approaches may be modified to suit the 
experimental goal. Ultimately, these techniques reduce the complexity of biological 
samples and thereby allow for more focused MS evaluations of glycan/peptide structures. 
In parallel to these advances, are improvements to MS instrumentation and novel data 
acquisition strategies. Importantly, these breakthroughs overcome previous analytical 
limitations which hindered detailed, high-throughput characterization of intact 
glycopeptides.  
  Current approaches to MS-based global glycoproteomics generally follow the 
scheme of: glycoprotein enrichment→ enzymatic digestion of glycoproteins → 
chromatographic separation → MS analysis → bioinformatics. Depending on the 
available instruments and the experimental goal, one of two sample preparations is 
typically adopted: 1. Enzymatic/Chemical release of glycans from carrier peptides and 
separate MS acquisitions for each species (glycans and formerly glycosylated peptides) 




have favored the former because of difficulties in ionizing hydrophilic intact 
glycopeptides and inefficient detection of low m/z glycan fragment ions(196).  This 
separate analysis approach has resulted in the development of glycomic (i.e. glycan only) 
MS strategies for elucidation of monosaccharide compositions and linkage 
conformations. As well, the formerly glycosylated peptides  may be analyzed by 
traditional tandem mass spectrometry techniques (MS/MS) to determine amino acid 
sequence and localization of N-linked glycan sites. One of the major failures of the 
separate analysis design results from the lack of an equivalent enzyme to PNGase-F for 
the release O-glycans. Chemically-induced techniques, including β-elimination, 
trifluoromethansulfonic acid, and hydrazinolysis have been employed for this purpose, 
however low-specificity and irreversible modification to glycan/peptide structures impair 
characterization(171,178,197,198). In addition, chemical derivatization is almost always 
a necessity for glycomic analyses, adding additional time to sample preparation. The two 
major MS ionization strategies for glycomics, matrix-assisted laser desorption ionization 
(MALDI) and electrospray ionization (ESI), both benefit from derivatization methods 
such as permethylation. This process decreases the hydrophilicity of glycans entering the 
mass spectrometer, resulting in more efficient ionization and decreasing the chances for 
loss of labile substituents, such as sialic acid, from the oligosaccharides(175). At the 
same time, formerly-glycosylated peptide analysis suffers from the potential for false 
identification of N-linked glycan sites. The release of N-glycans by PNGase-F results in a 
deamidation reaction on Asn residues carrying the oligosaccharides, producing a mass 
shift of .9840Da. Although this change is easily detectable by MS, the potential for 




for glycosite assignment(199,200). Intact glycopeptide analysis is employed to 
simultaneously acquire information on glycan site/structure and peptide identification. 
Challenges to this type of MS approach owe principally to the differing chemical 
properties between the peptide and the attached glycan(s). This may result in preferential 
data acquisition of only one of the species or complicated mass spectra containing 
information derived from both types of molecules. In addition, complex mixtures of 
glycopeptides and non-glycosylated peptides may result in the suppression of signal from 
the analytes of interest. Subsequently, several of MS strategies have been instituted for 
intact glycopeptides, including combinations of MALDI or ESI-based ionizations, single-
stage or tandem MS ion fragmentations, and data acquisition with various mass 
analyzers(178,196). As well, bioinformatic platforms have evolved to keep pace with this 
type of experiment. For example, the development of glycomic and glycoproteomic data 
analysis softwares and curated databases containing information on N- and O- linked 
structures identified from various MS methods(201,202).  
 Of the available approaches for intact glycopeptide studies, tandem MS platforms 
are of particular utility because they allow for repeated cycles of precursor ion selection 
and fragmentation(178,203). This translates into efficient coverage of ion species 
representing the diversity of glycoforms present in biological samples. A general scheme 
for Tandem MS analysis begins with the ionization of molecules (“precursor ions”), 
followed by selection and fragmentation of precursor ions of interest (now called 
“product ions”) and finally the detection of mass to charge ratios (m/z). The resulting m/z 
can then be searched against databases of known values to identify various molecular 




application of various fragmentation techniques for intact glycopeptides is used to gain 
information on glycan structures or site localization/peptide sequences. For example, 
collision-induced dissociation (CID) is a relatively low-energy approach which tends to 
cleave labile glycosidic bonds. The production of glycan-based spectra, with low or no 
fragmentation of the underlying peptide structures, makes CID suitable for glycan 
structural information but not for glycosite or peptide identification(173,203). Alternative 
CID-based methods utilize the detection of glycan-specific product (oxonium) ions for 
the selective isolation and secondary evaluation of precursor molecules from which they 
were derived(167,173,203). For example, oxonium ions produced from a first round of 
CID may be used to trigger a second fragmentation to acquire complementary 
information on glycosylation site and peptide sequence. This type of approach requires 
instrument capabilities to detect low m/z diagnostic ions and therefore has previously 
been limited to triple quadrupole and quadrupole-time-of-flight (Q-TOF) type systems; 
which are not ideal for discovery phase efforts.  It should also be noted that the 
normalized collision energy used for CID approaches will influence the preferential 
dissociation of glycan and/or peptide structures and may therefore be modified to suit the 
experimental goal(173,203).  Electron transfer dissociation (ETD) and electron capture 
dissociation (ECD) are higher energy fragmentation methods which preferentially cleave 
peptide backbones, leaving glycan structures intact. These MS/MS modes produce 
ionization patterns distinct from CID, making them favorable for peptide sequencing and 
identifying glycosylation sites, rather than glycan structural information(178,196,203). 
ECD is often carried out on Fourier Transform Ion Cyclotron Resonance (FT-ICR)-type 




operate using similar molecular mechanisms and have utility for PTM localization studies 
including N- and O-glycosylation and phosphorylation(196,203). More recently, higher-
energy collisional dissociation (HCD) has been employed for intact glycopeptide 
analysis. This type of fragmentation is specific to OrbiTrap-type hybrid MS/MS systems 
and may be used to attain information on glycosylation sites as well as some glycan 
structural information(167,204). OrbiTrap mass spectrometers combine linear ion trap 
and Fourier transform mass analyzers for the production of high resolution/high mass 
accuracy measurements. Technological advances in these systems allow for the detection 
of low m/z glycan oxonium ions from HCD; which CID-based ion trap only instruments 
fail to achieve. On these instruments, data acquisition strategies implementing HCD 
combined with CID or ETD have been used to determine glycan structure, site, and 
peptide sequencing in a single run(167,204,205). For discovery phase efforts, hybrid 
instruments are preferable over triple-quadrupole instruments because they combine high 
trapping capacity for ions over a wide range of masses, low mass product ion detection, 
and high resolution accurate mass analyzers for confident identifications.    
1.4.5 Bioinformatics for Glycoproteomics  
Critical to the analytical advances facilitating MS glycomic and glycoproteomic 
investigations are developments in bioinformatic databases and software for interpreting 
this data. Various approaches to searching acquired mass spectra of peptide ions against 
known/theoretical values have been developed, each having distinct 
advantages/disadvantages. Proteomic databases, such as the UniProt Knowledgebase, 
contain information regarding amino acid sequences, PTMs, functional descriptions, and 




annotated (Swiss-Prot) or computationally-analyzed (TrEMBL) records of proteins 
stemming from multiple species. The application of search engine programs, such as 
Mascot or Sequest, facilitates comparison of experimentally-observed mass spectra 
against databases for the identification of peptides/proteins. However these search engine 
programs are limited in their ability to simultaneously consider multiple peptide 
modifications and have failed to keep pace with the high resolution type of data 
commonly acquired in modern MS systems(202). Advancements in search engine 
software for intact glycopeptide analysis have been made through the production of 
programs which consider multiple fragmentation strategies and data derived from high 
resolution/accurate mass systems. For example, Byonic™ software allows users to 
examine acquired spectra considering multiple or unexpected peptide modifications, as 
well as having a dedicated glycopeptide search function(202). Importantly, analyses may 
be set to consider data derived from multiple fragmentation strategies including HCD and 
ETD as well as allowing users to define monosaccharide masses or apply software-
included theoretical masses. In addition to the search engine innovations for MS-based 
glycoproteomics has been the development of glycan structural databases.   The 
Consortium for Functional Glycomics (CFG) contains a library of N- and O-linked 
oligosaccharide structures identified and validated from experimental observations. This 
public resource provides a platform for researchers to both query and submit data related 
to glycosyl transferase expression, glycan structures, protein-glycan interaction from 
various tissue and cell-based samples(201,206,207). The CFG glycan database be utilized 
to identify for glycan structures based on monosaccharide content, molecular weight 





Importantly, these options provide a means for interpreting data derived from various MS 









































The goal of this research project was to assess the application of novel 
glycoproteomic and glycomic workflows in experimental approaches useful for NSCLC 
biomarker discovery. These methods include: 1. Azido-sugar metabolic labeling, alkyne-
agarose bead enrichment and LC-MS/MS to identify proteins undergoing differential 
sialylation, 2. Sialic acid linkage-specific esterification and high-resolution mass 
spectrometry for glycan structural studies, and 3. MALDI-MS imaging of N-glycans in 
human lung tissue to both identify glycoforms and discern their spatial distribution.   
    The rationale for this work is seeded in the critical need for biomarkers to 
predict the disease course of NSCLC. Glycosylation is one of the most common post-
translational modifications  and has a well-established influence on the biological 
properties of glycoproteins associated with the acquisition of invasive phenotypes. 
Several lines of research suggest that altered glycosylation accompanies NSCLC 
progression and metastatic dissemination. In particular, glycans carrying sialic acid 
moieties are thought to contribute to the invasive properties of lung tumors through 
interruption of cell-cell and cell-matrix contacts. Previous efforts to attain detailed 
characterization of sialoglycoproteins during tumor progression have been hindered by 
laborious sample preparations and inefficient techniques for the selective study of these 
molecules. Recent advances in experimental approaches and instrumental analyses are 
now capable of defining glycan microheterogeneity in workflows conducive to high-
throughput investigations. Cumulatively, these innovations are capable of defining 
glycoprotein properties including quantity, sites of glycan attachment, oligosaccharide 
composition, monosaccharide linkage conformations, and the architecture of glycans 




assessing the specificity of putative glycoprotein biomarkers. Therefore, we 
hypothesized that the application of new mass spectrometry-based glycoproteomic and 
glycomic methods can provide a detailed characterization of sialoglycoproteins in non-
small cell lung cancer. This hypothesis will be tested by the following specific aims: 
Aim 1: Evaluate the utility of azido-sugar metabolic labeling, alkyne-agarose bead 
enrichment, and LC-MS/MS for identifying differentially sialylated glycoproteins in a 
cell model of NSCLC. 
This aim entails: 
A. Optimization of the azido-sugar labeling, gene induction, enrichment, on-bead 
trypsin digest, and LC-MS/MS workflow. These experiments will evaluate the 
incorporation of the analog sugars for sialic acid (ManNAcAz) and N-
acetylgalactosamine (GalNAcAz), the use of cell lysate and supernatant 
fractions as starting materials, and provide initial data regarding differentially 
captured glycoproteins following the induction of TGFβ1, Zeb, or empty 
vector.  
B. Double metabolic labeling of H358 cells (SILAC and ManNAcAz), alkyne-
agarose bead enrichment, and LC-MS/MS. This approach provides very 
reliable quantitative data on captured sialoglycoproteins following TGFβ1 or 
empty vector induction. 
C. SILAC quantification of non-alkyne agarose bead enriched H358 cell lysate. 
Data from these experiments can used to identify protein level changes which 




D. A secondary digestion using PNGase-F to release the sugar-conjugated 
peptides attached to the previously-trypsin digested alkyne beads. LC-MS/MS 
analysis of released peptides provides information on the specific 
glycosylation sites where ManNAcAz is being incorporated. In addition, 
proteins not detected following trypsin digest may also be revealed by this 
method. 
E. Permethylation and sialic acid linkage specific esterification of cleaved N-
linked carbohydrates from H358 cell lysate followed by MALDI-FT-ICR 
analysis of derivatized structures. This approach will identify preliminary 
trends in the expression of specific sialylated N-glycans in the TGFβ1 and 
EV-induced cells.       
Aim 2: Investigate NSCLC-associated N-linked glycan structures in a set of matched 
human lung tissues and proximal fluids using a novel sample preparation and high-
resolution MS analysis workflow.  
Experiments include:  
A. Proteomic evaluation of Bronchoalveolar lavage fluid by in-solution trypsin 
digestion, LC-MS/MS, and label-free quantification. This catalogues the 
protein content of BAL which will be useful as a reference for future studies 
targeting the specific carriers of N-linked structures identified from glycomic 
evaluations. 
B. Sialic acid linkage-specific esterification and MALDI-FT-ICR structural 
analysis of N-glycans in pooled samples of bronchoalveolar lavage fluid and 




glycomic studies in lung cancer proximal fluids. In addition, initial trends in 
the expression of sialylated structures, and their anomeric configurations, will 
be catalogued for reference as more samples are procured.  
C. On-tissue PNGase-F digest and MALDI-FTICR mass spectrometry imaging  
of N-linked glycans from human lung.  Concurrent histological assessment 
will be performed to define regions of interest in these tissues. Direct 
comparison of spatial distribution of glycans to defined pathological features 
will be useful to identify putative cancer-specific oligosaccharide structures.     
D. Evaluate trends in the expression pattern of N-glycans between the tissues and 
proximal fluids. This will be useful as a preliminary assessment of how the 
expression of glycan structures translates between tissues of origin and 





















Glycoproteomic and Glycomic Approaches to 
Evaluate TGFβ1-induced effects on 











Glycosylation is the most common post-translational modification, estimated to 
occur on approximately 50% of all proteins. Glycans influence protein-folding, 
localization, protein-protein interaction, and alterations in the expression/structure of 
specific moieties have been identified in several disease states, including cancer(63). The 
identification of specific glycan motifs has previously demonstrated utility for 
prognostic/therapeutic monitoring of various malignancies. For example, current 
biomarkers based on this principle include CA15-3, CA19-9, CA125, and AFP-
L3(118,144,155,157,161). Despite the abundance of information these molecules carry, 
the clinical value of these assays are hindered by low sensitivity/specificity. 
Consequently, newer approaches to evaluating putative glycoprotein biomarkers are 
emphasizing the detection and quantification of specific glycosylation sites and 
structures. This work is in-part being driven by advances in up-front analytical 
techniques, which have multiple applications for discovery phase endeavors. For 
instance, glycan metabolic labeling and click chemistry-based enrichment has recently 
emerged as an efficient method for assessing glycosylation from in vitro 
models(190,195). This type of approach is based on the incorporation of analog sugars, 
bearing small, inert chemical functional groups, onto nascent glycoproteins. Following 
experimental procedures, glycoproteins which have incorporated the analog sugars are 
covalently bound to a solid-support and digested directly for the evaluation of proteins 
which incorporated them. Additionally, this method may be further employed for the 
identification of N-linked sites of glycosylation following the release of glycopeptides by 




developments and technology innovations capable of discerning individual glycan 
structures and, in some cases, anomeric linkages of the constituent monosaccharides. By 
combining these approaches for a total assessment of the glycoproteome, a more 
comprehensive view of how pathology influences these processes might be attained.   
Therefore, we set forth to define alterations in sialic-acid containing glycoprotein 
populations in a cell culture model of NSCLC.  An azido-sugar metabolic labeling 
approach was instituted, allowing biorthogonal incorporation of the analogs onto nascent 
glycoproteins followed by the induction of TGFβ1, Zeb, or an empty vector control (EV). 
To increase the breadth of the initial screen, alterations in O-linked glycosylation were 
profiled by including a sample set treated with an N-acetylgalactosamine analog 
(GalNAcAz). Glycoproteins incorporating the azido-sugar analogs were selectively 
pulled down by reaction with alkyne agarose beads (i.e. “Click reaction”) and digested 
with trypsin. Peptides were analyzed by LC-MS/MS and normalized spectral counts were 
generated for quantitative evaluation of proteins incorporating the analog sugars. Next, a 
double metabolic labeling strategy (SILAC and ManNAcAz labels) was implemented as 
a secondary means to quantify captured glycoproteins following the induction of TGFβ1. 
This approach was also useful for assessing if protein level changes were contributing to 
differential capture. To this end, we applied SILAC relative protein quantification before 
and after alkyne-agarose bead enrichment in TGFβ1 and EV-induced cells.  Further 
utility of for our methods was achieved by applying a PNGase-F digest to the previously 
trypsin-digested beads; allowing us to investigate the localization of N-linked glycans 




and EV-induced cells were evaluated using two different derivatization strategies and 
MALDI-FT-ICR acquisition.   
 
3.2 Materials and Methods 
3.2.1 Cell Culture 
H358 non-small cell lung cancer cells were kindly provided by Dr. Robert 
Gemmill. Cells were grown at 37⁰C, 5% CO2 in RPMI-1640 media supplemented with 
10% fetal bovine serum and 1x Penicillin/Streptomycin/Amphotericin (MP Biomedicals). 
Tetracycline/Doxycycline-inducible TGFβ ligand 1, Zeb,  or Empty Vector (EV) genes 
were stably-integrated using the Flp-In T-Rex system (Invitrogen) prior to receipt. 
Selection was maintained by the addition of Blasticidin (Fisher Scientific) at 5µg/ml and 
Hygromycin (Fisher Scientific) at 100µg/ml to media throughout culturing and 
experiments.  
3.2.2 Azido-Sugar Metabolic Labeling 
The workflow for H358 Azido-Sugar metabolic labeling is depicted in Figure 2. 
1 x 106 cells were plated on 10cm polystyrene tissue culture dishes (Corning) in 6ml of 
RPMI-1640 media with supplements for 48 hours. At the 48 hour time-point, culture 
media was removed and cells were gently washed with sterile 1x PBS. Fresh media and 
40µM azido sugar analog, either tetraacetylated N-azidoacetyl-D-mannosamine 
(ManNAcAz) (Life Technologies) or tetraacetylated N-azidoacetyl-D-N-






















































































































































incorporation for 48 hours.  At the 96 hour time-point culture media was discarded, 
replaced with fresh media containing 1% FBS, and 100ng/ml Doxycycline hydrochloride 
(MP Biomedicals) was added to the appropriate sample groups. 24 hours later, cells were 
loosened by non-enzymatic dissociation and the resulting culture media/intact cell 
mixture was centrifuged at 800rpm, 4⁰C, for 5 minutes in 15ml conical tubes. 
Supernatant was allocated to new 15ml conical tubes and immediately stored at -80⁰C. 
Cell pellets were washed with 5ml sterile 1xPBS, centrifuged, and the supernatant was 
discarded. The resulting cell pellets were immediately stored at -80⁰C. Three biological 
replicates were prepared for ManNAcAz -treated cells and two for GalNAcAz-treated. 
3.2.3 Agarose-alkyne Bead Enrichment of Azido-Sugar bearing 
Glycoproteins 
3.2.3.1 Sample Preparation 
Cell pellets were processed for enrichment by combining technical replicates were 
combined and  thawed on ice for 10 minutes in 1ml urea lysis buffer (8M Urea, 200mM 
Tris pH8, 4% CHAPS, 1M NaCl). Complete cell lysis was achieved through probe 
sonication (Fisher Scientific) at 30% power using 6x 3 second pulses while the samples 
remained on ice. Cell lysates were then centrifuged at 800 rpm, 4⁰C, 5 minutes and 
800µL of the resulting supernatant was used as input for the enrichment. Conditioned cell 
media samples were thawed on ice and technical replicates were combined. The media 
samples were concentrated using Amicon Ultra 3000Da MWCO filter units (EMD 
Millipore) by serial centrifugations at 4⁰C, 2683 x g, for 45-60 minutes until the entire 
volume had been processed. 800µL of the resulting concentrated media was used as input 























































































































































































































































































For the enrichment of glycoproteins bearing the tetraacetylated azide sugar 
analogs, the Invitrogen Click-iT® Protein Enrichment Kit (#C10416) was used(208). 
This method encompasses a 3 day procedure in which glycoproteins bearing the azide 
functionality are bound to alkyne functional groups on agarose beads in the presence of a 
copper catalyst, producing a 1,4 disubstituted 1,2,3-triazole linkage. On the second day, 
agarose bead-bound samples are reduced, alkylated, and subjected to a set of stringent 
washes to remove unbound/non-specifically bound constituents followed by overnight 
digestion with trypsin. On day 3, samples are acidified, desalted, concentrated, and stored 
at -20°C until analysis. Reduction was performed using 10 mM Dithirothreitol (DTT) 
(Sigma) at 70⁰C and alkylation with 40 mM Iodoacetamide (IAA) (Sigma) in the dark. 
Washing was carried out as prescribed by the Click-iT® Enrichment protocol: 5x 2ml 
wash with SDS wash buffer, 5x 2ml wash with 8M Urea (Sigma), and 5x 2ml wash with 
20% acetonitrile (Fisher). On-bead digestion was performed with 5μl of 0.2μg/μl 
proteomic grade trypsin (Sigma) for 16 hours at 37°C. Peptides were acidified by the 
addition of 2µL Trifluoroacetic acid (Sigma) and desalted using Waters Sep-Pak® C18 
cartridges. The resulting peptides were vacuum-concentrated and stored at -20°C until 
LC-MS/MS analysis. Enrichment procedures are depicted in Figure 3 
3.2.4 Azide-Sugar Incorporation Western Blot 
H358 whole cell lysates (TGFβ and EV) derived from the ManNAcAz metabolic 
labeling (section 3.2.2) were lysed in RIPA buffer (10mM Tris-Cl pH 8, 1mM 
Ethylenediaminetetracetic acid (EDTA), 140mM Sodium Chloride, .1% Sodium dodecyl 
















































































































































probe-sonication. Protein concentration was measured by Bichinoninic acid (BCA) assay 
from a commercially available kit (Pierce #23227). 50µg total protein was allocated for 
biotinylation of ManNAcAz-bearing glycoproteins by the Click-iT® Biotin glycoprotein 
detection kit (Invitrogen) as prescribed by the manufacturer. Biotinylated samples were 
speedvac concentrated and reconstituted in RIPA buffer prior to denaturation. Samples 
were separated by electrophoresis through 4-12% Bis-Tris SDS-PAGE (Life 
Technologies) and protein was transferred to a nitrocellulose membrane (LiCor 
Biosciences) for blotting. Following transfer, the membrane was blocked in 1:3 Licor 
blocking buffer diluted with 1x PBS and incubated with 1:5000 Streptavidin-IR800 
(LiCor Biosciences) in blocking buffer containing .1% SDS for one hour at room 
temperature with rocking. The membrane was washed 5 times with 1x PBS containing 
.1% Tween (Fisher) and a final wash with 1xPBS without detergent.  A LiCor Odyssey 
infrared imager (LiCor, Lincoln, NE, USA) was used to visualize the membrane. To 
assess consistency of protein loading, an identical SDS-PAGE gel was run and blotted 
with 1:5000 rabbit anti-GAPDH (Cell Signaling Technology) and 1:20,000 goat anti-
rabbit IR-800 (LiCor Biosciences).   
3.2.5 LC-MS/MS and Bioinformatics for Label-Free Quantification 
Concentrated digests were resuspended in 15μl buffer A (97.8% HPLC-grade 
H2O, 2% acetonitrile, 0.2% formic acid), the entire contents of which was loaded onto a 
25cm x .0075mm C-18 reversed phase LC column (packed in house, Waters ODS C18). 
Liquid chromatography (LC)-electrospray ionization (ESI) -tandem mass spectrometry 
(MS/MS) on a linear ion trap mass spectrometer (LTQ, ThermoFischer) coupled to a LC 




acetonitrile, 0.2% formic acid to 50% acetonitrile, 0.2% formic acid.  Data-Dependent 
Analysis was selected to perform MS/MS on the 10 most intense ions in each MS spectra 
with a minimum ion count of 1000. Acquired data were searched using Mascot (version 
2.4.1, Matrix Science, London, UK) via Proteome Discoverer (version 1.4.0.288, Thermo 
Scientific).  The data were searched against a UniProt SwissProt Homo sapien database 
(2014_07 release) containing both canonical and isoform entries, which was concatenated 
with entries from the common Repository of Adventitious Proteins (40,872 entries). 
Precursor mass tolerance was set to 2 Da and fragment mass tolerance to 1 Da. Enzyme 
specificity was trypsin, allowing for two missed cleavages. Carbamidomethyl (Cys) was 
specified as a fixed modification and protein N-term acetylation, deamidation (Asn, Gln), 
Gln→pyro-Glu (N-term Gln), and oxidation (Met) were set as variable modifications. 
False positive rates were determined by searching against an automated decoy database 
within Mascot. Protein identifications were confirmed using ProteoIQ (version 2.3.08, 
Premier Biosoft, Palo Alto, CA) by specifying >1 peptide and protein false discovery rate 
(FDR) <5%. Protein FDR was calculated within ProteoIQ using separate searches against 
target and reverse decoy databases. The decoy database was the target database reversed. 
ProteoIQ was used to generate normalized spectral counts (nSCs) for use as relative 
quantification of protein expression levels for comparisons between cell groups. 
Designation of “Glycoproteins” was done by cross-referencing identified proteins against 
the glycoprotein keyword, KW-0325, in the UniProt Knowledge Base. A moderated t-test 
(limma package, R) was used to determine significant changes, which was defined as  p< 
0.05. These significant proteins were uploaded to the WebGestalt 




analysis. Enrichment was performed against the KEGG database with the entrez protein-
coding genes as a background. A hypergeometric test was used and required a minimum 
of two proteins for a pathway. Significant pathways were identified if Benjamini-
Hockberg (BH) adjusted p<0.05.  
3.2.6 Double Metabolic Labeling  
TGFβ and EV-inducible H358 bronchoalveolar adenocarcinoma cells were 
selected for a double-metabolic labeling approach encompassing: 1. Stable-isotope 
labeling of amino acids in cell culture (SILAC), followed by 2. Azido-sugar metabolic 
labeling using ManNAcAz.  For SILAC labeling, cells were cultured using Pierce® 
SILAC protein quantitation kits (#89982) with 13C6-L-Lysine and 13C6-15N4-L-Arginine 
(“Heavy”) or non-isotopic L-Lysine and L-Arginine (“Light”) in T75 tissue culture flasks 
for 6 doublings. Incorporation of heavy amino acids was verified >95% by MS prior to 
beginning the azido-sugar metabolic labeling procedures.  Azido-sugar metabolic labeling 
was carried out as described in section 3.2.2, with the following changes: 1. Cells were 
maintained in full (dialyzed) serum SILAC media throughout and, 2. 40ng/ml 
Doxycycline was used for induction of TGFβ or EV.  A total of three biological 
replicates, including a label-swap, were prepared for these experiments (Table 2). 
3.2.6.1 Sample Processing for Double Metabolic Labeling 
The rationale for our double metabolic labeling experiments is depicted in Figure 
4. Following double metabolic labeling procedures, cells were collected and stored at -
80⁰C as described in section 3.2.2. Pellets were processed for either: 1. SILAC relative 
quantification before agarose-alkyne bead enrichment (“SILAC-Only”), or 2. SILAC 




Table 2: H358 Sample Groups for Double 
Metabolic Labeling and Protein Quantification 
(Before and After Enrichment)




1. SILAC Heavy Label     
+40µM ManNAcAz
1. SILAC Heavy Label                
+40µM ManNAcAz
2. SILAC Light Label        
+40µM ManNAcAz









Figure 4: Rationale for Double M
etabolic-Labeling Approach. SILAC-Incorporated 
TGFβ1 and EV cells undergo the 120 hour azido-sugar m
etabolic labeling and gene 
induction procedure and are then m
ixed at a 1:1 ratio. Tw
o fractions are prepared 
for M
S acquisition:1.  W
ithout enrichm
ent (“SILAC-O



































Only pellets were thawed on ice in 500µL RIPA buffer  for 10 minutes followed by probe 
sonication at 30% power for 6 seconds with three repeats. Samples were centrifuged 
800rpm, 4⁰C, for 5 minutes and approximately 450µL of the resulting supernatant was 
saved to 1.5ml microcentrifuge tubes (Axygen) on ice. Protein quantification was 
achieved using the BCA assay and 100µg SILAC pair aliquots were prepared (50µg 
SILAC Heavy + 50µg SILAC Light) for in-solution trypsin digestion. Samples were 
reduced at 95⁰C with 10mM DTT for 5 minutes followed by alkylation with 40mM IAA 
in the dark for 30 minutes. 2µg of Trypsin was added to each SILAC pair sample and 
digestion proceeded at 37⁰C overnight. The resulting peptides were desalted using Pierce 
C18 spin columns (#89870), speedvac concentrated, and stored at 4⁰C until LC-MS/MS. 
For SILAC+Click samples, normalization of input for Heavy and Light pairs was 
accomplished by cell counting immediately following non-enzymatic dissociation. 5 x 
106 total cells (2.5 x 106 Heavy + 2.5 x 106 Light) were prepared for agarose-alkyne bead 
enrichment by the addition of 500µL Urea lysis buffer to each pellet, vigorous pipetting, 
and combining pairs to attain 1000uL total sample volume. Enrichment of ManNAcAz-
bearing glycoprotein was carried out as described in section 3.2.3 and samples were 
stored at 4⁰C until LC-MS/MS analysis.  
3.2.7 LC-MS/MS and Bioinformatics for Double Metabolic Labeling 
Concentrated digests were resuspended in 7µL buffer A (97.8% HPLC-grade 
H2O, 2% acetonitrile, 0.2% formic acid) for online 2-dimensional liquid chromatography. 
Samples were first loaded onto a strong cation exchange column (Biobasic, 50 x .5mm, 
Thermo) using a Dionex U3000 nano-LC system (Thermo Scientific). For SILAC-Only 




ammonium acetate (0, 5, 10, 20, 40, 50, 60, 75, 100, and 500mM) for 10 minutes at each 
concentration. For SILAC+Click samples, a 5-level SCX fractionation was utilized (0, 5, 
10, 50, 500mM). Peptides were eluted at each step directly onto a C18 trap column (C18 
pepMap 100, 5µm, 300µm x 5mm ID, Thermo) followed by a C18-reverse phase 
analytical column (75mm ID, 15cm) packed in-house with Waters YMC-ODS C18-AQ 
5mm resin. Peptides were eluted from the analytical column to an OrbiTrap Elite 
instrument (Thermo Scientific) using a 120 minute linear gradient of 2-50% buffer B 
(97.8% acetonitrile, 2% HPLC-grade H2O, .2% formic acid) at a flow rate of 200nL/min 
via a Nanospray Flex Ion source (Thermo Scientific). Data-dependent analysis was 
selected to perform MS/MS on the 20 most intense ions in each MS spectra with a 
minimum ion count of 1000. The survey scan was performed in the Orbitrap at a 
resolution of 60,000. For ion trap based CID,  the normalized collision energy was set to 
35% and dynamic exclusion was set to a repeat count of 2, repeat duration of 30 seconds, 
and exclusion duration of 180 seconds. Acquired data was searched using MaxQuant 
quantitative proteomics software (version 1.5.1.0) against a UniProt Swissprot Homo 
sapiens database (2014_7 release), which was concatenated with entries from the 
common Repository of Adventitious Proteins (40,872 entries total). Precursor mass 
tolerance was set to 4.5 ppm and fragment mass tolerance to 0.5 Da. Enzyme specificity 
was trypsin and 2 missed cleavages were allowed. Carbamidomethyl (Cys) was selected 
as a fixed modification and protein N-term acetylation, deamidation (Asn, Gln), pyro-Glu 
(N-term Gln), and oxidation (Met) were specified as variable modifications. The false 
discovery rate was set to 1% using a reversed target database generated in MaxQuant. 




amino acids per peptide. Protein quantification required a minimum ratio count of 2 
peptides, including all unmodified and variably-modified peptides (protein N-term 
acetylation and oxidized methionines). SILAC ratios generated in MaxQuant were post-
processed using Perseus statistical software (version 1.4.0.8). Reverse, contaminant, and 
“identified by site only” hits were filtered and removed. Replicate trimming was applied 
by calculating ±2 standard deviations of the mean of the log2 ratio distribution for every 
label-swap comparison (Heavy/Light*Light/Heavy) and discarding proteins falling 
outside of that range(209,210). Ratios were inverted so that all data was reported with 
respect to TGFβ expression and log2 transformed. A moderated t-test (limma package, R) 
was used to determine significant changes (n≥2 of 3 ratios), which was defined by  
Benjamini-Hockberg corrected p values. KEGG analysis of significant proteins in 
SILAC+Click group was carried out as described in section 3.2.5.  
3.2.8 PNGase-F Mediated Release of N-linked Glycopeptides  
Agarose-alkyne beads retaining ManNAcAz-bearing glycopeptides following on-
bead trypsin digestion (section 3.2.3.2) were stored at -20⁰C until processing. Beads were 
initially washed with 100µL RIPA buffer, vortexed, briefly centrifuged, and the 
supernatant was aspirated with a gel-loading tip and discarded. 100µL of HPLC H2O and 
1µg of recombinant Peptide-N-glycosidase-F (See Powers et al for enzyme information 
(211)) were added followed by incubation for 16 hours at 37⁰C. Following digestion, the 
supernatant was collected and the beads were washed with an additional 100µL of HPLC 
H2O, which was added to the supernatant.  The resulting 200µL aliquots were centrifuged 




3.2.9 LC-MS/MS and Bioinformatics for PNGase-F Mediated Release of N-
linked Glycopeptides 
Concentrated peptides were reconstituted in 7µL Buffer A and analyzed on the 
OrbiTrap Elite using the parameters described in section 3.2.5; with the exception that 
only a single dimension of chromatography was carried out (RPLC). Acquired data was 
searched using MaxQuant as described in section 3.2.7, with one peptide being required 
for protein identification. Post-processing using Perseus software was used to generate 
categorical headings (i.e. peptide sequence, deamidation site, protein ID) and data was 
exported to external data-processing software for the identification of putative N-linked 
glycosylation sites by manual annotation.   
3.2.10 H358 Global N-linked Glycomics  
3.2.10.1 Linkage-Specific Sialic Acid Esterification 
TGFβ and EV inducible H358 cells (+/- Doxycycline induction) were prepared as 
described in section 3.2.2, with the exception that no azido-sugar metabolic label was 
added. Samples were incubated at 4⁰C in 200µL of lysis buffer (1% SDS, 5mM EDTA, 
25mM Tris Base) for 1 hour. Probe sonication was performed at 30% power, 10 seconds 
and samples were centrifuged for 5 minutes, 800rpm, 4⁰C. Supernatant was transferred to 
new tubes and protein quantification was carried out by BCA assay. 250µg of protein was 
allocated to a fresh tube and total sample volume was brought up to 100µL in water. 
Protein precipitation was achieved by adding 400µL methanol (Fisher), 100µL 
chloroform (Fisher), 300µL HPLC H2O (Fisher), vortexing, and centrifugation at 14,000 
x g for 2 minutes. Supernatant was discarded and 400µL of methanol was added to the 




entire solution was decanted and protein pellets were allowed to air dry for 10 minutes. 
100µL of reducing solution (10mM DTT, 1% SDS) was added and dissolution of protein 
pellets proceeded by rigorous pipetting and vortexing. Samples were boiled for 10 
minutes and cooled to room temperature.  Nonidet P-40 (Boehringer) was added to a final 
concentration of 1%, as well as 1µg of PNGase-F. Digestion was carried out at 37⁰C for 
16 hours. On the next day, protein was re-precipitated by the addition of 400µL methanol, 
15 minute incubation at -80⁰C, and centrifugation at 15,000 x g for 10 minutes. At this 
point, the supernatant (containing released N-linked glycans) was collected and speedvac 
concentrated. 2µL of HPLC H2O and 40µL of Ethylating reagent ( 250mM 1-ethyl-3-(3-
(dimethylamino)propyl)-carbodiimide hydrochloride (EDC), 250mM 1-
Hydroxybenzotriazole hydrate (HOBt)) (Oakwood Chemical) were added, followed by 
incubation at 37⁰C for 1 hour. After incubation, 40µL of Acetonitrile was added and 
samples were incubated at -20⁰C for 20 minutes. Cotton tip HILIC solid-phase extraction 
of N-glycans was performed using the procedure described by Reiding et al and samples 
were eluted in 10µl HPLC H2O (212).  
3.2.10.2 Permethylation 
H358 TGFβ and EV cell pellets (+/- Doxycycline induction) were probe-sonicated 
in 1x PBS at 30% power for 10 seconds on ice. Protein was precipitated by the addition 
of cold methanol (80% final concentration) and centrifugation at 20,000 x g, 4°C, for 30 
minutes. Supernatant was removed and the protein pellets were reconstituted in 200µl 1x 
PBS. Protein was re-solubilized by vigorous pipetting and each sample was split into two 
100µl aliquots: one for PNGase-F (2.7µg per sample) digest and one as a no-enzyme 




samples were centrifuged at 20,000 x g, 4°C, for 30 minutes. The supernatant, containing 
the glycans, was speedvac concentrated and permethylation was carried out as described 
by Mechref et al.(213). Following permethylation, samples were speedvac concentrated 
and reconstituted in 10µl of 50% methanol.  
3.2.11 MALDI-FT-ICR Analysis and Bioinformatics of N-linked Glycans 
5µL of the Cotton tip HILIC eluate were spotted on an Anchorchip MALDI plate 
(Bruker Daltonics) with .3µL DHB matrix (5mg/ml 2,5-Dihydroxybenzoic acid (Sigma) 
in 50% acetonitrile, 1mM NaOH (Sigma)). After each spot dried, .2µL of ethanol (Fisher) 
was added for recrystallization. For Permethylated glycans, 1µl of sample and 1µl of 
DHB were spotted and allowed to air dry.  Spectra were acquired on a Solarix dual source 
7T FT-ICR mass spectrometer (Bruker Daltonics) in positive mode (m/z= 500-5000). A 
SmartBeam II laser was operated at 1000 Hz in random walk mode for the acquisition of 
10 average scans per spot, 75µm laser spot size. Acquired spectra were visualized using 
FlexImaging 4.1 (Bruker Daltonics) and exported to DataAnalysis 4.0 (Bruker Daltonics) 
for peak selection. Annotation of glycans was carried out using GlycoWorkbench 2.1 by 
searching spectra against the glycan structures database from the 
CFG(http://www.functionalglycomics.org/glycomics/molecule/jsp/carbohydrate/carbMoleculeH
ome.jsp)(214). Sialic acid linkage specificity was determined by identifying mass shifts of 
-18Da (α2-3) and +28Da (α2-6) relative to the non-derivatized mass of identified species 








3.3.1 Initial Quantification of Glycoproteins in TGFβ1, Zeb, and EV-
induced NSCLC Cells 
We first sought to identify how the induction of TGFβ1, Zeb, or EV would affect 
glycoprotein populations bearing either sialic acid or O-GalNAc moieties in the H358 
NSCLC cell line. An azido-sugar metabolic labeling strategy and alkyne-bead enrichment 
was utilized for the selective incorporation and pull-down of proteins potentially 
undergoing alternative glycosylation following induction of these genes. The workflow 
for these experiments can be summarized as: 1. Metabolic labeling of the TGFβ1, Zeb, 
and EV-inducible cells with either tetraacetylated N-azidoacetyl-D-mannosamine 
(ManNAcAz) or tetraacetylated N-azidoacetyl-D-N-acetylgalactosamine (GalNAcAz) and 
induction of gene expression, 2. Ligation of cell-lysate derived glycoproteins bearing the 
azido-sugars to alkyne-agarose beads via Click chemistry and removal of non-specific 
proteins, 3. Trypsin digest off of beads, LC-MS/MS, and label-free quantification bound 
glycoproteins (Figure 5).  
Prior to MS/MS analysis, an assessment of azido-sugar incorporation efficiency in 
the H358 cells was carried out. Cells were incubated in the presence of ManNAcAz for 
48 hours followed by doxycycline-induction of genes for 24 hours. Cell lysate was 
incubated with biotin-alkyne, separated via SDS-PAGE, and blotted using streptavidin-IR 

















Statistics and Pathway Analysis
Label-free 















Figure 6: H358 Cells Incorporate ManNAcAz. Cell lysate from the azido-sugar 
metabolic labeling procedure was incubated with biotin-alkyne. Approximately 
12.5µg was separated by 4-12% Bis-Tris PAGE, transferred to nitrocellulose, and 




presence of a broad smearing in both doxycycline-induced and non-induced TGFβ and 
EV H358 cells.  
 For MS/MS-based label-free quantification of captured glycoproteins, a total of 
1091 proteins were identified from all samples, including cell lysate and supernatant 
fractions, TGFβ, Zeb and EV-induced cells, and labeling with both ManNAcAz and 
GalNAcAz (Table 3, suppl. materials). Of the 1091 proteins, 387 matched the UniProt 
knowledge base keyword “glycoprotein” (KW-0325), 24 were isoform-specific 
identifications, and 17 proteins were identified as both canonical and isoform-specific. 
From this data, individual comparisons were nade between the cell-lysate derived 
experimental groups by applying a moderated t-test to the averaged log2 fold change of 
normalized spectral counts (nSC). Because significance was being deemed by the 
averaged fold change metric, 50% of the minimum observed nSC value (MOV) was 
applied for any protein which was not quantified in at least one biological replicate of a 
given comparison, so that no value would be zero. Table 4 summarizes the total number 
of proteins quantified, those reaching statistical significance (p< 0.05), and how many 
were up or down regulated for all comparisons.  
The induction of TGFβ following ManNAcAz-labeling resulted in the 
quantification of 598, 611, and 558 proteins relative to induced-EV, non-induced TGFβ, 
and induced-Zeb expression, respectively (Tables 5 – 7, suppl.. materials). The 
corresponding numbers of proteins which were captured at significantly different levels 
were 10, 16, and 57, respectively.  The proportion of glycoproteins identified in these 
experiments was 46% for both TGFβ vs. EV and induced vs. non-induced TGFβ and 
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the proteins captured at significantly different levels in induced TGFβ vs. induced-EV, 4 
pathways with induced vs. non-induced TGFβ, and 27 for TGFβ vs. Zeb expression. 
When TGFβ was induced in GalNAcAz-labeled cells, 455 and 463 proteins were 
quantified, relative to EV and non-induced TGFβ cells (Tables 8 and 9, suppl. 
materials). Of these quantified proteins, 14 and 9 were captured at significantly different 
levels, respectively. A total of 31% and 30% of the total quantified proteins matched the 
UniProt keyword search for glycoprotein and KEGG analysis identified three 
significantly enriched pathways related to TGFβ induction in the GalNAcAz-based 
experiments. Comparisons of ManNAcAz-labeled induced-Zeb versus induced-EV and 
non-induced Zeb cells (Tables 10 and 11, suppl. materials) resulted in a total of 543 
and 525 proteins quantified, respectively. Statistical significance was reached for 50 and 
51 of the proteins quantified in these comparisons. The proportion of total glycoproteins 
was 48% and 54%, and KEGG analysis identified 19 and 27 significantly enriched 
pathways for these experiments, respectively.  
3.3.2 Double Metabolic Labeling  
Several proteins potentially undergoing differential glycosylation following the 
induction of TGFβ were identified from the label-free quantification experiments. We 
next wanted to ascertain whether changes in underlying protein expression were 
contributing to the differential capture quantity. Therefore, SILAC metabolic labeling, for 
relative protein quantification, was included in the workflow prior to ManNAcAz 
labeling and gene induction. A total of 700 cell lysate-derived proteins were quantified in 
three biological replicates of SILAC and ManNAcAz labeled H358 TGFβ and EV 




suppl. materials). Of the 700 quantified proteins, 11% were identified as glycoproteins. 
For the equivalent three replicates which underwent the alkyne-agarose bead enrichment 
(“SILAC+Click”), 392 total proteins were quantified; 76% of which matched the UniProt 
glycoprotein keyword search (Table 13, suppl. materials). Comparison of proteins 
identified with and without enrichment revealed a total of 91 shared proteins between 
experiments (Table 14, suppl. materials).  We next wanted to identify which shared 
proteins were significantly changing in the SILAC+Click experiments while not 
significantly changing in the SILAC-Only experiments. Three Benjamini-Hockberg 
corrected p-value cutoffs (BHp= 0.05, 0.10, and 0.15) were applied to the averaged log2 
fold-change of the SILAC ratios (Table 15). At BHp = 0.05, 665 SILAC-Only and 58 
SILAC+Click proteins met this criteria. There were 5 proteins shared in this assessment, 
including CD276, Transmembrane emp24 domain-containing protein 9, Neutral amino 
acid transporter B, Aspartyl/asparaginyl beta-hydroxylase, and Sodium/potassium-
transporting ATPase subunit alpha-1. For BHp = 0.10, there were 651 SILAC-Only and 
77 SILAC+Click proteins; the same 5 proteins were identified in the overlap between 
groups. At BHp = 0.15 cutoff, 644 SILAC-Only and 92 SILAC+Click proteins remained. 
In addition to the 5 proteins shared from the lower BHp values, Host cell factor-1, 
Granulins, and Sodium/potassium-transporting ATPase subunit beta-1 fit our criteria at 
this significance level.  
An assessment of proteins significantly changing in both SILAC+Click and 
SILAC-Only experiments was also carried out. Two proteins, Integrin beta-4 and 






























































































































Table 15: Shared Proteins Significantly Different in SILAC+Click and N
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an equivalent examination at BHp <0.10 and BHp<0.15, a third protein, Myoferlin, was 
also significant in both groups.   
 Finally, the 58 SILAC+Click proteins captured at significantly different levels 
(BHp <0.05) were submitted for pathway analysis (Table 13). Enriched pathways 
represented by these proteins included: Metabolic processes (5 proteins), cell adhesion 
molecules (4 proteins), ECM-receptor interaction (2 proteins), Mucin type O-glycan 
biosynthesis (2 proteins), Folate biosynthesis (2 proteins), malaria (2 proteins), p53 
signaling pathway (2 proteins), complement and coagulation cascades (2 proteins), and 
phagosome (2 proteins).  
3.3.3 PNGase-F Release of N-linked Glycopeptides 
The previously-trypsin digested alkyne-agarose beads from our SILAC+Click 
experiments were retained to assess N-linked glycosylation sites where ManNAcAz was 
being incorporated (Figure 7). Following the removal of any carryover tryptic peptides, 
the beads were incubated with PNGase-F and evaluated the peptides by LC-MS/MS. We 
observed a total of 553 deamidated (Asn or Gln) peptides representing 224 unique 
proteins, of which 77% matched the UniProt glycoprotein keyword search. Peptide data 
was filtered to include only those with a deamidated Asn (411 peptides) and at least one 
N-linked glycan consensus sequence (N-X-S/T), narrowing the list to 385 peptides 
(Table 16, suppl. materials). From these 385 peptides, 170 unique proteins were 
represented, with 91% matching the glycoprotein keyword. We next cross-referenced a 
randomly selected subset of 55 observed peptides against the known glycosylation sites 
in the UniProt knowledge Base. In this selected set, 7 of the peptides were discovered to 

















































































































































































































terminal trypsin cleavage had occurred. Furthermore, 3 peptides were deamidated at Asn 
residues outside of their N-linked consensus sequence and 3 were observed having 
multiple deamidated Asn in their sequence (both within and outside of consensus 
sequences). A total of 43 of the 55 peptides had deamidation localizations which matched 
documented UniProt KB sites of glycosylation and 3 sites were identified in non-
annotated N-linked consensus sequences (Table 17, suppl. materials).   
In addition to sequence assessments, a comparison of the representative proteins 
from PNGase-F released peptides to those of the equivalent samples digested with trypsin 
(SILAC+Click experiments) was performed (Table 18, suppl. materials). A 63% 
overlap of proteins derived from PNGase-F peptide release was observed in the trypsin 
data. Glycoprotein content was 51%, 67%, and 92% in the identifications unique to 
PNGase-F, unique to trypsin, and the shared proteins, respectively.  
3.3.4 H358 Global N-linked Glycomics  
Global changes in the N-linked glycome of H358 cells induced or non-induced to 
express of TGFβ or EV were screened. Cell lysate-derived N-glycans were released by 
PNGase-F and prepared by one of two methods of derivatization prior to MALDI-FT-
ICR analysis: Permethylation or Linkage-specific sialic acid esterification. For the 
Permethylated glycans, evaluation was initially carried out in the 500-5000 m/z mass 
range from PNGase-F digested or no-enzyme controls (Figure 8). Obvious differences in 
the distribution of spectra from PNGase-F digested samples relative to no PNGase-F 
controls were observed; notably the presence of peaks above 2000 m/z in treated samples. 
We next compared the spectra of induced TGFβ and EV in the 1150-5000 mass range 




tri-, and tetra- antennary complex structures between the TGFβ and EV induced samples. 
Notably, one species, Hex6HexNAc5 (m/z = 2519.3), was observed only in the TGFβ- 
induced sample. In addition, mono- and tri-sialylated complex glycans were noted in the 
upper mass ranges of both samples. For the linkage-specific sialic acid glycan analysis, 
spectra were assessed from 1150-2600m/z (Figure 10). Several of the low-mass 
oligomannose species, including Hex6HexNAc2 through Hex9HexNAc2 shared 
identification in the permethylated data, including both TGFβ and EV groups.  The 
anomeric configuration of sialic acid on seven different bi-antennary complex glycans 
was resolved. These included Neu5Acα2-6 Hex5dHex1HexNAc4 (m/z = 2128.7) and 
Neu5Acα2-61Hex5dHex2HexNAc4 (m/z = 2275.8), which were also noted in the 
permethylated spectra. As a general observation, α2-6 linkages were predominant on 
mono-sialylated species, while di-sialyated glycans displayed a combination of α2-3 and 
α2-6. Relative peak abundance suggests the major species present in TGFβ and EV 
induced H358 cell lysate were Neu5Acα2-3Neu5Acα2-6Hex5dHex1HexNAc4 (m/z 
2402.8). However, a clear increase in the proportion of Neu5Acα2-
6Hex5dHex1HexNAc4 (m/z 2128.7) relative to m/z 2402.8 is evident in the TGFβ-
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3.4 Discussion     
 Our initial experiments evaluated glycoprotein quantities following azido-sugar 
metabolic labeling and alkyne-agarose bead capture of H358 cell lysate following the 
induction of TGFβ, Zeb, or EV. We compared experimental groups by LC-MS/MS and 
label-free quantification by calculating the average log2 fold change of nSCs and 
applying a moderated t-test to deem significance (p<0.05). Of note, the induction of 
TGFβ in ManNAcAz-labeled cells resulted in significant differences of the captured 
quantity of several glycoproteins relevant to processes such as cell adhesion, cytoskeletal 
regulation, ECM-receptor interaction, N- and O-glycan biosynthesis, solute transport, and 
metabolic pathways (Tables 5 -7). For example, relative to Zeb, TGFβ-induction resulted 
in the increased capture of Macrosialin, Cub-domain containing protein-1, Integrin alpha-
2, and Integrin beta-6. In addition, differences were apparent in several glycosyl 
transferase enzymes, including GALNT10, MGAT2, B4GALT1, and GALNT6, in the 
same comparison. Furthermore, the TGFβ1 ligand, which harbors three N-linked 
glycosylation sites, was the most significantly increased glycoprotein captured in all 
comparisons where its expression was induced. Experiments utilizing the GalNAcAz 
label with TGFβ induction identified significant differences in known O-linked 
glycoproteins such as SLC31A1 copper transporter and CD44. Moreover, the cell 
membrane-associated glycoprotein Basal cell adhesion molecule and cytoskeletal 
organization protein PDZ and LIM domain protein-7 were captured at altered levels with 
GalNAcAz labeling. In the final two comparisons, based on ManNAcAz labeling and 
Zeb-induction, we observed decreased capture of cell adhesion proteins (Intercellular 




based proteins (Thrombospondin-1 and Laminin), and cell surface receptors (Plexin-B2, 
Receptor tyrosine protein phosphatase alpha and Epidermal growth factor receptor).   
Further examination of data from comparisons where the Zeb gene was induced 
(Tables 7, 10 and 11) revealed a trend suggesting a bias towards lower nSC values for 
this experimental group. A review of the data for all of the individual samples indicates 
that this may be due to changes in the quality of MS acquisitions over the 14 month time 
period in which these experiments were carried out. This assertion is based on the total 
acquired spectra and normalization factor for each sample provided by the ProteoIQ 
software used for nSC generation (Table 3; rows 3 and 4). For example, within 
experiments performed at individual time-points (as indicated by the dates and colors on 
table 3 row 5), the total spectra and normalization factors are relatively consistent. 
However, large variations in these values are apparent when equivalent samples acquired 
at different time-points are compared.  In this regard, it is quite possible that the quality 
of online chromatographic separations varied over time because analyses were performed 
on a highly-operated core-facility mass spectrometer. We were prepared for this 
possibility and addressed it in the design of our data analysis. For each comparison 
(Tables 5-11), the equivalent replicates for each group were selected from experiments 
carried out at the same time-point (see Table 3: row 1). For example, if group A was 
being compared to group B, replicate 1 for group A was selected from the same 
experiment as replicate 1 for group B; the same being true for replicate 2 and replicate 3. 
This approach accounts for variability in instrument performance and alleviates any bias 
which would have been introduced from using data acquired over a long period. For our 




quantification, this strategy was an appropriate choice for a rapid, preliminary analysis 
prior to implementing a more reliable quantification method.   
The experimental groups studied in our label-free quantification served to 
establish the feasibility of our experimental procedures prior to double metabolic 
labeling. Two concentrations of doxycycline for induction (data not shown), two azido 
sugars (ManNAcAz and GalNAcAz), and samples derived from both cell lysate and 
secreted protein fractions were evaluated. In addition, glycoprotein capture following the 
induction of the gene Zeb, as well as non-induced controls, was assessed. We were able 
to identify significant differences in captured glycoproteins using label-free 
quantification and utilized this data as a guide for selection of TGFβ1 and EV 
experimental groups only in our double metabolic labeling experiments.   
  Next, protein level changes were gauged to determine if this was contributing to 
differential capture of azido-sugar labeled glycoproteins. SILAC relative protein 
quantification was used in these experiments, rather than label-free quantification, 
because of the increased reliability of data associated with this method(215). Three 
biological replicates of SILAC and ManNAcAz metabolic labeling were performed on 
TGFβ and EV- induced H358 cells and proteins were quantified both before (SILAC-
Only) and after alkyne-agarose bead capture (SILAC-Click). In order for this strategy to 
have merit, candidate proteins must be quantified in both of these fractions. Therefore a 
two-dimensional chromatographic separation (SCX and Reverse phase) of peptides was 
applied to maximize the number of identifications made in both groups. As a result, 700 
and 392 proteins were quantified in the SILAC-Only and SILAC+Click groups 




fractions (91 total). To investigate this low overlap, a GO Analysis was performed on 
total proteins quantified in each fraction (data not shown). The SILAC-Only group 
contained a diverse set of proteins representative of broad biological processes derived 
from intercellular, macromolecular complexes, and organelle-based components. 
Conversely, the majority of quantified hits from the SILAC+Click fraction stemmed from 
membrane-based and cell surface components. In addition, there was an obvious 
discrepancy in the proportion of glycoproteins identified for each fraction (11% v s. 
76%). Therefore, the lack of overlap between SILAC-Only and SILAC-Click may be 
explained by the efficiency with which the Click chemistry based enrichment selectively 
pulls down azido-sugar incorporated-glycoproteins. A more prudent approach to assess 
protein quantity prior to enrichment would be Western blot analysis. Candidates captured 
by alkyne-agarose beads at significantly different levels following TGFβ1 induction, with 
relevant biological functions to invasive phenotypes, could be specifically assayed for 
this purpose without the necessity of time consuming LC-MS/MS acquisitions and 
bioinformatics analyses.  
For statistical analysis of our double metabolic labeling, a moderated t-test was 
applied to the averaged log2 fold change of the SILAC ratios with respect to TGFβ1 
induction. Assessment of significance at BHp-values of 0.05, 0.10, and 0.15 was carried 
out to evaluate shared proteins which were significantly changing in SILAC+Click while 
not reaching significance in SILAC-Only. The same five proteins were observed meeting 
this criteria at both BHp = 0.05 and BHp = 0.10; however, an additional 3 proteins were 
included at BHp = 0.15. A UniProt search of these proteins indicated that seven of the 




alpha-1 not meeting the designation. Interestingly, the beta-1 subunit of this protein also 
fit inclusion criteria at BHp = 0.15, where it was observed to be decreasing about 30% 
following TGFβ1 induction and alkyne-agarose bead capture (Table 15). The Na/K 
ATPase is composed of heterodimeric alpha and beta subunits; where alpha carries out 
the catalytic role and beta functions in regulating plasma membrane localization of the 
pump. Recently, a role for the beta-1 subunit in epithelial cell polarity and cell-cell 
adhesion was identified and shown to be modulated by N-linked glycosylation (216,217). 
The authors conclude that hypo-glycosylated beta-1subunits resulted in decrease cell-cell 
contacts through modification of the ATPase’s stability within the adherens junction. 
Regarding the detection of the alpha-1 subunit in our SILAC+Click fractions, it is 
plausible that the intact, heterodimeric form of the ATPase was captured through 
ManNAcAz incorporation within the beta-1 subunit. Consistent with this is the absence 
of sequenced peptides identified from the alpha subunit in our PNGase-F mediated 
release of glycopeptides from the alkyne-agarose beads; whereas two unique beta-1 
peptides, covering two N-linked glycosylation sites, were identified (Table 16) .  
Another putative candidate identified from this work was CD276, which was 
captured at significantly decreased levels following the induction of TGFβ. This 
membrane-based-glycoprotein, also known as the T-cell B7-H3 co-stimulatory molecule, 
has previously been implicated in the progression of cancer through effects on anti-tumor 
immunity(218,219). However, very little information exists regarding the biological role 
of its 6 potential N-linked glycosylation sites. One recent methods-based study uncovered 
two sites of altered sialylation in CD276 stemming from hepatocellular carcinoma cells 




stimulatory molecules are constitutively expressed on airway epithelial cells and may 
contribute to increased immune surveillance and inflammation at these surfaces(221). 
Unfortunately, an assessment targeting the sialylation status of CD276 in lung cancer has 
yet to be carried out.  
The aspartyl/asparaginyl beta-hydroxylase (ASPH) was observed having the 
lowest relative change in protein expression following TGFβ induction while 
simultaneously having the largest significant difference following ManNAcAz capture 
(47% decrease following TGFβ1 induction). This glycoprotein is found in the ER plasma 
membrane where it functions in the hydroxylation of EGF-like domains of transient 
proteins. The expression of ASPH has previously been noted as up-regulated at the 
mRNA level in several tumor cell lines and has therefore been suggested for further 
scrutiny as a putative biomarker(222). A UniProt search of ASPH indicates that it has 
two predicted N-linked glycosylation sites based on its amino acid sequence, however no 
published reports have confirmed this.  In addition, Granulins was also identified from 
double metabolic labeling experiments as a possible candidate of altered sialylation. This 
secreted protein has functions in wound healing/tissue repair, inflammation, 
embryogenesis and has been implicated in the progression of multiple cancers (223,224). 
There are 5 predicted sites of N-linked glycosylation on granulins and a recent 
publication has characterized 4 of them(225). Interestingly, although the authors noted 
the presence of several different fucosylated complex N-glycans, none of the species 
were sialyated.  
The lack of protein-level data on the remainder of the significantly different 




analysis of these 58 proteins identified that they were enriched in pathways related to 
metabolic processes, cell adhesion, extracellular matrix-receptor interaction, and other 
pathways with relevance to the acquisition of invasive tumor phenotypes.  Targeted 
studies of each individual species may therefore be a warranted. For example, immuno-
precipitation could be used to attain more-purified starting material for intact 
glycopeptide analysis or glycomic studies. This approach would be contingent on the 
availability of highly-specific antibodies for each target and MS instrumentation capable 
of these types of acquisitions.  These methods, however, have the potential for providing 
detailed characterization of glycan structures and glycosylation site occupancy 
information which could then be assessed as differentiating characteristics, alone or in 
combination with other parameters, for biomarker development.     
   Following the double metabolic labeling experiments, we next investigated the 
value of LC-MS/MS analysis of PNGase-F released glycopeptides from previously 
trypsin-digested alkyne-agarose beads. This approach was used to specifically survey the 
N-linked glycopeptides which incorporated ManNAcAz; as a means to potentially 
identify the sites where this was occurring. The principle of these experiments was based 
on the enzymatic specificity of PNGase-F, which cleaves the linkage between the core 
GlcNAc and the asparagine residue of all N-glycans (with the exception of those bearing 
a core (α1,3) linked fucose). During this reaction, the asparagine to which the glycan was 
attached is deamidated (converting it to Aspartic Acid), resulting in a 1Da mass shift 
detectable by MS. This approach to glycosylation site identification has previously been 




chromatography, but never utilizing Click-chemistry-based alkyne bead enrichment 
(179,180,226).  
Over 500 deamidated peptides were initially identified from the PNGase 
experiments. Sequential data filtering, from all deamidated peptides (Asn + Glu) → 
deamidated Asn only → deamidated Asn only and at least one N-linked consensus 
sequence, was applied to reduce the list to the most probable group for harboring N-
glycans. This process brought the number of peptides down to 385, representing 170 
unique proteins (91% glycoproteins). A subset of these peptides were selected for cross-
reference to assess how our putative site localizations compared to those on UniProtKB. 
This approach was selected because of the large list of peptides and the requirement of 
manual annotation. We discovered that, for some individual proteins represented by 
multiple peptides in our list, the same deamidation site was being identified. This 
phenomenon appears to be a consequence of slight variation in where N- or C-terminal 
trypsin cleavage occurred. As expected, deamidated Asn outside of N-X-S/T sequences 
were identified for a few of the peptides, reiterating the potential for false site 
identifications due to random deamidations(227). Modern approaches to circumvent this 
are focused on performing PNGase-F digest in the presence of isotopically-labeled water 
for the incorporation of 18O into Asp following glycan release. This method, termed 
Isotope-coded glycosylation site specific tagging (IGOT) has demonstrated utility for 
increasing the fidelity of putative N-linked sites(228). We also evaluated how 
deamidation sites from our selected list were annotated in UniProtKB. This database 
makes use of two designations for the assignment of glycosylation: Published or 




sequence analysis are predicted sites based on the presence of an extracellular consensus 
sequence and confirmation from an external prediction service such as NetNGlyc 
(http://www.cbs.dtu.dk/services/NetNGlyc/). Of the 43 non-repetitious peptides queried 
in our selected list, 24 matched UniProt listed sites by sequence analysis, highlighting the 
lack of existing information on N-linked glycan localizations. Therefore experimental 
approaches capable of cataloguing these sites will be useful for creating libraries from 
which experimental data may be compared.  
An additional comparison of the protein identifications made following PNGase-F 
release to those discovered from the original trypsin digest was performed.  
Approximately 63% of the total proteins represented in the PNGase-F based experiments 
had already been observed in the Trypsin fraction. Several potentially relevant 
glycoproteins were uniquely identified with either enzyme; however this may be the 
result of non-equivalent chromatographic separation and/or data processing steps used for 
either analysis. For example, the trypsin based experiments were carried out using a 5-
step 2D-LC chromatographic separation prior to LC-MS/MS, while only a single 
dimension was used for PNGase-F release acquisitions. The 392 trypsin-based 
identifications were made based on the application of our quantification criteria; which 
included the requirement of ≥2 SILAC ratios from the 3 biological replicates. In addition, 
trypsin data was not limited to deamidated peptides only, whereas PNGase-F data was 
immediately filtered to include only peptides with this variable modification. Therefore a 
more even gauge of protein content might be attained by the application of standardized 




To provide a more comprehensive analysis of the glycosylation profile of the 
H358 cells induced to express TGFβ or EV, we explored the N-linked glycoforms 
detectable by PNGase-F release and MALDI-FT-ICR analysis. Two experiments were 
performed, each utilizing a different glycan derivatization strategy. Permethylation was 
carried out to optimize FT-ICR settings for the detection of sialic acid-bearing moieties 
and linkage-specific sialic acid esterification to increase the detail of identified structures. 
From this cumulative effort, a wide range of N-glycans were acquired, including 
oligomannose, bi- tri- and tetra- antennary complex glycans, mono- and tri-sialylated, and 
core-fucosylated species. We observed one glycan which was detected only in the 
permethylated TGFβ-induced group (figure 9, m/z = 2519.3). Furthermore, inferences 
regarding relative glycan abundance led us to discover a disproportionate increase one of 
the sialylated N-glycans in TGFβ relative to EV in the linkage-specific derivatization 
(figure 10, m/z = 2128.7).  
One of the limiting factors to our H358 total N-glycome data is that only one 
replicate for each derivatization method was examined. This was primarily due to 
excessive difficulties in attaining high-intensity spectra with the H358 cell lysate. For the 
linkage specific work, two protein precipitation methods were tested, two protein 
concentrations for PNGase-F digest, and serial cotton tip HILIC enrichment prior to 
attaining the presented spectra. Despite lack of demonstrated reproducibility, we believe 
that the application optimized methods used here will be beneficial for future 
glycoproteomic biomarker discovery endeavors. For example, by utilizing two distinct 
derivatization methods we were able to identify a more diverse set of glycans than would 




antennary and three tri-antennary species which were not observed in the linkage-specific 
experiment. At the same time, four distinct bi-antennary complex glycans, and their sialic 
acid linkages, were discerned exclusively in the esterification fraction.  
  Finally, the use of high-resolution/high mass accuracy MS analysis greatly 
facilitated the structural characterization of these glycans. This acquisition strategy is 
based on the sensitivity of the FT-ICR mass analyzer for resolving the individual 
monosaccharide constituents of a given glycan moiety(230). Importantly, this type of 
mass analyzer has demonstrated utility for use with various ionization techniques 
including ESI, MALDI, and fast-atom bombardment. Thus, FT-ICR analysis of N-linked 
glycans is an ideal platform for rapid, sensitive studies which can be carried out on vast 
array of MS instrumentation.  
In summary, we demonstrated approaches for evaluating glycoproteins 
incorporating an analog of sialic acid, glycoform structures, and the identification of 
putative N-linked glycosylation sites from the H358 NSCLC cells. A workflow was 
explored utilizing the incorporation of azido-sugars and gene induction followed by 
enrichment of glycoproteins bearing these analogs (Figure 11). LC-MS/MS and label-
free quantification was applied to gain an initial look at targets which may be undergoing 
alternative glycosylation as a result of TGFβ1 or Zeb induction. The approach was 
narrowed to assess only TGFβ-influenced alterations in sialylated proteins and included 
SILAC metabolic labeling. In these experiments, relative protein quantity was calculated 
both before and after alkyne agarose bead enrichment so that inferences could be made 
regarding how protein expression levels were affecting captured targets. Further utility 




secondary digest, with PNGase-F, to identify site localizations of where ManNAcAz was 
being incorporated. Finally, a preliminary analysis of the global N-glycome of the H358 
was carried out.  Two separate derivatization methods were implemented and glycans 
were resolved by high-resolution/high mass accuracy MALDI-FT-ICR to ascertain if 
TGFβ1 was influencing the glycoforms and/or types of sialic linkages present. The 
combined use of these methods provided  multi-faceted insight as to how TGFβ1 
influenced the glycoproteome of this model and we therefore assert that these techniques 















































































































































































































































4.1 Introduction  
 The initial stages of glycoproteomic biomarker discovery are most often carried 
out using materials derived from in vitro or animal models of disease, tissue lysates, or 
serum/plasma (14,231). Each discovery substrate has distinct advantages and 
disadvantages, therefore sample availability and experimental strategy are often deciding 
factors for selection. For example, plasma/serum matrices are easily obtainable and have 
established utility in clinical testing. However, these samples may not be ideal for the 
study of low-abundance proteins or post-translational modifications because of the need 
for extensive pre-analytical preparations to remove high-abundance proteins. Cell culture 
models provide a cheap, abundant source of materials and are compatible with metabolic-
labeling to confidently quantify large numbers of analytes. However, these systems may 
not truly be representative of the in vivo tumor microenvironment, often restricting the 
applicability of findings.  To circumvent these limitations, several approaches for  
biomarker discovery have shifted towards analyzing biofluids in direct contact with the 
tissue of interest (“Proximal fluids”)(15,232–234). These fluids contain tissue-specific 
leaked and secreted proteins at higher concentrations than found in serum. In addition, 
many proximal fluids are readily accessible (saliva, urine, tears) or routinely collected 
during diagnostic procedures (Bronchoalveolar lavage fluid (BAL), cerebrospinal fluid, 
gastric secretions). Furthermore, these types of samples are ideal for glycoproteomic or 
glycomic studies because of the frequency with which this PTM occurs along the 
secretory pathway. 
Another useful strategy for biomarker discovery has been the analysis of tumor 




materials because of their direct nature; without dilution of analytes in heterogeneous 
substrates. In the past, workflows for the preparation of tissue-derived samples required 
laborious processing steps and were incompatible with concurrent examinations to define 
histological features. More recently, methods have been developed for intact tissue 
profiling and spatial resolution of proteins, lipids, and glycan species(211,236,237). 
Importantly, these imaging mass spectrometry procedures can be used to define the 
distribution of various analytes in fresh-frozen or formalin-fixed paraffin embedded 
tissues and may be carried out in parallel to pathological examinations.  
At the same time as biomarker efforts using proximal fluids and tissue-imaging 
approaches are moving forward, innovations in pre-analytical sample preparations and 
MS-instrumentation have come about. These advances have been  integral in facilitating 
glycomic-based biomarker studies(230). For example, evolving derivatization methods 
have synergized with the development of high-resolution and mass accuracy MS systems 
to provide a robust means for the structural characterization of sialylated carbohydrate 
molecules. One such procedure, recently described by Reiding et al., encompasses 
chemical modification of sialic acid for the discrimination of anomeric linkages(212). 
When this method is combined with highly sensitive instrumentation, such as a MALDI- 
FT-ICR, a more detailed structural evaluation can be performed than previously possible. 
While the use of MALDI-FT-ICR is not novel for oligosaccharide analysis, 
implementation of this strategy for investigations based on proximal fluid derived 
glycans has not been previously investigated.  
Therefore, we implemented a novel approach to the characterization of disease-




acid derivatization and MALDI-FT-ICR analysis.  Pathologically-defined matched 
human samples, including BAL fluid and saliva, as well as fresh frozen lung tissue 
(tumor and adjacent normal) were obtained from the lung cancer bio-specimen repository 
network. Fluids were pooled and processed for derivatization and cotton-tip HILIC 
enrichment of N-linked glycans. Fresh frozen tissues were sectioned at 5µm thickness 
and processed on-slide prior to MALDI-FT-ICR acquisition of N-linked glycans; 
duplicate slides were prepared for histological evaluation by a board-certified pathologist.    
 
4.2 Materials and Methods 
4.2.1 Samples Description 
  10 de-identified, matched sets of human samples (5 benign, 3 squamous cell 
carcinoma, 2 adenocarcinoma) were obtained from the Lung Cancer Bio-specimen 
Resource Network (LCBRN). The included bio-specimens, and a link to the LCBRN 
website where the methods for collection are describe, can be found in Table 19. All 
samples were stored at -80⁰C until processing.   
4.2.2 Bronchoalveolar Lavage Fluid Proteomics 
4.2.2.1 Sample preparation and In-solution digest 
The 10 BAL samples were thawed on ice and 75µl aliquots were prepared as a 
working solution. 3µl of each samples was visualized by polyacrylamide gel 
electrophoresis (SDS-PAGE) (4-12% NuPage ®Bis-Tris Gel, Life Technologies) and 
silver stained (SilverQuest™, Life Technologies) to approximate total protein quantity. 
Normalized samples were brought up to 75µL total volume in 50 mM NH4HCO3 




room temperature, IAA was added to a final concentration of 20mM and alkylation 
proceeded for 30 minutes in the dark. Samples were digested at 37⁰C for 16 hours with 
2µg proteomics grade trypsin. Following digestion, samples were desalted by µC18 Zip-
Tip (Milipore), speedvac concentrated, and stored at -20⁰C until LC-MS/MS.  
4.2.2.2 LC-MS/MS and Bioinformatics 
LC-MS/MS, Bioinformatics, and generation of normalized spectral counts for 
BAL samples were performed as described in section 3.2.5. Gene Ontology (GO) 
analysis of proteins uniquely identified in cancer-associated BAL fluid was performed 
using Web-based gene set analysis toolkit (Webgestalt: 
http://bioinfo.vanderbilt.edu/webgestalt/)(238,239). Protein identifications were 
compared to the normal distribution of genes in the human genome to identify biological 
processes and cellular components which were enriched (BHp <0.05) relative to expected 
distribution. Specifications included: Organism = Homo sapiens, Id Type = 
uniprot/swissprot accession, Ref Set = entrezgene, Significance Level = Top10, Statistics 
Test = Hypergeometric, Multiple test correction = Benjamini Hockberg, Minimum 
number of genes = 2.  
4.2.3 N-linked Glycomics of Human Biofluids 
Pooled BAL samples were prepared from each diagnostic group (Benign, SCC, 
AC) at 100µL total volume. Two saliva pools were prepared at 200µL total volume: 1. 
Benign- 40µL of each benign sample and, 2. Metastatic- 40µL from each of the 
metastatic groups (SCC+AC).   Linkage-specific sialic acid esterification proceeded as 
described in section 3.2.10.1. MALDI-FT-ICR N-glycan analysis and bioinformatics 




4.2.4 N-linked Glycan Imaging of Lung Tissue 
4.2.4.1 Sample preparation 
Flash frozen lung tissues were prepared for MALDI-Imaging Mass Spectrometry 
(MALDI-IMS) by the formalin-fixed paraffin embedded method described by Powers et 
al.(240). Tissues were sectioned at 5µm and mounted onto positively charged glass slides 
compatible with the Bruker FT-ICR adaptor plate. Citraconic anhydride (Thermo) was 
used for antigen retrieval. Following buffer exchange and desiccation, .2µL of 
recombinant PNGase-F were applied uniformly using an ImagePrep spray station (Bruker 
Daltonics) and slides were incubated at 37⁰C for 2 hours in a humidified chamber. Slides 
were desiccated for 10 minutes and matrix (0.021g α-Cyano-4-hydoxycinnamic acid 
(Sigma) in 3 ml 50% acetonitrile/50% water and 12µl 25% trifluoroacetic acid) was 
applied using the TM-sprayer™ (HTX Technologies). Duplicate slides of each tissue 
were prepared for hematoxylin and eosin staining, and definition of histological features 
was performed by a board-certified pathologist.  
4.2.4.2 N-glycan MALDI Imaging Mass Spectrometry 
Released N-glycans were acquired directly on tissue with a Solarix dual source 7T 
FT-ICR mass spectrometer (m/z= 500-5000). A SmartBeam II laser operating at 2000 Hz 
was used to acquire spectra across at a raster width of 50µm.  Detected glycan species 
were viewed using FlexImaging 4.1 software. Identifications were made by searching 
spectra in the range of m/z = 1000-4000 against the glycan structures database of the 
Consortium for Functional Glycomics. Glycan structural annotations were produced in 







Table 19: Lung Cancer Bio -specimentResource Network Sample Types
Collection protocol for each specimen can be found at http://avillage.web.virginia.edu/LungBio/standard-operating-procedures
Diagnosis:
Benign





















































































4.3.1 Bronchoalveolar Lavage Fluid Proteomics 
We examined the proteomic contents of 10 human BAL fluids for an initial 
survey of constituents detectable by LC-MS/MS. These samples were derived from a 
pathologically defined set of matched biofluids and tissues, including 5x benign, 3x 
squamous cell carcinoma (SCC), and 2x adenocarcinoma (ADC). In addition, we gauged 
the relative abundance of identified proteins by label-free quantification to provide a 
well-annotated resource from which future studies may be compared.   
Total protein abundance of each sample was estimated by SDS-PAGE and silver 
staining (Figure 12).  Darker banding patterns were observed in the cancer relative to 
benign samples, with the exception of sample W0099. This visual assessment was used to 
gauge individual sample input for an in-solution trypsin digest and LC-MS/MS analysis 
of proteomic content. A total of 332 proteins were quantified from all samples following 
the application of post-processing parameters for the production of normalized spectral 
counts (Table 20, suppl. materials). Of the total proteins discovered, 35% matched the 
Uniprot glycoprotein keyword search. Grouping of the individual samples into two 
categories (Cancer and Benign) for comparison resulted in the identification of 25 
proteins distinctly quantified in cancer-associated BALs and 12 unique to Benign (Table 
21, suppl. materials).  Glycoproteins identified only in the cancer group included 
Osteopontin, Clusterin, and Mucin-4. Conversely, Sialic acid synthase was quantified 





Figure 12: Bronchoalveolar Lavage Fluid Protein Content.  3µl 
BAL fluid separated by 4-12%






shared proteins, discrepancies were obvious in the nSC quantity of cell adhesion and 
extracellular glycoproteins including an increase in CD59, Galectin-3 binding protein, 
Mucin-5, and Mesothelin, as well as decreases in the redox-related proteins Catalase, 
Peroxiredoxin-6, and Thioredoxin reductase-1, in the cancer group relative to benign.  
GO analysis of proteins uniquely identified from cancer BALs revealed significant 
enrichment of intracellular non-membrane-bounded, extracellular, and cytoskeletal 
cellular components, amongst others (Table 22). In addition, biological processes 
represented included protein-DNA complex assembly, chromatin assembly, and 
nucleosome organization.   
4.3.2 N-linked Glycomics of Human Bio-fluids 
Matched human biofluids, including BAL and saliva, were processed for N-linked 
glycan profiling by linkage-specific sialic acid esterification and FT-ICR analysis. Total 
acquired spectra from each BAL pool (Bn, SCC, and ADC) were first evaluated from 
1200- 3250 m/z (Figure 13). We observed abundant spectra (>108 intensity) in each pool 
and therefore annotated individual peaks to assess differences between groups (Figures 
14-16). A peak at m/z = 2301.8, correlating to a di-α2-6-sialylated bi-antennary complex 
glycan, was the most prevalent species observed in all BAL samples. Within the benign 
pool, there was an increased abundance of Hex9HexNAc2 (m/z = 1905.7), 
Hex5dHex2HexNAc4 (m/z = 1955.7), and Hex5dHex1HexNAc4 (m/z = 1809.7) relative 
to SCC and ADC (Figure 14).  The ADC pool had a distinct increase in an α2-6-mono-
sialylated bi-antennary complex glycan (Figure 14: m/z = 1982.8) as well as an apparent 
decrease in the relative peak height of two di-sialylated bi-antennary complex glycans 
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= α2,3 sialic acid
= α2,6 sialic acid
Figure 14: BAL Pool FT-ICR Spectra (m
































































































































































































































































































































Figure 16: BAL Pool FT-ICR Spectra (m
/z = 2940-3185)
= α2,3 sialic acid
= α2,6 sialic acid





















































































Pooled saliva samples were next examined over the mass range of m/z = 1160-
3250 (Figure 17).  Clear differences in the spectra of the benign and cancer were 
apparent, therefore we assessed which structures were predominant in each group 
(Figures 18 - 20). In the benign pool, the tri-antennary complex glycan 
Hex3dHex1HexNAc5 (m/z = 1688.7) was the most prevalent. This species was followed 
by a near equal distribution of m/z = 1850.7 and 2101.8, correlating to a core-fucosylated 
tri-antennary and a tri-fucosylated bi-antennary glycan, respectively (Figure 18 and 20).  
There was also an apparent increase in an α2-6-mono-sialylated tri-antennary glycan (m/z 
= 2169.8) and a decrease in a di-fucosylated tri-antennary complex species (m/z = 
2320.9) in the benign pool relative to the cancer (Figure 20). The cancer pool presented 
with a slightly higher mass tri-antennary glycan, Hex4dHex1HexNAc4 (m/z = 1809.7) 
dominating peak height. In addition, the increased relative abundance of bi-antennary 
Hex5dHex2HexNAc4 (m/z = 1955.7) and tri-antennary Hex6dHex1HexNAc5 (m/z = 
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4.3.3 N-linked Glycan Tissue Imaging of NSCLC Tissue 
Human lung tissue was sectioned and processed for on-slide PNGase-F digest, 
matrix application, and MALDI-FT-ICR acquisition of released N-glycans (Figure 21). 
These included tumor and adjacent normal tissue from one adenocarcinoma and two 
squamous cell carcinomas. A duplicate slide of each was stained with hematoxylin and 
eosin and histological features were confirmed by a pathologist (Figure 22).  The 
distribution of individual peaks was compared against defined regions to determine how 
their expression correlated to histology (Figures 23a and 23b).  From this effort, we 
identified three glycans whose presence was increased in the tumor tissues (both ADC 
and SCC) relative to normal adjacent (m/z = 1419.5, 1743.6, and 2174.8). These 
structures correspond to Hex6HexNAc2, Hex8HexNAc2, and Hex6dHex1HexNAc5, 
respectively. In addition, three other species appeared to be up-regulated exclusively in 
the defined cancer region of ADC (m/z = 1955.7, 2320.8, and 2686.0). These glycans 
correlated to a set of di-fucosylated structures including Hex5dHex2HexNAc4, 
Hex6dHex2HexNAc5, and Hex7dHex2HexNAc6. There was also a single spectra, 
correlating to Hex3dHex1HexNAc4, which was selectively dominant in SCC tumor 
tissues (m/z = 1485.5). In addition, we identified several N-glycans whose expression did 


















































































































































































































































































































































































Figure 23b: Distribution of N









Here the application of recently-developed methods for N-linked glycomics on 
pathologically-graded, clinically-relevant NSCLC samples was assessed. A pre-analytical 
sialic acid linkage derivatization approach was applied to biofluids, including BAL and 
saliva, and acquired mass spectra using a high resolution accurate mass instrument.  We 
also performed an on-tissue PNGase-F digest and imaging mass spectrometry to spatially 
resolve glycans on tumor and adjacent normal tissues. The rationale for these 
experiments was seeded both in the methodology employed and the types of samples 
analyzed; to gauge their collective utility for future biomarker discovery efforts.    
 The proteome of human BAL pools (benign and cancer) was first evaluated to 
catalogue the components detectable in each diagnostic group by LC-MS/MS. This 
substrate has previously demonstrated relevance as a tool for diagnostic/prognostic 
evaluations of various pathologies, however explorations of its proteomic content are still 
rather new(15,233,234,241). We discovered over 300 proteins across the 10 samples 
analyzed and applied label-free quantification as a means initially assess relative 
abundance of each. General trends were observed in protein abundance based on the 
application of label-free quantification which would likely be of value exploring using 
isotopic labeling techniques such as, iTRAQ, or TMT methods.  In addition, based on the 
high nSC values obtained for albumin, IgG, and transferrin-related proteins, the 
application of up-front depletion/enrichment strategies would likely increase the depth of 
identifications for sub-proteomic investigations.  
The N-linked glycome of BAL fluid was analyzed using sialic acid linkage 




glycoforms derived from this proximal fluid that we know of.  In addition, we profiled 
structures present in matched saliva pooled samples to increase the breadth of 
investigation and discern the utility of these substrates for glycomic-based biomarker 
discovery efforts in NSCLC. An obvious difference in the distribution of peaks 
associated with N-linked glycan structures was apparent between BAL pools. The glycan 
structural database from the consortium for functional glycomics was utilized to make 
identifications based on FT-ICR accurate mass detection. Several bi- and tri-antennary 
complex structures, including core-fucosylated and mono-, di-, and tri-sialylated forms, 
were shared between pools. Based on relative peak intensity, we discovered the 
predominant species present in each group was a di-α2-6-sialylated bi-antennary complex 
glycan (Figure 13; m/z = 2301.8). Three glycans, including an oligomannose structure, 
appeared to be uniquely up-regulated within the benign pool (Figure 14).  As well, there 
was apparent down regulation of two structures (Figure 15; m/z = 2355.9 and 2401.9) in 
the ADC pool relative to benign and SCC. Furthermore, the application of linkage 
specific sialic acid esterification resolved the presence of di- and tri- sialylated complex 
glycans, displaying multiple anomeric configurations, in the higher mass ranges of these 
samples (Figure 16).  For saliva pools, there was a generalized decrease in the number of 
spectra correlating to sialylated glycan moieties relative to the BALs. Structures 
identified in saliva-based benign and cancer groups were predominantly lower mass bi- 
and tri- antennary complex glycans. Relative peak height suggested that the predominant 
species in the benign pool was by far a core fucosylated tri-antennary moiety, while the 
cancer group appeared to have a more even distribution of 3 main structures (Figure 17).  




pools. These included four of the most abundant peaks identified in saliva representing 
three fucosylated bi-antennary and one fucosylated tri-antennary complex glycans 
(Figures 18 and 19; m/z = 1793.7, 1809.7, 1850.7, and 1955.7).   
Intact lung tissue MALDI-FT-ICR imaging mass spectrometry was used to 
spatially profile the distribution of native N-glycans in tumor and normal-adjacent 
tissues.  Eight oligomannose structures were presented as a demonstration of how this 
data could be useful for defining specific features of histology. In addition, we cross-
referenced several peaks from the imaging data which had previously been identified in 
the proximal fluid studies. These included species whose localization appeared to 
correlate to increased expression in ADC only (Figure 24a and 24b; m/z = 1955.7), SCC 
only (Figure 25a and 25b; m/z = 1485.6), or within both cancer groups cancer (Figure 
26a and 26b; m/z = 1419.5). Conversely, we assessed potentially interesting spectra 
from the proximal fluids in the imaging data. For example, based on visual assessment of  
peak height, the core-fucosylated tri-antennary glycan (m/z = 1688.7) was the prevalent 
species in the benign saliva pool (Figure 17) .However, the  spatial distribution of this 
species, and peak height in the BAL pools, did not correlate with this observation (Figure 
27). In a similar manner, the high-mannose glycan (m/z = 1905.7) appeared to be more 
abundant in the benign BAL pools relative to SCC and ADC; yet imaging data suggested 













































































































Figure 24a: Distribution of m







































































































































































































































































































Figure 25a: Distribution of m










































































































































































































































































































Figure 26a: Distribution of m
















































































































































































































































































































Figure 27: Distribution of m









































































































































































































































































































Obvious caveats limit the ability to assess trends in glycan expression between 
substrates as presented. These include the use of pooled proximal fluid samples and the 
low number of tissues used for imaging. In addition, statistical analysis for evaluating 
differences in relative peak height was not performed and reproducibility has yet to be 
investigated.  Furthermore, the release of glycans from dominant endogenous 
glycoproteins in these substrates may overpower the detection of lower abundance 
species. Another limiting factor related to these investigations was the use of linkage-
specific sialic acid derivatization for proximal fluids only. This approach was adopted to 
both protect sialic-acid containing glycans during ionization and discern their anomeric 
configurations. However, an equivalent method for on-tissue derivatization has yet to be 
developed; precluding extensive detection of sialylated species for on-tissue experiments. 
As an alternative, increased identification of these glycans might be achieved by imaging 
mass spectrometry carried out in negative ionization mode(242).   
Bronchoalveolar lavage fluid and saliva are appropriate substrates for the 
discovery of disease-specific glycosylation patterns in NSCLC. These fluids are abundant 
sources of secreted/shed glycoproteins and are frequently collected during routine 
diagnostic or follow-up procedures. Saliva may be acquired regularly in copious volumes 
with minimum patient risk, while BAL fluids are typically available from patients 
presenting with a respiratory mass following bronchoscopy. Although BAL has been 
probed for diagnostic and prognostic utility based on cytological and (more recently) 
proteomic content, investigations of  N-linked glycoforms in this fluid are 
novel(233,234,243,244). Similarly, efforts to utilize saliva for biomarker discovery have 




Saliva is known to be an rich source of carbohydrate molecules stemming from mucins 
and high molecular weight glycoproteins, however explorations into the types of glycan 
structures it carries, and how they relate to specific pathologies, are 
limited(188,247,249,250). In addition, the presented methods could also be applied to 
proximal fluids such as exhaled breath condensate or pleural fluid. These materials 
contain proteomic content derived from the respiratory epithelium and early studies have 
demonstrated their feasibility for use in biomarker evaluations(251,252). While all of 
these fluids may be potent reservoirs of glycan molecules related to disease, 
consideration must be given to collection and processing procedures in order to reliably 
assess reproducibility of findings. This potential limitation will be addressed in our on-
going studies by continuing to use bio-repository maintained samples with well-
documented collection/processing procedures. The use of this sample resource will also 
provide us with follow-up patient data which will likely be of value for correlating glycan 
structures to specific outcomes such as disease recurrence and mortality rates.  
 In relation to the MALDI tissue imaging approach presented, one of the limiting 
factors was the inability to attain spatial resolution at cellular and sub-cellular levels. This 
constraint has the potential to decrease the specificity of detected glycans because of the 
heterogeneous cell populations present in and adjacent to tumor tissues. Efforts to address 
this have successfully used an overlapping laser shot approach where repeated ablation of 
tissue resulted in improved resolution  down to approximately 25µm(253). Alternatively, 
the use of smaller diameter lasers combined with a “transition geometry” method, where 
the MALDI laser is fired from behind the tissue, has also achieved higher definition in 




incorporating these strategies into our workflow was principally constrained by the time 
and analytical requirements necessary to carry out these approaches. The selection of a 
raster width of 50µm was therefore an appropriate compromise to attain moderately high 
resolution images in a time frame conducive to high-throughput studies.   
Another factor to consider for the glycan imaging studies was the discovery of 
inflammation and immune cell infiltrate within the tissues during histological assessment. 
This finding was unsurprising granted the established role for immune activation and 
inflammation in the pathogenesis of NSCLC(255).  Importantly, several studies have 
taken advantage of the presence of such infiltrating cells to research the prognostic 
significance specific populations may confer (7,256).  Further utility of our approach 
might therefore be achieved by incorporating a phenotypic evaluation of these infiltrating 
cells as an additional metric for prognostic considerations. Additionally, the discovery of 
immune cell and/or inflammatory-associated glycan epitopes from tissue imaging studies 
would be useful for this purpose, particularly if they could be translated into biofluids 
with relevance for clinical assays. 
In summary, the assessment of a combined approach to identify N-glycans 
derived from matched lung tissues and proximal fluids was presented (Figure 29).  
Oligosaccharides were released from BAL and saliva pools and underwent a sialic acid 
linkage-specific derivatization strategy. This procedure serves to both protect from the 
loss of labile sialic acid residues during ionization and allow for discernment of linkage 
conformations. At the same time, tumor and normal lung tissues matched to the proximal 
fluids were sectioned for histological analysis and on-tissue acquisition of N-glycans. 




relevant histological features of the tissue. All MS analyses were carried out on a 
MALDI-FT-ICR instrument, providing high-resolving power to differentiate a variety of 
oligomannose and complex glycans from each sample type. The implementation of these 
analytical strategies carried out on a set of matched samples was conducive to directly 
cross-referencing distinct glycan structures between tissues and biofluids. Therefore, on-
going studies focused to increasing the throughput, applying statistical analyses, and 
assessing reproducibility from these methods are likely to result in a whole new paradigm 
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5.1 Glycoproteomic and Glycomic Approaches to Evaluate 
TGFβ1-induced effects on Sialoglycoproteins in a Cell 
Culture Model of NSCLC 
5.1.1 Conclusions 
We hypothesized that the development of mass spectrometry-based 
glycoproteomic and glycomic workflows could be used to identify detailed characteristics 
in sialylated glycoproteins in NSCLC. To test this, investigations were carried out in the 
H358 cells using an azido-sugar metabolic labeling, alkyne agarose bead enrichment, and 
LC-MS/MS quantification strategy. Differential capture of glycoproteins incorporating 
ManNAcAz following TGFβ1 induction was assessed by both label-free and SILAC 
relative quantification. The double metabolic labeling strategy was also utilized to 
examine relative protein expression levels influenced by TGFβ1. In addition, the utility of 
a secondary digest using PNGase-F was gauged for surveying N-linked glycosylation 
sites. Finally, the global N-glycome of TGFβ1-induced H358 cells was acquired using an 
innovative pre-analytical strategy and MALDI-FT-ICR analysis. The application of these 
approaches revealed that:   
1. We developed a robust method for the interrogation of sialylated glycoproteins in a 
cell culture model of NSCLC by mass spectrometry. A multi-faceted approach, including 
quantification of glycoproteins incorporating a sialic acid analog following the induction 
of TGFβ1, elucidation of N-linked glycosylation sites, and structural evaluations of 




assessments of these strategies also demonstrated feasibility for the methods with the 
GalNAcAz label and cell culture supernatant fractions. 
2. H358 cells efficiently incorporate the ManNAcAz label onto nascent glycoproteins as 
demonstrated by WB analysis of cell lysates using biotin-alkyne/streptavidin-IR dye. The 
induction of TGFβ1 appears to increase the presentation of the analog dramatically.   
3.  ManNAcAz labeling and Click-chemistry alkyne-agarose bead enrichment are an 
efficient means to selectively study low-abundance glycoproteins. This was evidenced by 
the high proportion of glycoproteins identified in SILAC+Click experiments (76%) 
relative to SILAC-Only experiments (11%).  
4. The induction of TGFβ1 expression in ManNAcAz-labeled cells resulted in significant 
differences in the captured quantities of glycoproteins relevant to the acquisition of 
invasive phenotypes. Supporting this was KEGG enrichment analysis of proteins 
captured at significantly different levels representing cell adhesion, extracellular matrix, 
and cytoskeletal-related functions.  
5. The inclusion of SILAC with the azido-sugar metabolic labeling procedures provided a 
reliable means for quantifying the large number of glycoproteins identified. Even after 
the application of stringent post-processing parameters and replicate trimming, over 390 
proteins were quantified from Click enriched samples and 700 from non-enriched.    
6. The double metabolic labeling strategy provided limited information regarding how 
TGFβ1-influenced protein expression levels were contributing to differential capture 
quantities. This was evident from the low number of proteins shared between the SILAC-
Only and SILAC+Click fractions (91 total). Furthermore, only 5 proteins were found to 




BHp = 0.05 and 0.10.  A more prudent approach to assess protein expression may be to 
perform WB analysis on selected glycoproteins relevant to invasive biological processes.     
7.  The utility of the alkyne-agarose bead enrichment procedure can be extended by the 
application of a secondary digest to release bound N-linked glycopeptides. This strategy 
is useful for verification of N-linked sites where ManNAcAz was incorporated and may 
reveal additional glycoproteins not detected by the initial digest.  
8.  MALDI-FT-ICR analysis of H358 N-linked glycoforms, using two derivatization 
methods, identified an array of the most prominent oligosaccharide structures from TGFβ 
and EV-induced cells. The permethylation approach was useful for identification of 
oligomannose and tri- and tetra-antennary complex glycans. The linkage-specific 
esterification method resulted in elucidation of anomeric configurations of sialic acid on 
several bi-antennary complex glycans. 
5.1.2 Limitations of Azido-sugar Metabolic Labeling Studies 
The azido-sugar metabolic labeling, alkyne-agarose bead enrichment and LC-
MS/MS approach is a powerful tool for analyzing characteristics of sialylated 
glycoproteins, however there were some inherent technical and conceptual limitations 
associated with this strategy. These shortcomings are introduced here and discussed in 
more detail in the future studies section (5.1.3). 
 One limitation is the inability to release bound glycans from the alkyne agarose 
beads for structural evaluations. This limitation is due to the covalent nature of the Click 
reaction between the azide and alkyne functional groups. The strength of this reaction is 
an advantage for proteomic evaluations of captured glycoproteins, because it allows 




time, however, the glycans which incorporated the azido-sugar remain permanently 
bound to the beads and there is currently no method available to release them. Therefore, 
the presented approach provides proteomic and N-glycan site data on captured 
glycoproteins without concomitant information on the glycan structures which 
incorporated the analog sugars.  
 Another drawback is the lack of information that can be obtained regarding O-
linked glycosylation sites. This weakness is more related to the lack of an enzyme for O-
glycan release from the alkyne beads than it is to the azido-sugar labeling and enrichment 
methodology. Further adding to this constraint is the lack of an amino acid consensus 
sequence for the attachment of O-linked sugars. Peptides attached to the beads linked via 
an O-glycosylation linkage could be released by beta-elimination, but there is no way to 
verify what site was modified, or how many sites were modified, for a given protein. 
Therefore, the presented approach is currently only amenable to identifying sites of N-
linked glycosylation where the azido sugars are being incorporated, without equivalent 
information on sites of O-linked glycosylation.  
Another weakness related to N-linked glycosylation site identification is the 
inability to differentiate random deamidations on asparagine residues from PNGase-F-
mediated deamidations. Random deamidations may occur on asparagine or glutamine due 
to proteolytic degradation or because of side-chain reactions with glycine or 
serine/threonine residues. As a result, it is possible that some of the N-linked glycan sites 
identified were result chance occurrences; however the high proportion of peptides in 
which Asn was deamidated within an N-linked consensus sequence argues more for a 




Conceptual constraints also limit the relevance of information obtained in the 
presented approach.  For example, in our demonstration of the methods, only one cell 
model of lung cancer was assessed. In addition, a single time-point of gene-induction and 
only one mechanism for inducing invasive phenotypes was carried out during 
experimental procedures. Therefore the findings presented do not adequately represent all 
relevant changes in sialylation that occur during the entire time-course of TGFβ1-induced 
NSCLC progression;  rather, our method provided a “snapshot” of sialylation changes 
occurring in a limited representation of the disease.  
Another conceptual concern relates to the inability of the presented strategy to 
measure absolute protein and sialylation changes between experimental groups. Because 
the presented approach is based on relative quantification of captured glycoproteins, it is 
possible that differences in sialylation where missed when a given glycoprotein’s 
incorporation of the azido sugar was in opposition to changes in protein quantity. For 
example, if TGFβ1 caused increased sialylation while simultaneously decreasing protein 
quantity for a given glycoprotein (relative to empty vector cells), then no difference in 
captured quantity would be seen between the groups. Therefore, the presented method is 
limited in that some of the differences in sialylation were likely over- or under-estimated. 
5.1.3 Future Studies 
The goal of this work was to develop methods and evaluate experimental 
approaches tailored to future glycoproteomic/glycomic biomarker studies in NSCLC. The 
initial experiments using azido sugar labeling and Click chemistry enrichment with label-
free quantification demonstrated feasibility for the use of both ManNAcAz and 




and subsequent investigations were carried out only for ManNAcAz-labeled cell lysate 
fractions following TGFβ1 induction. Therefore a more in-depth investigation into cell 
culture supernatant glycoproteins (i.e. secreted products) may be beneficial for translating 
in vitro findings into frequently used clinical fluids. An added benefit for this type of 
approach  is that this method has previously been shown to maintain selectivity for low 
abundance glycoproteins without the complete removal of serum supplements from cell 
culture media(194). Furthermore, we have carried out preliminary assessments of this 
approach for the detection of exosomal glycoproteins (data not shown). These non-
classical secreted vesicles have shown promise as a cancer biomarker discovery source as 
they carry tumor-specific protein products and may be isolated from multiple biological 
fluids(257,258). Therefore we additionally propose to implement the SILAC double 
metabolic labeling strategy for the quantification of exosomal glycoprotein cargo as a 
future direction.  
Other variables to the presented strategy that will be addressed by future studies 
include a dedicated approach centered on the use of other sugar analogs, such as those for 
Fucose, GalNAc, or GlcNAc. These studies may provide a more comprehensive view of 
how other classes of glycoproteins respond to specific stimuli such as TGFβ1. As well, 
for increasing the likelihood that in vitro findings will be representative of in vivo 
disease, additional studies would benefit from applying these methods to multiple cell 
models. For the presented work, parallel investigations using A549 or HCC4006 cells 
may have highlight inconsistencies or uncover common trends with the H358 model. 
Similar to this, utilization of alternative mechanisms for the production of specific 




changes are truly of a consequence these processes. For example, as an alternative to the 
use of TGFβ1 to induce invasive characteristics, future studies might use  hepatocyte 
growth factor or epidermal growth factor treatments, knockdowns of miR200, or the 
modification of E-cadherin to achieve this outcome. 
The primary workflow utilized for azido sugar labeling and TGFβ1 induction (Figure 
2) was based on a previously optimized procedure described by Yang et al with slight 
modifications (193). Specifically, cells are incubated with the analog sugars for 48 hours, 
followed by a media change and the addition of doxycycline for 24 hours prior to 
collection of lysates and cell culture media.  In order to gain a better perspective as to 
how sialylation is affected by TGFβ1 expression, different gene induction time-points 
should be utilized. For example, studies with extended exposure to TGFβ1 or 
experimental approaches where analog sugar metabolic labeling occurs after doxycycline 
treatment would be worthwhile endeavors.   
 In chapter 3, we utilized a broad-approach to identify large populations of 
glycoproteins potentially undergoing alternative sialylation in response to TGFβ1 
stimulation. The logical next step from these investigations would be to critically 
evaluate the individual proteins identified from this work.  Future studies will therefore 
employ approaches such as immunoprecipitation to selectively focus on the glycosylation 
of specific targets. Glycoproteins captured at significantly different levels from 
SILAC+Click will be individually evaluated for protein expression levels by WB prior to 
moving forward. Mass spectrometry analyses such as HCD-PD-ETD will be employed to 
simultaneously gauge individual glycans and their site localizations on a given 




Gemmill, have already begun assessing the utility for this type of approach on putative 
targets such as Neuropilin-2. Furthermore, PNGase-F based release of N-glycans and 
utilization of linkage-specific derivatization methodology can be used as a parallel 
approach to both verify oligosaccharide structures and attain sialic acid linkage 
information from the individual targets.  
Modifications to our strategy for glycosylation site assessment would also be an 
appropriate endeavor for future work. One of the central limitations to the method 
presented was that only N-linked glycopeptides were released. Implementing an approach 
for release of O-linked glycopeptides, such as beta elimination or hydrazinolysis, would 
be useful for assessing additional glycoproteins incorporating the analog. For O-linked 
site elucidation, difficulties arise because of the lack of consensus sequence for these 
glycans. Therefore, for this specific goal, exoglycosidase release of bead-bound 
glycopeptides followed by intact glycopeptide analysis would be the best approach.  
Another avenue worth exploring would be accounting for the SILAC labels 
incorporated into peptides released from the alkyne beads by PNGase-F.  This strategy 
would allow us to record the ratios of peptides derived from either experimental 
condition (TGFβ or EV) because the samples are mixed at 1:1 ratio prior to alkyne bead 
enrichment. This strategy has the potential to provide quantitative information on 
sialylation occurring at distinct glycosylation sites.  
Quantitative glycomic studies may also be carried out using the cell culture model of 
NSCLC. These investigations have the potential to uncover trends in the expression of 
specific glycan structures which warrant further exploration in clinically-relevant samples 




interest in human biofluids/tissues). In an experimental approach similar to SILAC, 
isotopic detection of amino sugars with glutamine (iDAWG), has shown promise for the 
quantification of  N- and O-glycan structures (259,260). This method is based on the 
metabolic incorporation of isotopically labeled nitrogen into GlcNAc, GalNAc, and sialic 
acid monosaccharides, which all rely on the side chain of glutamine as their source of 
nitrogen for biosynthesis.     
 
5.2 Glycomic Assessment of Human NSCLC Biofluids and Tissue 
5.2.1 Conclusions 
In aim 2, we tested the application of new glycomic mass spectrometry 
acquisition strategies in human biofluids and lung tissues to investigate their utility in 
clinically-relevant sample types. A set of matched proximal fluids and tissue representing 
cases of benign disease, adenocarcinoma, and squamous cell carcinoma were utilized for 
“proof-of-concept” experiments. The proteome of BAL fluids was characterized by LC-
MS/MS and preliminary trends were highlighted between the diagnostic groups. N-linked 
glycans from pooled samples of BAL and saliva were subjected to a linkage-specific 
sialic acid esterification method prior to acquisition on a high resolution/high mass 
accuracy instrument. Normal and tumor lung tissue were sectioned for histological 
analysis and tissue imaging mass spectrometry of native N-glycans. The application of 
these methods demonstrated that:  
1. A detailed characterization of N-linked glycan structures present in proximal fluids and 
tissues of lung cancer can be accomplished by using a combination of recently-developed 




sialylated N-glycans in biofluids and the application of tissue imaging mass spectrometry 
to correlate specific oligosaccharides to histological features of the tissues. The use of 
MALDI-FT-ICR for all MS acquisitions provided a high level of precision and mass 
accuracy for resolving structures in each starting material. The use of matched samples 
allowed for direct comparison of structures between the fluids/tissues, representing a 
whole new paradigm in biomarker discovery efforts. Furthermore, this was the first 
demonstration of feasibility for the use of BAL fluid as glycomic biomarker reservoir that 
we know of.  
2. Bronchoalveolar lavage fluid contains a diverse set of proteins representing biological 
processes such as wound healing, inflammatory response and coagulation. Over 300 
proteins were identified, approximately 35% of which matched the Uniprot keyword for 
glycoprotein. The application of label-free quantification was a convenient means for 
assessing preliminary trends in the quantity of proteins between cancer and benign 
samples.  
3. BAL and saliva contain a repertoire of N-linked glycan structures composed of 
oligomannose and bi-/ tri-antennary complex glycans. The presented approach resulted in 
the identification of 24 glycans in BAL from m/z = 1200-3185 and 16 glycans from 
saliva from m/z =1400-2375. The derivatization method resolved the anomeric 
configurations for 11 and 5 sialylated glycans in BAL and saliva, respectively.  A total of 
11 glycans shared identification in both BAL and saliva in the m/z = 1400-2375 range.  
4. The application of imaging mass spectrometry methodology was amenable to defining 
spatial distribution of N-glycans within tumor and normal adjacent lung tissue. The 




comparison of oligosaccharide localization to pertinent histological features as well as 
cross-reference in BAL and saliva.   
5.2.2 Limitations of Human Biofluids and Tissue Imaging Glycomic Studies  
The implementation of sialic acid linkage specific esterification and MALDI-FT-
ICR analysis of BAL and saliva was an efficient method for identifying sialylated glycan 
structures in these fluids. In addition, our workflow for MALDI imaging mass 
spectrometry of human lung facilitated cross-reference of prevalent N-glycans to defined 
histological features of the tissue, as well as against matched proximal fluids. While these 
methods and biofluids carry great potential for future biomarker studies, there are some 
limitations associated with the presented workflow. These potential drawbacks are 
introduced here and alternative approaches are discussed in the future studies section 
(5.2.3).  
The first constraint is related to the depth of coverage for BAL proteomic studies. 
This data was acquired following an in-solution trypsin digest, linear-ion trap mass 
spectrometry, and label-free quantification of detected proteins. This was an appropriate 
strategy to initially catalogue the protein-carriers of glycan structures present in this fluid. 
However, high-abundance metabolic proteins in the fluid, and the relatively-low 
resolution MS instrument used for acquisitions, likely hindered the identification of 
lower-abundance species. Furthermore, the application of a label-free quantification 
strategy is not the preferred method for analyzing starting materials containing a wide 
range of protein concentrations.  
 The next limitation relates to the incompatibility of the sialic acid linkage specific 




out on fluid-based starting materials, the final step before MS is to enrich for sialylated 
glycans using cotton-tip HILIC. However, because the workflow for imaging MS relies 
on the analysis of intact (non-homogenized) tissues, no equivalent enrichment can be 
carried out on these types of samples. Therefore the presented strategy for sialic acid 
linkage specific esterification cannot currently be applied to intact tissue samples prior to 
MALDI-imaging mass spectrometry, thus limiting the number of sialylated glycans 
detected in imaging analyses.  
 Another factor to consider is that the glycomic studies carried out on tissues/fluids 
were limited to acquisition of N-glycans only. Similar to the limitation stated in the 
azido-sugar labeling and enrichment experiments, this relates primarily to the lack of an 
enzyme which specifically releases O-linked glycans for structural elucidation of these 
oligosaccharides. 
 Conceptual limitations also hinder the ability to cross-reference findings between 
either of the presented approaches (in vitro and human proximal fluid/tissue studies).  
The azido-sugar labeling, enrichment, and LC-MS/MS method provides proteomic and 
glycosylation site information on sialoglycoproteins following 24 hours of TGFβ1 
stimulation. On the other hand, data obtained from the human tissues/proximal fluids 
methods provides information on the structure of sialylated N-glycans and their 
distribution in NSCLC tissues. Therefore each of the presented methods provides a 
distinct set of information which cannot be directly inter-related between sample types 






5.2.3 Future Studies 
The goal of the work presented in chapter 4 was to assess the implementation of 
innovative MS glycomic analyses on underutilized starting materials which may have 
merit for biomarker discovery efforts. Based on our success in identifying a variety of N-
linked glycans in each of these substrates, the most obvious next step will be to increase 
the number of samples studied so that trends in expression of specific glycan structures 
can be statistically evaluated. These efforts are already underway and relevant discoveries 
will be correlated to outcome information also available from the lung cancer bio-
specimen resource network.  In addition, these methods will be applied to a wider array 
of lung proximal fluids as they become available. For example, exhaled breath 
condensate and pleural fluid have both demonstrated promising results for proteomic 
studies of lung cancer(261,262).  
Another future endeavor will be to utilize an alternative means to quantify 
proteins present in the BAL fluid, such iTRAQ or TMT tags. Our study relied on LC-
MS/MS and label-free quantification to catalogue the BAL proteome and explore 
preliminary trends in the expression of proteins between diagnostic groups.  This 
approach was both rapid and suitable for this performing these experiments using limited 
sample volume. However as procurement of these samples increases, future work should 
be carried out using the most reliable quantitative methods for shotgun proteomic-type 
approaches.  
For imaging studies of N-glycans, a reasonable goal for future studies will be to 
develop a method for on-tissue sialic acid linkage specific derivatization. This 




and thereby facilitate greater overlap of structures identified between matched samples. 
The primary difficulty in achieving this end thus far has been the preservation of spatial 
distribution of liberated glycans. As an alternative, tissue-imaging performed in negative 
ionization mode also has the potential to accomplish this feat. In addition to these goals, 
our workflow will also be modified to study glycan distribution following release with 
glycosidases such as sialidase or fucosidase. This strategy would be worthwhile to gain a 
better perspective of glycan diversity as it relates to tissue architecture. Furthermore, to 
address the spatial resolution limitation of imaging mass spectrometry, methods such as 
laser capture microdissection (LCM) could be implemented prior to MS analysis(263).  
For example, using LCM to selectively isolate transformed cells, without inclusion of 
adjacent heterogeneous cell populations, could serve to verify the specificity of cancer-
associated glycan species. This approach has previously demonstrated utility in 
proteomic and glycomic investigations and therefore would be an appropriate follow-up 
to tissue imaging studies.  
Finally, to address the conceptual limitation of not being able to directly compare 
findings between the in vitro and human biofluids/tissues methods, we have begun 
optimizing a strategy for intact glycopeptide analysis of biofluids and cell lysate (Figure 
30). This method is based on a 2,2,2-trifluoroethanol acid and ammonium bicarbonate 
solubilization of membrane proteins, HILIC enrichment of glycopeptides, and HCD-PD-
ETD acquisition on the OrbiTrap Elite instrument. Data from this technique will serve to 
verify glycan structures identified from MALDI-FT-ICR analyses as well as discern the 
specific glycosylation sites and protein carriers from which they were derived. By using 




glycopeptide analysis, glycoproteins and glycan structures of interest can be cross-
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Figure 30: Bridging Findings Betw








1.  American Cancer Society. Lung Cancer (Non-Small Cell) [Internet]. 2014. Available 
from: http://www.cancer.org/acs/groups/cid/documents/webcontent/003115-
pdf.pdf 
2.  American Cancer Society. Cancer Facts & Figures 2014 [Internet]. Atlanta: American 
Cancer Society; 2014. Available from: 
http://www.cancer.org/acs/groups/content/@research/documents/webcontent/ac
spc-042151.pdf 
3.  Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, et al. Non-
small cell lung cancer. J Natl Compr Cancer Netw JNCCN. 2012 Oct 1;10(10):1236–
71.  
4.  Horn L, Eisenberg R, Guis D, Kimmelshue K, Massion P, Putnam J, et al. Cancer of the 
Lung: Non-Small Cell Lung Cancer and Small Cell Lung Cancer. Abeloff’s Clinical 
Oncology. 5th ed. Philadelphia: El;sevier Saunders; 2014. p. 1143–92.  
5.  Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 
2008 Jul 24;454(7203):436–44.  
6.  Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002 Dec 
19;420(6917):860–7.  
7.  O’Callaghan DS, O’Donnell D, O’Connell F, O’Byrne KJ. The role of inflammation in 
the pathogenesis of non-small cell lung cancer. J Thorac Oncol Off Publ Int Assoc 
Study Lung Cancer. 2010 Dec;5(12):2024–36.  
8.  Cooper WA, Lam DCL, O’Toole SA, Minna JD. Molecular biology of lung cancer. J 
Thorac Dis. 2013 Oct;5 Suppl 5:S479–90.  
9.  Finigan JH, Kern JA. Lung cancer screening: past, present and future. Clin Chest Med. 
2013 Sep;34(3):365–71.  
10.  National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black 
WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed 
tomographic screening. N Engl J Med. 2011 Aug 4;365(5):395–409.  
11.  National Lung Screening Trial Research Team, Aberle DR, Berg CD, Black WC, Church 
TR, Fagerstrom RM, et al. The National Lung Screening Trial: overview and study 
design. Radiology. 2011 Jan;258(1):243–53.  
12.  Kerr KM, Bubendorf L, Edelman MJ, Marchetti A, Mok T, Novello S, et al. Second 
ESMO consensus conference on lung cancer: pathology and molecular biomarkers 




13.  Mehan MR, Williams SA, Siegfried JM, Bigbee WL, Weissfeld JL, Wilson DO, et al. 
Validation of a blood protein signature for non-small cell lung cancer. Clin 
Proteomics. 2014;11(1):32.  
14.  Li QK, Gabrielson E, Askin F, Chan DW, Zhang H. Glycoproteomics using fluid-based 
specimens in the discovery of lung cancer protein biomarkers: Promise and 
challenge. PROTEOMICS - Clin Appl. 2013 Jan;7(1-2):55–69.  
15.  Li QK, Shah P, Li Y, Aiyetan PO, Chen J, Yung R, et al. Glycoproteomic analysis of 
bronchoalveolar lavage (BAL) fluid identifies tumor-associated glycoproteins from 
lung adenocarcinoma. J Proteome Res. 2013 Aug 2;12(8):3689–96.  
16.  Travis WD, Brambilla E, Riely GJ. New Pathologic Classification of Lung Cancer: 
Relevance for Clinical Practice and Clinical Trials. J Clin Oncol. 2013 Mar 
10;31(8):992–1001.  
17.  Davidson MR, Gazdar AF, Clarke BE. The pivotal role of pathology in the 
management of lung cancer. J Thorac Dis. 2013 Oct;5 Suppl 5:S463–78.  
18.  Kumar V, Abbas A, Aster J, editors. Lungs. Robbins basic pathology. 9th ed. 
Philadelphia, PA: Elsevier/Saunders; 2013. p. 459–515.  
19.  Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong K-K. Non-small-cell lung 
cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014 Jul 24;14(8):535–46.  
20.  Drilon A, Rekhtman N, Ladanyi M, Paik P. Squamous-cell carcinomas of the lung: 
emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol. 
2012 Oct;13(10):e418–26.  
21.  Li MO, Wan YY, Sanjabi S, Robertson A-KL, Flavell RA. Transforming Growth Factor-β 
Regulation of Immune Responses. Annu Rev Immunol. 2006 Apr;24(1):99–146.  
22.  Massagué J. TGFβ signalling in context. Nat Rev Mol Cell Biol. 2012 Oct;13(10):616–
30.  
23.  Bierie B, Moses HL. Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde 
of cancer. Nat Rev Cancer. 2006 Jul;6(7):506–20.  
24.  Bierie B, Moses HL. Transforming growth factor beta (TGF-β) and inflammation in 
cancer. Cytokine Growth Factor Rev. 2010 Feb;21(1):49–59.  
25.  Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. 
Nat Rev Cancer. 2010 Jun;10(6):415–24.  
26.  Daly AC, Randall RA, Hill CS. Transforming Growth Factor -Induced Smad1/5 




Essential for Anchorage-Independent Growth. Mol Cell Biol. 2008 Nov 
15;28(22):6889–902.  
27.  Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-
beta family signalling. Nature. 2003 Oct 9;425(6958):577–84.  
28.  Heldin C-H, Vanlandewijck M, Moustakas A. Regulation of EMT by TGFβ in cancer. 
FEBS Lett. 2012 Jul;586(14):1959–70.  
29.  Wang X-J, Han G, Owens P, Siddiqui Y, Li AG. Role of TGFβ-Mediated Inflammation in 
Cutaneous Wound Healing. J Investig Dermatol Symp Proc. 2006 Sep;11(1):112–7.  
30.  Xie L, Law BK, Aakre ME, Edgerton M, Shyr Y, Bhowmick NA, et al. Transforming 
growth factor beta-regulated gene expression in a mouse mammary gland epithelial 
cell line. Breast Cancer Res BCR. 2003;5(6):R187–98.  
31.  Zhang YE. Non-Smad pathways in TGF-β signaling. Cell Res. 2009 Jan;19(1):128–39.  
32.  Levy L, Hill C. Alterations in components of the TGF-β superfamily signaling 
pathways in human cancer. Cytokine Growth Factor Rev. 2006 Feb;17(1-2):41–58.  
33.  Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S, et al. High levels of 
transforming growth factor beta 1 in patients with colorectal cancer: association 
with disease progression. Gastroenterology. 1996 Feb;110(2):375–82.  
34.  Wikström P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. Transforming growth 
factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome 
in prostate cancer. The Prostate. 1998 Sep 15;37(1):19–29.  
35.  Walker RA, Dearing SJ. Transforming growth factor beta 1 in ductal carcinoma in situ 
and invasive carcinomas of the breast. Eur J Cancer Oxf Engl 1990. 1992;28(2-
3):641–4.  
36.  Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, Cohen A. High levels of 
transforming growth factor beta 1 correlate with disease progression in human 
colon cancer. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res 
Cosponsored Am Soc Prev Oncol. 1995 Aug;4(5):549–54.  
37.  Reiss M. TGF-β and cancer. Microbes Infect. 1999 Dec;1(15):1327–47.  
38.  Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin 
Invest. 2009 Jun;119(6):1420–8.  
39.  Willis BC, Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic 




40.  Branton MH, Kopp JB. TGF-beta and fibrosis. Microbes Infect Inst Pasteur. 1999 
Dec;1(15):1349–65.  
41.  Alcaraz A, Mrowiec A, Insausti CL, García-Vizcaíno EM, Ruiz-Canada C, López-
Martínez MC, et al. Autocrine TGF-β Induces Epithelial to Mesenchymal Transition in 
Human Amniotic Epithelial Cells. Cell Transplant. 2013 Aug 9;22(8):1351–67.  
42.  Ewen ME, Oliver CJ, Sluss HK, Miller SJ, Peeper DS. p53-dependent repression of 
CDK4 translation in TGF-beta-induced G1 cell-cycle arrest. Genes Dev. 1995 Jan 
15;9(2):204–17.  
43.  Wahl SM, Allen JB, Weeks BS, Wong HL, Klotman PE. Transforming growth factor 
beta enhances integrin expression and type IV collagenase secretion in human 
monocytes. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4577–81.  
44.  Freire-de-Lima L. Sweet and Sour: The Impact of Differential Glycosylation in Cancer 
Cells Undergoing Epithelialâ€“Mesenchymal Transition. Front Oncol [Internet]. 2014 
Mar 25 [cited 2014 Oct 29];4. Available from: 
http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00059/full 
45.  Maupin KA, Sinha A, Eugster E, Miller J, Ross J, Paulino V, et al. Glycogene Expression 
Alterations Associated with Pancreatic Cancer Epithelial-Mesenchymal Transition in 
Complementary Model Systems. Chammas R, editor. PLoS ONE. 2010 Sep 
27;5(9):e13002.  
46.  Zhang H, Meng F, Wu S, Kreike B, Sethi S, Chen W, et al. Engagement of I-branching 
{beta}-1, 6-N-acetylglucosaminyltransferase 2 in breast cancer metastasis and TGF-
{beta} signaling. Cancer Res. 2011 Jul 15;71(14):4846–56.  
47.  Pinho SS, Oliveira P, Cabral J, Carvalho S, Huntsman D, Gärtner F, et al. Loss and 
recovery of Mgat3 and GnT-III Mediated E-cadherin N-glycosylation is a mechanism 
involved in epithelial-mesenchymal-epithelial transitions. PloS One. 
2012;7(3):e33191.  
48.  Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. 
Cell. 2006 Sep 8;126(5):855–67.  
49.  Varki A, Freeze HH, Vacquier VD. Glycans in Development and Systemic Physiology. 
In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, et al., editors. 
Essentials of Glycobiology [Internet]. 2nd ed. Cold Spring Harbor (NY): Cold Spring 
Harbor Laboratory Press; 2009 [cited 2015 Jan 5]. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK1906/ 
50.  Tran DT, Ten Hagen KG. Mucin-type O-Glycosylation during Development. J Biol 




51.  Dube DH, Bertozzi CR. Glycans in cancer and inflammation — potential for 
therapeutics and diagnostics. Nat Rev Drug Discov. 2005 Jun;4(6):477–88.  
52.  Christiansen MN, Chik J, Lee L, Anugraham M, Abrahams JL, Packer NH. Cell surface 
protein glycosylation in cancer. PROTEOMICS. 2014 Mar;14(4-5):525–46.  
53.  Ono M, Hakomori S. Glycosylation defining cancer cell motility and invasiveness. 
Glycoconj J. 2004;20(1):71–8.  
54.  Taniguchi N, Miyoshi E, Ko JH, Ikeda Y, Ihara Y. Implication of N-
acetylglucosaminyltransferases III and V in cancer: gene regulation and signaling 
mechanism. Biochim Biophys Acta. 1999 Oct 8;1455(2-3):287–300.  
55.  Xu Q, Isaji T, Lu Y, Gu W, Kondo M, Fukuda T, et al. Roles of N-
Acetylglucosaminyltransferase III in Epithelial-to-Mesenchymal Transition Induced 
by Transforming Growth Factor 1 (TGF- 1) in Epithelial Cell Lines. J Biol Chem. 2012 
May 11;287(20):16563–74.  
56.  Granovsky M, Fata J, Pawling J, Muller WJ, Khokha R, Dennis JW. Suppression of 
tumor growth and metastasis in Mgat5-deficient mice. Nat Med. 2000 
Mar;6(3):306–12.  
57.  Freire-de-Lima L, Gelfenbeyn K, Ding Y, Mandel U, Clausen H, Handa K, et al. 
Involvement of O-glycosylation defining oncofetal fibronectin in epithelial-
mesenchymal transition process. Proc Natl Acad Sci. 2011 Oct 25;108(43):17690–5.  
58.  Varki A, Lowe JB. Biological Roles of Glycans. In: Varki A, Cummings RD, Esko JD, 
Freeze HH, Stanley P, Bertozzi CR, et al., editors. Essentials of Glycobiology 
[Internet]. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 
2009 [cited 2014 Oct 30]. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK1897/ 
59.  Jamal BT, Nita-Lazar M, Gao Z, Amin B, Walker J, Kukuruzinska MA. N-glycosylation 
status of E-cadherin controls cytoskeletal dynamics through the organization of 
distinct β-catenin- and γ-catenin-containing AJs. Cell Health Cytoskelet. 2009 Sep 
16;2009(1):67–80.  
60.  Freeze HH, Schachter H. Genetic Disorders of Glycosylation. In: Varki A, Cummings 
RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, et al., editors. Essentials of 
Glycobiology [Internet]. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor 
Laboratory Press; 2009 [cited 2015 Jan 7]. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK1939/ 
61.  Jaeken J, Matthijs G. Congenital disorders of glycosylation: a rapidly expanding 




62.  Haltiwanger RS, Lowe JB. Role of glycosylation in development. Annu Rev Biochem. 
2004;73:491–537.  
63.  Varki A, Kannagi R, Toole BP. Glycosylation Changes in Cancer. In: Varki A, Cummings 
RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, et al., editors. Essentials of 
Glycobiology [Internet]. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor 
Laboratory Press; 2009 [cited 2014 Oct 30]. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK1963/ 
64.  Moremen KW, Tiemeyer M, Nairn AV. Vertebrate protein glycosylation: diversity, 
synthesis and function. Nat Rev Mol Cell Biol. 2012 Jun 22;13(7):448–62.  
65.  Rini J, Esko J, Varki A. Glycosyltransferases and Glycan-processing Enzymes. In: Varki 
A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, et al., editors. Essentials 
of Glycobiology [Internet]. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor 
Laboratory Press; 2009 [cited 2014 Oct 30]. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK1921/ 
66.  Varki A, Esko JD, Colley KJ. Cellular Organization of Glycosylation. In: Varki A, 
Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, et al., editors. Essentials of 
Glycobiology [Internet]. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor 
Laboratory Press; 2009 [cited 2014 Oct 30]. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK1926/ 
67.  Bertozzi CR, Rabuka D. Structural Basis of Glycan Diversity. In: Varki A, Cummings 
RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, et al., editors. Essentials of 
Glycobiology [Internet]. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor 
Laboratory Press; 2009 [cited 2014 Oct 30]. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK1955/ 
68.  Esko JD, Kimata K, Lindahl U. Proteoglycans and Sulfated Glycosaminoglycans. In: 
Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, et al., editors. 
Essentials of Glycobiology [Internet]. 2nd ed. Cold Spring Harbor (NY): Cold Spring 
Harbor Laboratory Press; 2009 [cited 2015 Jan 7]. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK1900/ 
69.  Stanley P, Schachter H, Taniguchi N. N-Glycans. In: Varki A, Cummings RD, Esko JD, 
Freeze HH, Stanley P, Bertozzi CR, et al., editors. Essentials of Glycobiology 
[Internet]. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 
2009 [cited 2014 Oct 30]. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK1917/ 
70.  Freeze HH, Esko JD, Parodi AJ. Glycans in Glycoprotein Quality Control. In: Varki A, 
Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, et al., editors. Essentials of 




Laboratory Press; 2009 [cited 2014 Oct 30]. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK1958/ 
71.  Brockhausen I, Schachter H, Stanley P. O-GalNAc Glycans. In: Varki A, Cummings RD, 
Esko JD, Freeze HH, Stanley P, Bertozzi CR, et al., editors. Essentials of Glycobiology 
[Internet]. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 
2009 [cited 2014 Oct 30]. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK1896/ 
72.  Desai PR. Immunoreactive T and Tn antigens in malignancy: role in carcinoma 
diagnosis, prognosis, and immunotherapy. Transfus Med Rev. 2000 Oct;14(4):312–
25.  
73.  Stanley P, Cummings RD. Structures Common to Different Glycans. In: Varki A, 
Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, et al., editors. Essentials of 
Glycobiology [Internet]. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor 
Laboratory Press; 2009 [cited 2014 Oct 30]. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK1892/ 
74.  Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia. 
2001 Jul;6(3):339–53.  
75.  Du J, Meledeo MA, Wang Z, Khanna HS, Paruchuri VDP, Yarema KJ. Metabolic 
glycoengineering: sialic acid and beyond. Glycobiology. 2009 Dec;19(12):1382–401.  
76.  Varki A, Schauer R. Sialic Acids. In: Varki A, Cummings RD, Esko JD, Freeze HH, 
Stanley P, Bertozzi CR, et al., editors. Essentials of Glycobiology [Internet]. 2nd ed. 
Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2009 [cited 2014 Oct 
30]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1920/ 
77.  Harduin-Lepers A, Vallejo-Ruiz V, Krzewinski-Recchi MA, Samyn-Petit B, Julien S, 
Delannoy P. The human sialyltransferase family. Biochimie. 2001 Aug;83(8):727–37.  
78.  Schultz MJ, Swindall AF, Bellis SL. Regulation of the metastatic cell phenotype by 
sialylated glycans. Cancer Metastasis Rev. 2012 Dec;31(3-4):501–18.  
79.  Mühlenhoff M, Rollenhagen M, Werneburg S, Gerardy-Schahn R, Hildebrandt H. 
Polysialic acid: versatile modification of NCAM, SynCAM 1 and neuropilin-2. 
Neurochem Res. 2013 Jun;38(6):1134–43.  
80.  Büll C, Stoel MA, den Brok MH, Adema GJ. Sialic acids sweeten a tumor’s life. Cancer 
Res. 2014 Jun 15;74(12):3199–204.  





82.  Samraj AN, Läubli H, Varki N, Varki A. Involvement of a non-human sialic Acid in 
human cancer. Front Oncol. 2014;4:33.  
83.  Schreiber SC, Giehl K, Kastilan C, Hasel C, Mühlenhoff M, Adler G, et al. 
Polysialylated NCAM represses E-cadherin-mediated cell-cell adhesion in pancreatic 
tumor cells. Gastroenterology. 2008 May;134(5):1555–66.  
84.  Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: 
glycodynamics and functions. EMBO Rep. 2006 Jun;7(6):599–604.  
85.  Guo H-B, Lee I, Kamar M, Akiyama SK, Pierce M. Aberrant N-glycosylation of beta1 
integrin causes reduced alpha5beta1 integrin clustering and stimulates cell 
migration. Cancer Res. 2002 Dec 1;62(23):6837–45.  
86.  Renkonen J, Paavonen T, Renkonen R. Endothelial and epithelial expression of sialyl 
Lewis(x) and sialyl Lewis(a) in lesions of breast carcinoma. Int J Cancer J Int Cancer. 
1997 Jun 20;74(3):296–300.  
87.  Miyake M, Taki T, Hitomi S, Hakomori S. Correlation of expression of H/Le(y)/Le(b) 
antigens with survival in patients with carcinoma of the lung. N Engl J Med. 1992 Jul 
2;327(1):14–8.  
88.  Nakamori S, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, Sasaki Y, et al. 
Increased expression of sialyl Lewisx antigen correlates with poor survival in patients 
with colorectal carcinoma: clinicopathological and immunohistochemical study. 
Cancer Res. 1993 Aug 1;53(15):3632–7.  
89.  Drake PM, Cho W, Li B, Prakobphol A, Johansen E, Anderson NL, et al. Sweetening 
the Pot: Adding Glycosylation to the Biomarker Discovery Equation. Clin Chem. 2010 
Feb 1;56(2):223–36.  
90.  Miyoshi E, Nishikawa A, Ihara Y, Saito H, Uozumi N, Hayashi N, et al. Transforming 
growth factor beta up-regulates expression of the N-acetylglucosaminyltransferase 
V gene in mouse melanoma cells. J Biol Chem. 1995 Mar 17;270(11):6216–20.  
91.  Pinho SS, Seruca R, Gärtner F, Yamaguchi Y, Gu J, Taniguchi N, et al. Modulation of E-
cadherin function and dysfunction by N-glycosylation. Cell Mol Life Sci. 2011 
Mar;68(6):1011–20.  
92.  Partridge EA. Regulation of Cytokine Receptors by Golgi N-Glycan Processing and 
Endocytosis. Science. 2004 Oct 1;306(5693):120–4.  
93.  Zhao Y-Y, Takahashi M, Gu J-G, Miyoshi E, Matsumoto A, Kitazume S, et al. 
Functional roles of N-glycans in cell signaling and cell adhesion in cancer. Cancer Sci. 




94.  Abbott KL, Nairn AV, Hall EM, Horton MB, McDonald JF, Moremen KW, et al. 
Focused glycomic analysis of the N-linked glycan biosynthetic pathway in ovarian 
cancer. PROTEOMICS. 2008 Aug;8(16):3210–20.  
95.  Ishibashi K, Nishikawa A, Hayashi N, Kasahara A, Sato N, Fujii S, et al. N-
acetylglucosaminyltransferase III in human serum, and liver and hepatoma tissues: 
increased activity in liver cirrhosis and hepatoma patients. Clin Chim Acta Int J Clin 
Chem. 1989 Dec 15;185(3):325–32.  
96.  Yoshimura M, Nishikawa A, Ihara Y, Taniguchi S, Taniguchi N. Suppression of lung 
metastasis of B16 mouse melanoma by N-acetylglucosaminyltransferase III gene 
transfection. Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8754–8.  
97.  Yoshimura M, Ihara Y, Matsuzawa Y, Taniguchi N. Aberrant glycosylation of E-
cadherin enhances cell-cell binding to suppress metastasis. J Biol Chem. 1996 Jun 
7;271(23):13811–5.  
98.  Itzkowitz SH, Yuan M, Montgomery CK, Kjeldsen T, Takahashi HK, Bigbee WL, et al. 
Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res. 
1989 Jan 1;49(1):197–204.  
99.  Ju T, Aryal RP, Stowell CJ, Cummings RD. Regulation of protein O-glycosylation by 
the endoplasmic reticulum-localized molecular chaperone Cosmc. J Cell Biol. 2008 
Aug 11;182(3):531–42.  
100.  Radhakrishnan P, Dabelsteen S, Madsen FB, Francavilla C, Kopp KL, Steentoft C, 
et al. Immature truncated O-glycophenotype of cancer directly induces oncogenic 
features. Proc Natl Acad Sci. 2014 Sep 30;111(39):E4066–75.  
101.  Ju T, Lanneau GS, Gautam T, Wang Y, Xia B, Stowell SR, et al. Human tumor 
antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Res. 2008 Mar 
15;68(6):1636–46.  
102.  Marcos NT, Bennett EP, Gomes J, Magalhaes A, Gomes C, David L, et al. 
ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues. Front 
Biosci Elite Ed. 2011;3:1443–55.  
103.  Vázquez-Martín C, Cuevas E, Gil-Martín E, Fernández-Briera A. Correlation 
analysis between tumor-associated antigen sialyl-Tn expression and ST6GalNAc I 
activity in human colon adenocarcinoma. Oncology. 2004;67(2):159–65.  
104.  Yang JM, Byrd JC, Siddiki BB, Chung YS, Okuno M, Sowa M, et al. Alterations of O-





105.  Ogata S, Maimonis PJ, Itzkowitz SH. Mucins bearing the cancer-associated 
sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity. Cancer Res. 
1992 Sep 1;52(17):4741–6.  
106.  Van de Wiel-van Kemenade E, Ligtenberg MJ, de Boer AJ, Buijs F, Vos HL, Melief 
CJ, et al. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J 
Immunol Baltim Md 1950. 1993 Jul 15;151(2):767–76.  
107.  Van Vliet SJ, Paessens LC, Broks-van den Berg VCM, Geijtenbeek TBH, van Kooyk 
Y. The C-Type Lectin Macrophage Galactose-Type Lectin Impedes Migration of 
Immature APCs. J Immunol. 2008 Sep 1;181(5):3148–55.  
108.  Glinsky VV, Glinsky GV, Rittenhouse-Olson K, Huflejt ME, Glinskii OV, Deutscher 
SL, et al. The role of Thomsen-Friedenreich antigen in adhesion of human breast and 
prostate cancer cells to the endothelium. Cancer Res. 2001 Jun 15;61(12):4851–7.  
109.  Clement M. Expression of sialyl-Tn epitopes on beta1 integrin alters epithelial 
cell phenotype, proliferation and haptotaxis. J Cell Sci. 2004 Oct 1;117(21):5059–69.  
110.  Julien S. ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly 
modifies their O-glycosylation pattern and enhances their tumourigenicity. 
Glycobiology. 2005 Jul 13;16(1):54–64.  
111.  Kannagi R. Molecular mechanism for cancer-associated induction of sialyl Lewis X 
and sialyl Lewis A expression-The Warburg effect revisited. Glycoconj J. 
2004;20(5):353–64.  
112.  Läubli H, Borsig L. Selectins promote tumor metastasis. Semin Cancer Biol. 2010 
Jun;20(3):169–77.  
113.  Koike T, Kimura N, Miyazaki K, Yabuta T, Kumamoto K, Takenoshita S, et al. 
Hypoxia induces adhesion molecules on cancer cells: A missing link between 
Warburg effect and induction of selectin-ligand carbohydrates. Proc Natl Acad Sci U 
S A. 2004 May 25;101(21):8132–7.  
114.  Brockhausen I, Yang JM, Burchell J, Whitehouse C, Taylor-Papadimitriou J. 
Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer 
cells. Eur J Biochem FEBS. 1995 Oct 15;233(2):607–17.  
115.  Altschuler Y, Kinlough CL, Poland PA, Bruns JB, Apodaca G, Weisz OA, et al. 
Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state. Mol 
Biol Cell. 2000 Mar;11(3):819–31.  
116.  Rahn JJ, Chow JW, Horne GJ, Mah BK, Emerman JT, Hoffman P, et al. MUC1 
mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin 




117.  Winter JM, Tang LH, Klimstra DS, Brennan MF, Brody JR, Rocha FG, et al. A Novel 
Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and 
Mesothelin as Biomarkers. Andre F, editor. PLoS ONE. 2012 Jul 6;7(7):e40157.  
118.  Duffy MJ, Evoy D, McDermott EW. CA 15-3: Uses and limitation as a biomarker 
for breast cancer. Clin Chim Acta. 2010 Dec;411(23-24):1869–74.  
119.  Smagghe BJ, Stewart AK, Carter MG, Shelton LM, Bernier KJ, Hartman EJ, et al. 
MUC1* Ligand, NM23-H1, Is a Novel Growth Factor That Maintains Human Stem 
Cells in a More Naïve State. Tang YL, editor. PLoS ONE. 2013 Mar 7;8(3):e58601.  
120.  Seales EC, Jurado GA, Singhal A, Bellis SL. Ras oncogene directs expression of a 
differentially sialylated, functionally altered β1 integrin. Oncogene. 2003 Oct 
16;22(46):7137–45.  
121.  Uemura T, Shiozaki K, Yamaguchi K, Miyazaki S, Satomi S, Kato K, et al. 
Contribution of sialidase NEU1 to suppression of metastasis of human colon cancer 
cells through desialylation of integrin β4. Oncogene. 2009 Mar 5;28(9):1218–29.  
122.  Seales EC. Hypersialylation of 1 Integrins, Observed in Colon Adenocarcinoma, 
May Contribute to Cancer Progression by Up-regulating Cell Motility. Cancer Res. 
2005 Jun 1;65(11):4645–52.  
123.  Bellis SL. Variant glycosylation: an underappreciated regulatory mechanism for 
beta1 integrins. Biochim Biophys Acta. 2004 May 27;1663(1-2):52–60.  
124.  Gu J, Taniguchi N. Regulation of integrin functions by N-glycans. Glycoconj J. 
2004;21(1-2):9–15.  
125.  Pretzlaff RK, Xue VW, Rowin ME. Sialidase treatment exposes the beta1-integrin 
active ligand binding site on HL60 cells and increases binding to fibronectin. Cell 
Adhes Commun. 2000;7(6):491–500.  
126.  Semel AC, Seales EC, Singhal A, Eklund EA, Colley KJ, Bellis SL. Hyposialylation of 
integrins stimulates the activity of myeloid fibronectin receptors. J Biol Chem. 2002 
Sep 6;277(36):32830–6.  
127.  Woodard-Grice AV, McBrayer AC, Wakefield JK, Zhuo Y, Bellis SL. Proteolytic 
shedding of ST6Gal-I by BACE1 regulates the glycosylation and function of 
alpha4beta1 integrins. J Biol Chem. 2008 Sep 26;283(39):26364–73.  
128.  Pocheć E, Lityńska A, Amoresano A, Casbarra A. Glycosylation profile of integrin 





129.  Tangvoranuntakul P, Gagneux P, Diaz S, Bardor M, Varki N, Varki A, et al. Human 
uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc 
Natl Acad Sci. 2003 Oct 14;100(21):12045–50.  
130.  Hildebrandt H, Mühlenhoff M, Gerardy-Schahn R. Polysialylation of NCAM. Adv 
Exp Med Biol. 2010;663:95–109.  
131.  Bax M, van Vliet SJ, Litjens M, García-Vallejo JJ, van Kooyk Y. Interaction of 
Polysialic Acid with CCL21 Regulates the Migratory Capacity of Human Dendritic 
Cells. Neyrolles O, editor. PLoS ONE. 2009 Sep 14;4(9):e6987.  
132.  Hildebrandt H, Becker C, Glüer S, Rösner H, Gerardy-Schahn R, Rahmann H. 
Polysialic acid on the neural cell adhesion molecule correlates with expression of 
polysialyltransferases and promotes neuroblastoma cell growth. Cancer Res. 1998 
Feb 15;58(4):779–84.  
133.  Roth J, Zuber C, Wagner P, Taatjes DJ, Weisgerber C, Heitz PU, et al. 
Reexpression of poly(sialic acid) units of the neural cell adhesion molecule in Wilms 
tumor. Proc Natl Acad Sci U S A. 1988 May;85(9):2999–3003.  
134.  Tanaka F, Otake Y, Nakagawa T, Kawano Y, Miyahara R, Li M, et al. Expression of 
polysialic acid and STX, a human polysialyltransferase, is correlated with tumor 
progression in non-small cell lung cancer. Cancer Res. 2000 Jun 1;60(11):3072–80.  
135.  Trouillas J, Daniel L, Guigard M-P, Tong S, Gouvernet J, Jouanneau E, et al. 
Polysialylated neural cell adhesion molecules expressed in human pituitary tumors 
and related to extrasellar invasion. J Neurosurg. 2003 May;98(5):1084–93.  
136.  Al-Saraireh YMJ, Sutherland M, Springett BR, Freiberger F, Ribeiro Morais G, 
Loadman PM, et al. Pharmacological inhibition of polysialyltransferase ST8SiaII 
modulates tumour cell migration. PloS One. 2013;8(8):e73366.  
137.  Packer NH, von der Lieth C-W, Aoki-Kinoshita KF, Lebrilla CB, Paulson JC, Raman 
R, et al. Frontiers in glycomics: Bioinformatics and biomarkers in disease An NIH 
White Paper prepared from discussions by the focus groups at a workshop on the 
NIH campus, Bethesda MD (September 11–13, 2006). PROTEOMICS. 2008 
Jan;8(1):8–20.  
138.  Hayes DF, Zurawski VR, Kufe DW. Comparison of circulating CA15-3 and 
carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol Off J Am 
Soc Clin Oncol. 1986 Oct;4(10):1542–50.  
139.  Stieber P, Molina R, Chan DW, Fritsche HA, Beyrau R, Bonfrer JMG, et al. Clinical 





140.  Stieber P, Molina R, Chan DW, Fritsche HA, Beyrau R, Bonfrer JM, et al. 
Evaluation of the analytical and clinical performance of the Elecsys CA 15-3 
immunoassay. Clin Chem. 2001 Dec;47(12):2162–4.  
141.  Bon GG, von Mensdorff-Pouilly S, Kenemans P, van Kamp GJ, Verstraeten RA, 
Hilgers J, et al. Clinical and technical evaluation of ACS BR serum assay of MUC1 
gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays. 
Clin Chem. 1997 Apr;43(4):585–93.  
142.  Sturgeon CM, Duffy MJ, Stenman U-H, Lilja H, Brünner N, Chan DW, et al. 
National Academy of Clinical Biochemistry laboratory medicine practice guidelines 
for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian 
cancers. Clin Chem. 2008 Dec;54(12):e11–79.  
143.  Huang Z-B. Prognostic value of preoperative serum tumor markers in gastric 
cancer. World J Clin Oncol. 2014;5(2):170.  
144.  Ballehaninna UK, Chamberlain RS. Serum CA 19-9 as a Biomarker for Pancreatic 
Cancer—A Comprehensive Review. Indian J Surg Oncol. 2011 Jun;2(2):88–100.  
145.  Świderska M, Choromańska B, Dąbrowska E, Konarzewska-Duchnowska E, 
Choromańska K, Szczurko G, et al. Review The diagnostics of colorectal cancer. 
Współczesna Onkol. 2014;1:1–6.  
146.  Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal 
carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979 
Nov;5(6):957–71.  
147.  Tessler DA, Catanzaro A, Velanovich V, Havstad S, Goel S. Predictors of cancer in 
patients with suspected pancreatic malignancy without a tissue diagnosis. Am J 
Surg. 2006 Feb;191(2):191–7.  
148.  Kim YC, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, et al. Can preoperative CA19-9 
and CEA levels predict the resectability of patients with pancreatic adenocarcinoma? 
J Gastroenterol Hepatol. 2009 Dec;24(12):1869–75.  
149.  Safi F, Schlosser W, Kolb G, Beger HG. Diagnostic value of CA 19-9 in patients 
with pancreatic cancer and nonspecific gastrointestinal symptoms. J Gastrointest 
Surg Off J Soc Surg Aliment Tract. 1997 Apr;1(2):106–12.  
150.  Zhang S, Wang Y-M, Sun C-D, Lu Y, Wu L-Q. Clinical value of serum CA19-9 levels 
in evaluating resectability of pancreatic carcinoma. World J Gastroenterol WJG. 
2008 Jun 21;14(23):3750–3.  
151.  Halloran CM, Ghaneh P, Connor S, Sutton R, Neoptolemos JP, Raraty MGT. 




to determine resectability of pancreatic malignancy. Br J Surg. 2008 Apr;95(4):453–
9.  
152.  Waraya M, Yamashita K, Katagiri H, Ishii K, Takahashi Y, Furuta K, et al. 
Preoperative serum CA19-9 and dissected peripancreatic tissue margin as 
determiners of long-term survival in pancreatic cancer. Ann Surg Oncol. 2009 
May;16(5):1231–40.  
153.  Kim J-E, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of 
carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an 
asymptomatic population. J Gastroenterol Hepatol. 2004 Feb;19(2):182–6.  
154.  Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a 
monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981 
Nov;68(5):1331–7.  
155.  Munkarah A, Chatterjee M, Tainsky MA. Update on ovarian cancer screening. 
Curr Opin Obstet Gynecol. 2007 Feb;19(1):22–6.  
156.  Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ, et al. Three biomarkers identified 
from serum proteomic analysis for the detection of early stage ovarian cancer. 
Cancer Res. 2004 Aug 15;64(16):5882–90.  
157.  Understanding CA 125 Levels: A Guide for Ovarian Cancer Patients [Internet]. 
Foundation for Women’s Cancer; 2011. Available from: 
http://www.foundationforwomenscancer.org/wp-content/uploads/CA125levels.pdf 
158.  Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, et al. Large 
prospective study of ovarian cancer screening in high-risk women: CA125 cut-point 
defined by menopausal status. Cancer Prev Res Phila Pa. 2011 Sep;4(9):1401–8.  
159.  Gronlund B, Høgdall C, Hilden J, Engelholm SA, Høgdall EVS, Hansen HH. Should 
CA-125 response criteria be preferred to response evaluation criteria in solid tumors 
(RECIST) for prognostication during second-line chemotherapy of ovarian 
carcinoma? J Clin Oncol Off J Am Soc Clin Oncol. 2004 Oct 15;22(20):4051–8.  
160.  Rustin GJS, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, et al. 
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian 
cancer). J Natl Cancer Inst. 2004 Mar 17;96(6):487–8.  
161.  Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, et 
al. Laboratory Medicine Practice Guidelines for use of tumor markers in liver, 
bladder, cervical, and gastric cancers National Academy of Clinical Biochemistry. Clin 




162.  Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for 
hepatocellular carcinoma. Clin Chim Acta Int J Clin Chem. 2001 Nov;313(1-2):15–9.  
163.  Sato Y, Nakata K, Kato Y, Shima M, Ishii N, Koji T, et al. Early recognition of 
hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J 
Med. 1993 Jun 24;328(25):1802–6.  
164.  National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in 
Oncology: Hepatobiliary Cancers [Internet]. 2014. Available from: 
http://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf 
165.  Han X, Aslanian A, Yates JR. Mass spectrometry for proteomics. Curr Opin Chem 
Biol. 2008 Oct;12(5):483–90.  
166.  Peterman SM, Mulholland JJ. A novel approach for identification and 
characterization of glycoproteins using a hybrid linear ion trap/FT-ICR mass 
spectrometer. J Am Soc Mass Spectrom. 2006 Feb;17(2):168–79.  
167.  Singh C, Zampronio CG, Creese AJ, Cooper HJ. Higher Energy Collision 
Dissociation (HCD) Product Ion-Triggered Electron Transfer Dissociation (ETD) Mass 
Spectrometry for the Analysis of N -Linked Glycoproteins. J Proteome Res. 2012 Sep 
7;11(9):4517–25.  
168.  Alley WR, Mann BF, Novotny MV. High-sensitivity Analytical Approaches for the 
Structural Characterization of Glycoproteins. Chem Rev. 2013 Apr 10;113(4):2668–
732.  
169.  Krokhin O, Ens W, Standing KG, Wilkins J, Perreault H. Site-specific N-
glycosylation analysis: matrix-assisted laser desorption/ionization quadrupole-
quadrupole time-of-flight tandem mass spectral signatures for recognition and 
identification of glycopeptides. Rapid Commun Mass Spectrom RCM. 
2004;18(18):2020–30.  
170.  Thaysen-Andersen M, Packer NH. Advances in LC–MS/MS-based 
glycoproteomics: Getting closer to system-wide site-specific mapping of the N- and 
O-glycoproteome. Biochim Biophys Acta BBA - Proteins Proteomics. 2014 
Sep;1844(9):1437–52.  
171.  Sullivan B, Addona TA, Carr SA. Selective detection of glycopeptides on ion trap 
mass spectrometers. Anal Chem. 2004 Jun 1;76(11):3112–8.  
172.  Sandra K, Devreese B, Van Beeumen J, Stals I, Claeyssens M. The Q-Trap mass 
spectrometer, a novel tool in the study of protein glycosylation. J Am Soc Mass 




173.  Cao L, Tolić N, Qu Y, Meng D, Zhao R, Zhang Q, et al. Characterization of intact N- 
and O-linked glycopeptides using higher energy collisional dissociation. Anal 
Biochem. 2014 May;452:96–102.  
174.  Kubota K, Sato Y, Suzuki Y, Goto-Inoue N, Toda T, Suzuki M, et al. Analysis of 
glycopeptides using lectin affinity chromatography with MALDI-TOF mass 
spectrometry. Anal Chem. 2008 May 15;80(10):3693–8.  
175.  Leymarie N, Zaia J. Effective use of mass spectrometry for glycan and 
glycopeptide structural analysis. Anal Chem. 2012 Apr 3;84(7):3040–8.  
176.  Zhang Y, Jiao J, Yang P, Lu H. Mass spectrometry-based N-glycoproteomics for 
cancer biomarker discovery. Clin Proteomics. 2014;11(1):18.  
177.  Lai ZW, Nice EC, Schilling O. Glycocapture-based proteomics for secretome 
analysis. PROTEOMICS. 2013 Feb;13(3-4):512–25.  
178.  Pan S, Chen R, Aebersold R, Brentnall TA. Mass Spectrometry Based 
Glycoproteomics--From a Proteomics Perspective. Mol Cell Proteomics. 2011 Jan 
1;10(1):R110.003251–R110.003251.  
179.  Kaji H, Yamauchi Y, Takahashi N, Isobe T. Mass spectrometric identification of N-
linked glycopeptides using lectin-mediated affinity capture and glycosylation site–
specific stable isotope tagging. Nat Protoc. 2007 Jan;1(6):3019–27.  
180.  Zhang H, Li X-J, Martin DB, Aebersold R. Identification and quantification of N-
linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass 
spectrometry. Nat Biotechnol. 2003 Jun;21(6):660–6.  
181.  Chen R, Jiang X, Sun D, Han G, Wang F, Ye M, et al. Glycoproteomics analysis of 
human liver tissue by combination of multiple enzyme digestion and hydrazide 
chemistry. J Proteome Res. 2009 Feb;8(2):651–61.  
182.  Berven FS, Ahmad R, Clauser KR, Carr SA. Optimizing performance of 
glycopeptide capture for plasma proteomics. J Proteome Res. 2010 Apr 5;9(4):1706–
15.  
183.  Parker BL, Palmisano G, Edwards AVG, White MY, Engholm-Keller K, Lee A, et al. 
Quantitative N-linked Glycoproteomics of Myocardial Ischemia and Reperfusion 
Injury Reveals Early Remodeling in the Extracellular Environment. Mol Cell 
Proteomics. 2011 Aug 1;10(8):M110.006833–M110.006833.  
184.  Yeh C-H, Chen S-H, Li D-T, Lin H-P, Huang H-J, Chang C-I, et al. Magnetic bead-
based hydrophilic interaction liquid chromatography for glycopeptide enrichments. J 




185.  Mysling S, Palmisano G, Højrup P, Thaysen-Andersen M. Utilizing ion-pairing 
hydrophilic interaction chromatography solid phase extraction for efficient 
glycopeptide enrichment in glycoproteomics. Anal Chem. 2010 Jul 1;82(13):5598–
609.  
186.  Alley WR, Mechref Y, Novotny MV. Use of activated graphitized carbon chips for 
liquid chromatography/mass spectrometric and tandem mass spectrometric analysis 
of tryptic glycopeptides. Rapid Commun Mass Spectrom. 2009 Feb 28;23(4):495–
505.  
187.  Engholm-Keller K, Larsen MR. Titanium dioxide as chemo-affinity 
chromatographic sorbent of biomolecular compounds — Applications in acidic 
modification-specific proteomics. J Proteomics. 2011 Dec;75(2):317–28.  
188.  Larsen MR, Jensen SS, Jakobsen LA, Heegaard NHH. Exploring the Sialiome Using 
Titanium Dioxide Chromatography and Mass Spectrometry. Mol Amp Cell 
Proteomics. 2007 Jul 9;6(10):1778–87.  
189.  Palmisano G, Lendal SE, Engholm-Keller K, Leth-Larsen R, Parker BL, Larsen MR. 
Selective enrichment of sialic acid–containing glycopeptides using titanium dioxide 
chromatography with analysis by HILIC and mass spectrometry. Nat Protoc. 2010 
Nov;5(12):1974–82.  
190.  Laughlin ST, Agard NJ, Baskin JM, Carrico IS, Chang PV, Ganguli AS, et al. 
Metabolic labeling of glycans with azido sugars for visualization and 
glycoproteomics. Methods Enzymol. 2006;415:230–50.  
191.  Hanson SR, Hsu T-L, Weerapana E, Kishikawa K, Simon GM, Cravatt BF, et al. 
Tailored Glycoproteomics and Glycan Site Mapping Using Saccharide-Selective 
Bioorthogonal Probes. J Am Chem Soc. 2007 Jun;129(23):7266–7.  
192.  Slade PG, Hajivandi M, Bartel CM, Gorfien SF. Identifying the CHO secretome 
using mucin-type O-linked glycosylation and click-chemistry. J Proteome Res. 2012 
Dec 7;11(12):6175–86.  
193.  Yang L, Nyalwidhe JO, Guo S, Drake RR, Semmes OJ. Targeted Identification of 
Metastasis-associated Cell-surface Sialoglycoproteins in Prostate Cancer. Mol Cell 
Proteomics. 2011 Jun 1;10(6):M110.007294–M110.007294.  
194.  Roper SM, Zemskova M, Neely BA, Martin A, Gao P, Jones EE, et al. Targeted 
glycoprotein enrichment and identification in stromal cell secretomes using azido 
sugar metabolic labeling. PROTEOMICS - Clin Appl. 2013 Jun;7(5-6):367–71.  
195.  Best MD. Click Chemistry and Bioorthogonal Reactions: Unprecedented 





196.  Frost DC, Li L. Recent Advances in Mass Spectrometry-Based Glycoproteomics. 
Advances in Protein Chemistry and Structural Biology [Internet]. Elsevier; 2014 
[cited 2014 Nov 18]. p. 71–123. Available from: 
http://linkinghub.elsevier.com/retrieve/pii/B9780128004531000038 
197.  Gerken TA, Gupta R, Jentoft N. A novel approach for chemically deglycosylating 
O-linked glycoproteins. The deglycosylation of submaxillary and respiratory mucins. 
Biochemistry (Mosc). 1992 Jan 28;31(3):639–48.  
198.  Edge ASB. Deglycosylation of glycoproteins with trifluoromethanesulphonic acid: 
elucidation of molecular structure and function. Biochem J. 2003 Dec 1;376(Pt 
2):339–50.  
199.  Palmisano G, Melo-Braga MN, Engholm-Keller K, Parker BL, Larsen MR. Chemical 
Deamidation: A Common Pitfall in Large-Scale N-Linked Glycoproteomic Mass 
Spectrometry-Based Analyses. J Proteome Res. 2012 Mar 2;11(3):1949–57.  
200.  Zaia J. Mass Spectrometry and Glycomics. OMICS J Integr Biol. 2010 
Aug;14(4):401–18.  
201.  Baycin Hizal D, Wolozny D, Colao J, Jacobson E, Tian Y, Krag SS, et al. 
Glycoproteomic and glycomic databases. Clin Proteomics. 2014;11(1):15.  
202.  Bern M, Kil YJ, Becker C. Byonic: Advanced Peptide and Protein Identification 
Software. In: Baxevanis AD, Petsko GA, Stein LD, Stormo GD, editors. Current 
Protocols in Bioinformatics [Internet]. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 
2012 [cited 2014 Dec 1]. Available from: 
http://doi.wiley.com/10.1002/0471250953.bi1320s40 
203.  Wuhrer M, Catalina MI, Deelder AM, Hokke CH. Glycoproteomics based on 
tandem mass spectrometry of glycopeptides. J Chromatogr B. 2007 Apr;849(1-
2):115–28.  
204.  Segu ZM, Mechref Y. Characterizing protein glycosylation sites through higher-
energy C-trap dissociation. Rapid Commun Mass Spectrom. 2010 May 
15;24(9):1217–25.  
205.  Scott NE, Parker BL, Connolly AM, Paulech J, Edwards AVG, Crossett B, et al. 
Simultaneous Glycan-Peptide Characterization Using Hydrophilic Interaction 
Chromatography and Parallel Fragmentation by CID, Higher Energy Collisional 
Dissociation, and Electron Transfer Dissociation MS Applied to the N-Linked 
Glycoproteome of Campylobacter jejuni. Mol Cell Proteomics. 2011 Feb 




206.  Raman R, Venkataraman M, Ramakrishnan S, Lang W, Raguram S, Sasisekharan 
R. Advancing glycomics: implementation strategies at the consortium for functional 
glycomics. Glycobiology. 2006 May;16(5):82R – 90R.  
207.  Aoki-Kinoshita KF. Using databases and web resources for glycomics research. 
Mol Cell Proteomics MCP. 2013 Apr;12(4):1036–45.  
208.  Click-iT Protein Enrichment Kit [Internet]. Invitrogen; 2011. Available from: 
https://tools.lifetechnologies.com/content/sfs/manuals/mp10416.pdf 
209.  Urbaniak MD, Martin DMA, Ferguson MAJ. Global quantitative SILAC 
phosphoproteomics reveals differential phosphorylation is widespread between the 
procyclic and bloodstream form lifecycle stages of Trypanosoma brucei. J Proteome 
Res. 2013 May 3;12(5):2233–44.  
210.  Quackenbush J. Microarray data normalization and transformation. Nat Genet. 
2002 Dec;32 Suppl:496–501.  
211.  Powers TW, Jones EE, Betesh LR, Romano PR, Gao P, Copland JA, et al. Matrix 
assisted laser desorption ionization imaging mass spectrometry workflow for spatial 
profiling analysis of N-linked glycan expression in tissues. Anal Chem. 2013 Oct 
15;85(20):9799–806.  
212.  Reiding KR, Blank D, Kuijper DM, Deelder AM, Wuhrer M. High-throughput 
profiling of protein N-glycosylation by MALDI-TOF-MS employing linkage-specific 
sialic acid esterification. Anal Chem. 2014 Jun 17;86(12):5784–93.  
213.  Mechref Y, Kang P, Novotny MV. Solid-phase permethylation for glycomic 
analysis. Methods Mol Biol Clifton NJ. 2009;534:53–64.  
214.  Ceroni A, Maass K, Geyer H, Geyer R, Dell A, Haslam SM. GlycoWorkbench: A 
Tool for the Computer-Assisted Annotation of Mass Spectra of Glycans †. J Proteome 
Res. 2008 Apr;7(4):1650–9.  
215.  Orsburn BC. SILAC in Biomarker Discovery. In: Zhou M, Veenstra T, editors. 
Proteomics for Biomarker Discovery [Internet]. Totowa, NJ: Humana Press; 2013 
[cited 2015 Feb 4]. p. 123–31. Available from: http://link.springer.com/10.1007/978-
1-62703-360-2_11 
216.  Vagin O, Tokhtaeva E, Sachs G. The role of the beta1 subunit of the Na,K-ATPase 
and its glycosylation in cell-cell adhesion. J Biol Chem. 2006 Dec 22;281(51):39573–
87.  
217.  Bab-Dinitz E, Albeck S, Peleg Y, Brumfeld V, Gottschalk KE, Karlish SJD. A C-
terminal lobe of the beta subunit of Na,K-ATPase and H,K-ATPase resembles cell 




218.  Velonas V, Woo H, Remedios C, Assinder S. Current Status of Biomarkers for 
Prostate Cancer. Int J Mol Sci. 2013 May 24;14(6):11034–60.  
219.  Turtoi A, Dumont B, Greffe Y, Blomme A, Mazzucchelli G, Delvenne P, et al. Novel 
comprehensive approach for accessible biomarker identification and absolute 
quantification from precious human tissues. J Proteome Res. 2011 Jul 1;10(7):3160–
82.  
220.  Azuma K, Serada S, Takamatsu S, Terao N, Takeishi S, Kamada Y, et al. 
Identification of Sialylated Glycoproteins in Doxorubicin-Treated Hepatoma Cells 
with Glycoproteomic Analyses. J Proteome Res. 2014 Nov 7;13(11):4869–77.  
221.  Kim J, Myers AC, Chen L, Pardoll DM, Truong-Tran Q-A, Lane AP, et al. 
Constitutive and Inducible Expression of B7 Family of Ligands by Human Airway 
Epithelial Cells. Am J Respir Cell Mol Biol. 2005 Sep;33(3):280–9.  
222.  Xue. The distribution and expression profiles of human Aspartyl/Asparaginyl 
beta-hydroxylase in tumor cell lines and human tissues. Oncol Rep [Internet]. 2010 
Sep 27 [cited 2015 Feb 3];24(5). Available from: http://www.spandidos-
publications.com/or/24/5/1257 
223.  Bateman A, Bennett HPJ. The granulin gene family: from cancer to dementia. 
BioEssays News Rev Mol Cell Dev Biol. 2009 Nov;31(11):1245–54.  
224.  He Z, Ismail A, Kriazhev L, Sadvakassova G, Bateman A. Progranulin (PC-cell-
derived growth factor/acrogranin) regulates invasion and cell survival. Cancer Res. 
2002 Oct 1;62(19):5590–6.  
225.  Songsrirote K, Li Z, Ashford D, Bateman A, Thomas-Oates J. Development and 
application of mass spectrometric methods for the analysis of progranulin N-
glycosylation. J Proteomics. 2010 Jun 16;73(8):1479–90.  
226.  Lewandrowski U, Moebius J, Walter U, Sickmann A. Elucidation of N-
glycosylation sites on human platelet proteins: a glycoproteomic approach. Mol Cell 
Proteomics MCP. 2006 Feb;5(2):226–33.  
227.  Yang H, Zubarev RA. Mass spectrometric analysis of asparagine deamidation and 
aspartate isomerization in polypeptides: General. ELECTROPHORESIS. 2010 
Jun;31(11):1764–72.  
228.  Kaji H, Saito H, Yamauchi Y, Shinkawa T, Taoka M, Hirabayashi J, et al. Lectin 
affinity capture, isotope-coded tagging and mass spectrometry to identify N-linked 




229.  Park Y, Lebrilla CB. Application of Fourier transform ion cyclotron resonance 
mass spectrometry to oligosaccharides. Mass Spectrom Rev. 2005 Mar;24(2):232–
64.  
230.  Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the 
long and uncertain path to clinical utility. Nat Biotechnol. 2006 Aug;24(8):971–83.  
231.  Nguyen EV, Gharib SA, Schnapp LM, Goodlett DR. Shotgun MS proteomic 
analysis of bronchoalveolar lavage fluid in normal subjects. Proteomics Clin Appl. 
2014 Oct;8(9-10):737–47.  
232.  Magi B, Bargagli E, Bini L, Rottoli P. Proteome analysis of bronchoalveolar lavage 
in lung diseases. PROTEOMICS. 2006 Dec;6(23):6354–69.  
233.  Meyer KC. Bronchoalveolar lavage as a diagnostic tool. Semin Respir Crit Care 
Med. 2007 Oct;28(5):546–60.  
234.  Balog CIA, Stavenhagen K, Fung WLJ, Koeleman CA, McDonnell LA, Verhoeven A, 
et al. N-glycosylation of Colorectal Cancer Tissues: A liquid chromatography and 
mass spectrometry-based investigation. Mol Cell Proteomics. 2012 Sep 1;11(9):571–
85.  
235.  Caprioli RM, Farmer TB, Gile J. Molecular Imaging of Biological Samples: 
Localization of Peptides and Proteins Using MALDI-TOF MS. Anal Chem. 1997 
Dec;69(23):4751–60.  
236.  Jones EE, Powers TW, Neely BA, Cazares LH, Troyer DA, Parker AS, et al. MALDI 
imaging mass spectrometry profiling of proteins and lipids in clear cell renal cell 
carcinoma. PROTEOMICS. 2014 Apr;14(7-8):924–35.  
237.  Wang J, Duncan D, Shi Z, Zhang B. WEB-based GEne SeT AnaLysis Toolkit 
(WebGestalt): update 2013. Nucleic Acids Res. 2013 Jul;41(Web Server issue):W77–
83.  
238.  Zhang B, Kirov S, Snoddy J. WebGestalt: an integrated system for exploring gene 
sets in various biological contexts. Nucleic Acids Res. 2005 Jul 1;33(Web Server 
issue):W741–8.  
239.  Powers TW, Neely BA, Shao Y, Tang H, Troyer DA, Mehta AS, et al. MALDI 
Imaging Mass Spectrometry Profiling of N-Glycans in Formalin-Fixed Paraffin 
Embedded Clinical Tissue Blocks and Tissue Microarrays. Batra SK, editor. PLoS ONE. 
2014 Sep 3;9(9):e106255.  
240.  Foster MW, Morrison LD, Todd JL, Snyder LD, Thompson JW, Soderblom EJ, et al. 
Quantitative proteomics of bronchoalveolar lavage fluid in idiopathic pulmonary 




241.  Zaia J. Mass spectrometry of oligosaccharides. Mass Spectrom Rev. 2004 
Jun;23(3):161–227.  
242.  Lenz AG, Meyer B, Costabel U, Maier K. Bronchoalveolar lavage fluid proteins in 
human lung disease: analysis by two-dimensional electrophoresis. Electrophoresis. 
1993 Mar;14(3):242–4.  
243.  De Torre C, Ying S-X, Munson PJ, Meduri GU, Suffredini AF. Proteomic analysis of 
inflammatory biomarkers in bronchoalveolar lavage. Proteomics. 2006 
Jul;6(13):3949–57.  
244.  Drake RR, Cazare LH, Semmes OJ, Wadsworth JT. Serum, salivary and tissue 
proteomics for discovery of biomarkers for head and neck cancers. Expert Rev Mol 
Diagn. 2005 Jan;5(1):93–100.  
245.  Hu S, Arellano M, Boontheung P, Wang J, Zhou H, Jiang J, et al. Salivary 
proteomics for oral cancer biomarker discovery. Clin Cancer Res Off J Am Assoc 
Cancer Res. 2008 Oct 1;14(19):6246–52.  
246.  Vieira AC, An HJ, Ozcan S, Kim J-H, Lebrilla CB, Mannis MJ. Glycomic analysis of 
tear and saliva in ocular rosacea patients: the search for a biomarker. Ocul Surf. 
2012 Jul;10(3):184–92.  
247.  Xiao H, Zhang L, Zhou H, Lee JM, Garon EB, Wong DTW. Proteomic analysis of 
human saliva from lung cancer patients using two-dimensional difference gel 
electrophoresis and mass spectrometry. Mol Cell Proteomics MCP. 2012 
Feb;11(2):M111.012112.  
248.  Oztürk LK, Emekli-Alturfan E, Kaşikci E, Demir G, Yarat A. Salivary total sialic acid 
levels increase in breast cancer patients: a preliminary study. Med Chem Shāriqah 
United Arab Emir. 2011 Sep;7(5):443–7.  
249.  Ruhl S. The scientific exploration of saliva in the post-proteomic era: from 
database back to basic function. Expert Rev Proteomics. 2012 Feb;9(1):85–96.  
250.  Fumagalli M, Ferrari F, Luisetti M, Stolk J, Hiemstra P, Capuano D, et al. Profiling 
the Proteome of Exhaled Breath Condensate in Healthy Smokers and COPD Patients 
by LC-MS/MS. Int J Mol Sci. 2012 Oct 29;13(12):13894–910.  
251.  Soltermann A, Ossola R, Kilgus-Hawelski S, von Eckardstein A, Suter T, Aebersold 
R, et al. N-glycoprotein profiling of lung adenocarcinoma pleural effusions by 
shotgun proteomics. Cancer. 2008 Mar 7;114(2):124–33.  
252.  Jurchen JC, Rubakhin SS, Sweedler JV. MALDI-MS imaging of features smaller 




253.  Zavalin A, Todd EM, Rawhouser PD, Yang J, Norris JL, Caprioli RM. Direct imaging 
of single cells and tissue at sub-cellular spatial resolution using transmission 
geometry MALDI MS. J Mass Spectrom. 2012 Nov;47(11):i – i.  
254.  Bremnes RM, Al-Shibli K, Donnem T, Sirera R, Al-Saad S, Andersen S, et al. The 
role of tumor-infiltrating immune cells and chronic inflammation at the tumor site 
on cancer development, progression, and prognosis: emphasis on non-small cell 
lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2011 
Apr;6(4):824–33.  
255.  Suzuki K, Kachala SS, Kadota K, Shen R, Mo Q, Beer DG, et al. Prognostic Immune 
Markers in Non-Small Cell Lung Cancer. Clin Cancer Res. 2011 Aug 15;17(16):5247–
56.  
256.  Principe S, Jones EE, Kim Y, Sinha A, Nyalwidhe JO, Brooks J, et al. In-depth 
proteomic analyses of exosomes isolated from expressed prostatic secretions in 
urine. PROTEOMICS. 2013 May;13(10-11):1667–71.  
257.  Duijvesz D, Luider T, Bangma CH, Jenster G. Exosomes as biomarker treasure 
chests for prostate cancer. Eur Urol. 2011 May;59(5):823–31.  
258.  Fang M, Lim J-M, Wells L. Quantitative Glycomics of Cultured Cells Using Isotopic 
Detection of Aminosugars with Glutamine (IDAWG). In: Arkin AP, Mahal L, 
Romesberg F, Shah K, Shamu C, Thomas C, editors. Current Protocols in Chemical 
Biology [Internet]. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2010 [cited 2015 Feb 
20]. Available from: http://doi.wiley.com/10.1002/9780470559277.ch090207 
259.  Orlando R, Lim J-M, Atwood JA, Angel PM, Fang M, Aoki K, et al. IDAWG: 
Metabolic Incorporation of Stable Isotope Labels for Quantitative Glycomics of 
Cultured Cells. J Proteome Res. 2009 Aug 7;8(8):3816–23.  
260.  Chen C-D, Wang C-L, Yu C-J, Chien K-Y, Chen Y-T, Chen M-C, et al. Targeted 
Proteomics Pipeline Reveals Potential Biomarkers for the Diagnosis of Metastatic 
Lung Cancer in Pleural Effusion. J Proteome Res. 2014 Jun 6;13(6):2818–29.  
261.  Conrad DH, Goyette J, Thomas PS. Proteomics as a Method for Early Detection of 
Cancer: A Review of Proteomics, Exhaled Breath Condensate, and Lung Cancer 
Screening. J Gen Intern Med. 2008 Jan;23(S1):78–84.  
262.  Norris JL, Caprioli RM. Imaging mass spectrometry: A new tool for pathology in a 
molecular age. PROTEOMICS - Clin Appl. 2013 Dec;7(11-12):733–8.  
263.  Korekane H, Shida K, Murata K, Ohue M, Sasaki Y, Imaoka S, et al. Evaluation of 
laser microdissection as a tool in cancer glycomic studies. Biochem Biophys Res 





Stephen Roper was born in Kerrville, TX. in December of 1979. He is the youngest of 
four children, including two sisters and a brother. His parents, John and Evelyn Roper, 
worked as school teachers and always encouraged Stephen to pursue his curiosity in the 
medical sciences. After graduating from high school in 1998, Stephen attended junior 
college where he majored in vocational nursing and obtained his license to practice as a 
nurse in the state of Texas. He continued his education at Texas Tech University where 
he received a Bachelor’s of Science degree in Biology in 2004. He worked as a North 
Pacific Groundfish Observer in the Bering Sea for a year before he decided to return to 
school for further training in the biological sciences. In 2007, Stephen graduated from 
Texas Tech University Health Sciences Center with a Master’s of Science degree in 
Molecular Pathology. He obtained employment as a medical technologist at the 
University of Texas MD Anderson Cancer Center in the molecular diagnostics lab. After 
two years of service in this setting, Stephen decided that he would like to continue his 
education by pursuing a PhD in Biomedical Science. He accepted a position in the 
Eastern Virginia Medical School graduate program in 2009 and began his studies in 
cancer proteomics under the direction of Dr. Richard Drake. In July 2011, Dr. Drake was 
offered an esteemed position at the Medical University of South Carolina (MUSC) and 
invited Stephen to continue his studies with him at this new school. After four additional 
years of study at MUSC, Stephen obtained his PhD in Biomedical Science in May of 
2015.  
 
195 
 
